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ABSTRACT 
Huntington’s disease, one of nine CAG repeat diseases, is triggered by an expansion of a 
polyglutamine (polyQ) tract in the huntingtin (htt) protein. The aggregation of the first exon of  
htt (and fragments thereof) is believed to be intricately tied to the pathology of Huntington’s 
disease. Recent work in the field has identified a crucial role for the first seventeen residues of 
huntingtin (httNT), implicated in a wide range of cellular processes, in modulating the 
aggregation of htt both in vitro and in vivo. The focus of this work has been to identify the 
biophysical mechanisms underlying httNT mediated aggregation. Using a combination of 
experimental and computational techniques, we demonstrate the crucial role of the amphipathic 
helical propensity of httNT in mediating initial oligomerization of htt fragments and by extension, 
the aggregation of polyQ containing htt fragments. We also assess the effect of post-translational 
modifications (PTMs) within the httNT sequence on the aggregation of htt fragments, providing a 
biophysical perspective to the role that these PTMs might play in HD pathology.  Finally, in 
addition to the role of httNT in directing the initial oligomerization of htt fragments, we also 
provide evidence for a role of polyQ expansion in stabilizing htt fragment oligomers. Overall, the 
results of these studies not only add to our understanding of htt exon-1 aggregation but also 
provide additional clues for the ultimate role that aggregation plays in HD pathology.  
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 1 
1.0  INTRODUCTION (I): STRUCTURAL BIOLOGY OF HUNTINGTON’S 
DISEASE. 
1.1 INTRODUCTION. 
With the identification of the IT15 gene in chromosome 4 that harbors the CAG repeats 
implicated in Huntington’s disease (HD) (1), the study of the disease shifted from the clinical 
setting into the cellular milieu. Since then, a lot of the progress made towards our current 
understanding of HD comes from studies that have aimed to investigate disease pathology from a 
structural biology perspective. The discovery of intra-nuclear inclusions in post-mortem HD 
brains that were enriched in aggregates of the protein huntingtin (htt) (2), the translation product 
of the IT15 gene, underscored for the first time the importance of adding a structural perspective 
to HD research. Over the past decade there has been a substantial increase in the application of 
structural and biophysical techniques to the study of different aspects of HD, not just limited to 
protein aggregation. While the study of htt aggregation and its relevance to HD pathology 
remains a major focus, biophysical approaches to HD research have added a whole new 
dimension to our understanding of a wide-range of cellular processes ranging from cellular 
localization to protein-protein interactions.  
The CAG repeat expansion at the DNA level translates to a stretch of polyglutamine 
(polyQ) residues in the first exon of the protein huntingtin (htt). The exact function of the 
 2 
huntingtin protein is still unclear though it has been implicated in several cellular processes 
based on its interactions with other proteins (Table 1-1). Most structural biology textbooks 
emphasize the hierarchy of structure, from the primary sequence level, to secondary and tertiary 
structural elements to quaternary structures. In the case of htt, there are substantial complexities 
at each of these levels. At the primary sequence level, this is manifested through the diverse 
sequence architecture and post-translational processing of the protein. The secondary and tertiary 
structures of htt are intricately tied to not only sequence context but also cellular roles. Similarly, 
in recent years there has been some evidence for a quaternary structure of htt that might underlie 
its binding and/or aggregation properties. Each of these levels can directly modulate the cellular 
fate of htt and, by extension, the pathology of HD. This chapter aims to review our current 
knowledge of these different levels of htt structure and their possible roles in HD pathology.  
 
Structural biology of HD at the nucleic acid level: The study of HD from a structural biology 
perspective has almost exclusively focused on htt, the prima culpie in HD. Due to constraints of 
space, this focus on htt is also maintained in this chapter. Yet, as is now becoming apparent, 
there are some interesting structural aspects to HD at the nucleic acid level as well. CAG repeats 
in the huntingtin gene in chromosome 4 have been extensively studied in terms of their ability to 
promote replication instability which in the majority of cases leads to CAG expansion, a trigger 
for HD (1). CAG repeats, selectively enriched in exons in human DNA (3), have been observed 
to form unusual structures that are held together by Watson-Crick base pairing and through 
mismatched base-pairs, structures that can substantially modulate fundamental processes of 
DNA replication and repair (4). At the RNA level too, CAG repeats have been known to form 
stable hairpins and several recent studies have focused on exploring the possibility of a toxic 
 3 
gain-of-function at the RNA level (5). The finding that RNA transcripts of expanded CAG 
repeats do not require a starting ATG for translation, possibly because of their propensities to 
form hairpins (6) underscores the importance of exploring the structural effects of CAG repeats. 
The reader is referred to these reviews (4, 7) for a detailed report of the current state of research 
relating to the structural biology of CAG repeats.  
1.2 HUNTINGTIN SEQUENCE: STRINGING TOGETHER COMPLEX BUILDING 
BLOCKS.  
Huntingtin is a 3144 amino acid protein (based on a normal polyQ repeat of 23) that is 
believed to be crucial to normal functioning of the basal ganglia (8) though the exact function is 
still unclear. This 350KDa protein is also characterized by a diverse sequence architecture which 
might explain its putative role as a cellular hub of protein-protein interactions (9). This section 
highlights some of the important components of the diverse htt sequence and their evolutionary 
and functional significance.  
1.2.1 PolyQ stretch. 
The polyQ stretch in htt, the fundamental disease locus in HD, is located in the N–
terminal segment. The length of the polyQ tract varies between individuals with 17 glutamine 
residues the most common in non-disease patients and 40 residues being fully-penetrant amongst 
HD patients (10, 11). Phylogenetic analysis show that the polyQ stretch is an ancient acquisition 
in htt, dating back to a four residue NHQQ sequence in the sea-urchin (12) which gradually 
expanded into the polymorphic stretch that it has become in humans. The exact biological 
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1.2.2 Sequence domains flanking polyQ.  
The polyQ stretch in htt is flanked by two disparate and yet interesting sequence regions. 
N-terminal to the polyQ stretch lie the first seventeen residues of htt (httNT) which are highly 
conserved. This sequence, characterized by a mix of hydrophilic and hydrophobic residues, 
seems to modulate htt’s partitioning between intra- and extra-nuclear compartments (28-30) and 
its propensity to form aggregates (28, 31). Following the polyQ stretch in htt, is the C-terminal 
region of htt exon-1 which is characterized by a preponderance of proline residues. Interestingly, 
this stretch of proline residues seems to have been acquired following the evolutionary expansion 
of the polyQ stretch thereby supporting the hypothesis that these proline residues serve to down-
regulate the deleterious effects of polyQ expansion (19, 32).  
1.2.3 HEAT repeats. 
The huntingtin sequence is characterized by a series of 37-43 residues called HEAT 
repeats (33) (named after the proteins they were first identified in: huntingtin, elongation factor 
3, subunit A of protein phosphatase 2A and TOR). The HEAT repeats, which typically occur in 
tandem, have assumed particular relevance because of their role in protein-protein interactions 
(see below). Though there is some debate about the number and organization of these HEAT 
repeats (12, 34), it is believed that there are at least three conserved clusters of such repeats (27).  
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1.2.4 Post-translational modifications in huntingtin. 
The large size of the htt protein makes it an ideal candidate for several post-translational 
modifications (PTMs) that are increasingly believed to be crucially tied to htt’s functional roles 
and its link to HD pathology. Both ubiquitination (2, 35) and SUMOylation (19) in htt have been 
described and are believed to compete for the same lysine residues in httNT (Fig 1-1) and regulate 
htt’s stability, localization and effects on HD pathology. Additionally, full-length (fl) htt has 539 
potential phosphorylation sites (14) and thus far, at least eleven phosphorylation sites have been 
characterized. Phosphorylation at some of these sites is believed to be tied to crucial pathological 
processes. For instance phosphorylation at serine 434 has been shown to reduce caspase cleavage 
at residue 513 and protects against toxicity (36) while phosphorylation at serine 536 reduces 
cleavage by calpains at this site (14). Similarly, phosphorylation at threonine 3 was shown to 
reduce neurodegeneration in a fly model of HD (17). More dramatically, transgenic (tg) mice 
expressing fl-htt with a S13D/S16D mutation to mimic the observed phosphorylation at these 
residues (37) did not develop the disease and lacked typical pathology seen in HD mice (16). 
Some of the other PTMs in htt that have been linked to HD pathology include palmitoylation at 
cysteine 214 that is linked to aggregation and toxicity (20) and acetylation at lysine 444 
(amongst others) which has been shown to promote autophagosomal degradation (38). Taken 
together these observations highlight a crucial role for PTMs in modulating pathology possibly 
by altering the biophysical properties of htt.  
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1.2.5 Proteolytic processing of huntingtin. 
Fl-htt purified from mammalian cells has been observed to be susceptible to significant 
proteolysis (39). Proteolytic processing of htt has been implicated as a trigger for HD pathology, 
forming smaller fragments which have a higher tendency to aggregate and which are the major 
components of neuronal intranuclear inclusions in post-mortem HD brains (2). Further support 
for such a “toxic fragment” hypothesis (40) comes from the finding that mice expressing 
truncated versions of htt exhibit a shorter life-span than do those expressing fl-htt (41) and the 
observation that inhibiting the cleavage of htt protects against aggregation and toxicity (24). Both 
wt and expanded htt are cleaved by caspases 2, 3, 6 and 7 at residues 513, 552 and 586 (22-24, 
42). Interestingly, wt-htt can itself interact with caspase-3 when over-expressed thereby 
potentially allowing for an up-regulation of caspase activation under conditions of htt depletion 
(25). In addition to caspases, htt has also been found to be cleaved by other proteolytic enzymes 
like the calpains (21) and aspartyl endopeptidases (43). The cleavage sites for calpain 1 and 2 
had earlier been mapped to the residues 469 and 536 (21) though more recent work suggests that 
calpain 1 can also cleave at positions 8 and 15 in httNT, an event that might be crucial for htt 
clearance (26). On the other hand, residues between 104 and 114 have been identified as the site 
of cleavage by aspartyl-endopeptidases releasing two fragments that differentially build up in 
cytoplasmic and nuclear inclusions (43). In addition to the ones mentioned above, new sites of 
proteolytic cleavage (and new proteases) are continuously being identified which might play a 
significant role in HD pathology (44-46). In any case, a direct effect of the proteolytic processing 
of htt observed in vivo is that it has allowed structural biologists to focus on these shorter 
fragments of htt which are more amenable to experiments and which might be the more relevant 
protein motifs in HD.    
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1.3 HUNTINGTIN: A HUB OF PROTEIN INTERACTIONS.  
1.3.1 Huntingtin as an interaction scaffold.  
Several in vitro and in vivo studies have ascribed a crucial role for htt as a hub of protein-
protein interactions, interactions that influence a host of cellular processes (Table 1-1). The 
identification of diverse interacting partners strengthens the case for a multi-functional role for 
htt in the cell. This has led to the hypothesis that at the center of this multi-functionality lies the 
ability of htt to act as a molecular scaffold for protein interactions, facilitating the transfer of 
information across the cell. (47). However, htt’s susceptibility to proteolysis (39) and its 
propensity to aggregate do raise questions about htt’s ability to mediate such a scaffolding role.  
The interactions of htt with transcription factors is of particular interest given the preponderance 
of polyQ sequences in transcriptional factors and the hypothesis that aggregate sequestration of 
polyQ rich transcription factors might be responsible for transcriptional dysregulation observed 
in HD (48). However, the ability of htt to interact with a wide –range of transcription-related 
proteins (49) without a polyQ tract points to a role for htt in transcriptional regulation that is 
distinct from one based on polyQ annealing.  One such role could be htt’s ability to act as a 
critical scaffold that brings together essential components of the transcription machinery (47). 
The binding of htt to Sp1 and its co-activator TAFII130 (50) has also been cited as an example in 
support of this hypothesis (47). Furthermore, htt has been implicated in at least one other protein 
complex involved in transcriptional repression (51).  
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Binding Partner Function Htt binding 
site 
polyQ 
effect on 
binding  
Transcription: 
CA 150 (52) 
CBP(53) 
CtBP(54) 
HYP-A,B(55) 
HYB-C(55) 
NCOR(51) 
NF-κB(34) 
SP1(50, 56) 
TAFII130(50) 
TBP(57) 
P53(53) 
REST-NRSE(58) 
Sin3a(53) 
 
Trafficking/Endocytosis: 
HYP-J(55) 
HIP 1(59) 
HIP 14(60) 
PACSIN 1(61) 
SH3GL3(62) 
HAP1(63) 
PSD-95(64) 
 
 
Signaling: 
Calmodulin(65)  
CIP-4(66) 
FIP2(55) 
GRb2(67) 
IP31(68) 
RasGAP(67) 
TRAF6(69) 
MLK-2(70) 
 
Other: 
Cystathione β-synthase(71) 
GADPH(72) 
HIP2(35) 
Rhes(73) 
Gp78(74) 
TpR (75) 
TRiC(76) 
 
Transcription activator 
Transcription activator 
Transcription repressor 
RNA splicing 
Transcription factor 
Transcription repressor 
Transcription factor 
Transcription activator 
Transcription activator 
Transcription factor 
Transcription factor 
Transcription suppressor 
Transcription repressor 
 
 
Endocytosis 
Endocytosis/pro-apoptotic 
Trafficking/endocytosis 
endocytosis 
endocytosis/vesicle recycling 
Trafficking/endocytosis 
Synaptic scaffold 
 
 
 
Ca+ regulation 
Cdc42 signaling  
GTPase Rab8 interactor 
Growth factor signaling  
Calcium signaling  
Ras GTPase  
E3 ubiquitin ligase 
Mixed-lineage kinase  
 
 
Cys generation 
Glycolytic enzyme 
Ubiquitin conjugase  
SUMO-E3 ligase 
Ubiquitin ligase 
Nuclear Export 
Chaperonin 
 
Unknown 
NT(1-588) 
Unknown  
NT(polypro) 
NT(polypro) 
NT(1-171) 
HEAT repeats 
NT(1-171) 
NT(1-480) 
Unknown  
NT(polypro) 
NT(1-550) 
NT(1-171) 
 
 
NT(1-550) 
NT(1-550) 
NT(1-550) 
NT(polypro) 
NT(polypro) 
NT(1-230) 
Unknown  
 
 
 
Unknown  
NT(1-152) 
NT(1-550) 
NT(polypro) 
NT(1-158) 
NT(polypro) 
NT(1-171) 
NT(polypro) 
 
 
NT(1-171) 
NT(polypro) 
NT(1-540) 
NT(1-171) 
HEAT 2/3 
NT(1-17) 
NT(1-17) 
 
No. 
Yes (↑) 
Yes (↓) 
Yes (↑) 
Yes (↑) 
Yes (↑) 
Unknown 
Yes (↑) 
No 
Unknown 
No 
Yes (↓) 
Yes (↑) 
 
 
Yes (↓) 
Yes (↓) 
Yes (↓) 
Yes (↑) 
Yes (↑) 
Yes (↑) 
Yes (↓) 
 
 
 
Yes (↑) 
Yes (↑) 
Unknown  
Unknown  
Yes (↑) 
Unknown  
No 
Yes (↓) 
 
 
No 
Yes (↑) 
No 
Yes (↑) 
Yes (↑) 
Yes (↓) 
No 
Table 1-1: Reported interaction partners of htt.  
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1.3.2 Structural loci of huntingtin interactions. 
The majority of htt’s interactions are localized to the N–terminal region of htt comprising 
residues 1-588, probably because of the fact that most of the yeast two-hybrid experiments have 
used this fragment as the “bait”. Nevertheless, this particular sequence stretch in huntingtin is 
particularly attractive because of the presence of the polyQ stretch, and the proline rich sequence 
C terminal to it, and the first HEAT repeat cluster in this region.  
1.3.2.1 HEAT repeats. 
The ability to form super-helical structures (Fig 1-2.A) that can promote protein-protein 
interactions and their presence in eukaryotic proteins implicated in several crucial cellular 
processes, make the HEAT repeats in htt excellent candidates for putative interaction sites.  Not 
surprisingly therefore, several of htt’s interacting partners have been observed to bind in the 
region containing HEAT repeats (Table 1-1).  
1.3.2.2 Proline-rich sequence.  
The proline-rich sequence adjacent to the polyQ stretch in htt exon-1 has been implicated 
as the major locus of htt interactions based primarily on its ability to interact with proteins that 
contain SH3 (Src homology) or WW domains that bind proline-rich motifs in the target ligands 
(77). Interestingly, in almost all of the interactions that are mediated by this proline-rich 
sequence, the strength of association is modulated by the length of the adjacent polyQ repeat 
region, leading to the hypothesis that polyQ expansion is linked to conformational changes in the 
adjacent proline-rich region which can directly impact htt’s interactions with its binding partners 
(61, 62, 70). However, the ability of polyQ expansion to promote aggregation, thereby 
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complicating interpretation of protein interactions (discussed below), presents a caveat to such a 
conformational re-arrangement hypothesis.  
1.3.2.3 PolyQ sequence. 
 In addition to being the site of the expansion that is the primary trigger for HD, the 
polyQ sequence in htt is also crucial to htt’s interactions with its binding partners. While polyQ 
expansion has been suggested to modulate interactions of htt with other proteins (Table 1-1), the 
polyQ stretch has itself been implicated as the binding site of only one other protein, GADPH 
(72). One explanation for this might be that self-association of polyQ in htt impairs its ability to 
bind other proteins. Yet, a role (albeit indirect) of polyQ in mediating protein interactions cannot 
be discounted. For instance, fusing a polyQ tract to a DNA binding domain was seen to activate 
transcription (78). A recent study by Schaefer et al (79) found that polyQ containing proteins 
interact with more partners than proteins lacking polyQ. Furthermore, they posit a structural role 
for polyQ in mediating protein-protein interactions in terms of its ability to adopt and extend a 
coiled-coil conformation in adjacent sequence domains in the bound state.  
1.3.2.4 The seventeen residue httNT sequence. 
The highly conserved N-terminal seventeen residues in htt have been the subject of 
considerable study in recent years because of their ability to modulate aggregation of htt exon-1 
in vitro (31) and in vivo (28) as well as their ability to directly influence htt localization by 
binding membranes (29).  Furthermore, the designation of this region as a MoRF (molecular 
recognition feature) (31) as well as its ability to adopt helical structures in complexes (80) make 
it an attractive candidate for mediating protein interactions. Thus far, the httNT  sequence has 
been implicated in interactions with Tpr  (nuclear pore protein translocated protein region) (75) 
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as well as the eukaryotic chaperonin TRiC (76). One possible explanation for the inability to 
identify more htt interaction partners binding to this sequence might be the reported 
sequestration of this region in htt exon-1 aggregates (31) which might be present in several of the 
methods used to identify interaction partners.  
1.3.3 Relevance of htt association states to protein-protein interactions.  
Most of htt’s interaction partners have been identified either by yeast-two hybrid 
screening or by employing biochemical approaches such as affinity purification, GST pull-down 
assays and/or co-immunoprecipitation. The results of such assays can easily be influenced by the 
aggregation states of htt. In fact, enrichment of aggregates in samples could provide an 
alternative explanation to the role of polyQ expansions in mediating htt interactions. Similarly, 
one could rationalize the observation that several interaction partners of htt bind shorter 
fragments more efficiently than they do fl-htt (56, 75, 81) by invoking the greater propensity of 
such fragments to aggregate. In fact,  a recent study by Davranche et al (82), demonstrated that 
polyQ aggregation can strongly bias the results of pull-down assays and that aggregate free 
preparation of htt N-terminal samples do not display any dependence on polyQ expansion in 
binding other proteins. They then proceed to argue that htt aggregates can selectively sequester 
binding epitopes thereby modulating htt’s interactions with its partners. Interestingly, an earlier 
study showed that N-terminal fragments of htt bind post-synaptic membranes in R6/2 mice in an 
oligomeric state (83) underscoring the importance of accounting for aggregation in analyzing 
htt’s interactions. 
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1.4 SOLUTION STRUCTURE OF HUNTINGTIN.  
The large size of the fl-htt molecule has made it inaccessible to high-resolution structure 
determination methods. Furthermore, the high propensity of htt fragments to aggregate make it 
challenging to determine the structure of the monomeric form in solution, if such a form even 
exists.  Thus, most of the efforts geared towards determining the solution structure of huntingtin 
have adopted a reductionist approach by looking at the structure of smaller sequence domains in 
isolation. In this section, we review some of the work that has been done in elucidating the 
structural properties of huntingtin in solution.  
1.4.1 HEAT repeats. 
The identification of HEAT sequences in htt and the prediction of such sequences 
forming helical structures painted a structural picture of htt for the first time (33). We now know 
that tandem HEAT repeats in proteins adopt helical structures that are believed to be the 
structural determinants to the multitude of interactions that such proteins participate in. A crystal 
structure of 15 tandem HEAT repeats in the PR65/A subunit of protein phosphatase 2A (84) 
shows that this molecule forms an extended, curved structure (Fig 1-2A) comprised entirely of 
helices connected by loops, akin to a molecular hook. Each HEAT motif has two anti-parallel 
helices that are stacked parallel to the adjacent repeat thereby forming a double-layer of helices 
across the entire length of the molecule (Fig 1-2.A, inset). Using molecular modeling techniques, 
Li et al showed that HEAT repeats in fl-htt adopt an extended conformation (39). The presence 
of exposed hydrophobic residues within intra-repeat turns that might become buried upon 
binding provides a structural basis to the implication that HEAT repeats serve to mediate protein-
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protein interactions (33).  More recently, Navarro and group (85) have found three clusters of α-
rods (3-D arrangements of elongated anti-parallel helices) matching the locations of the three 
HEAT clusters. Interestingly, they were able to show that these α-rods mediate intra- and inter-
molecular interactions suggesting that these structural clusters might be important determinants 
of fl-htt’s tertiary and/or quarternary structure (Fig 1-2.B). The presence of such a folded 
structure in fl-htt is also borne by results that indicate that fl-htt remains associated non-
covalently despite proteolytic cleavage (39).  
1.4.2 Structural studies on htt fragments. 
1.4.2.1 PolyQ structure. 
Studies of the solution conformation of polyQ sequences assume particular significance 
in the light of the toxic monomer hypothesis which suggests that expanded polyQ is associated 
with a conformational transition within the monomer which represents the toxic species (see 
discussion below and Fig 1-3). Thus, a multitude of computational and biophysical methods have 
been applied to investigating structural aspects of polyQ sequences. Fluorescence correlation 
spectroscopy studies of polyQ peptides showed that these sequences are inherently insoluble in 
water (a poor solvent for polyQ) adopting compact conformations across both short and long 
repeat lengths (86). Evidence for compact non β-sheet conformations across different polyQ 
repeat lengths was also observed in atomic force microscopy studies of polyQ sequences flanked 
by folded proteins which also ascribed substantial mechanical resilience to such conformations 
(87).  
Despite the inherent challenges posed by the insolubility of polyQ sequences, a multitude 
of structural tools have been applied to the study of polyQ structure. Circular dichroism studies 
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of synthetic polyQ peptides, of both pathological and non-pathological lengths, first showed that 
the polyQ sequences lack any stable secondary structural elements and exist predominantly as 
random-coils (88) in solution though there are hints of some helical propensities especially at 
lower temperatures (89). Since the CD spectra of random coil and PPII helical conformations are 
similar, it is possible that seemingly disordered proteins can adopt PPII helical conformations. In 
fact, PPII helical conformations have been observed in polyQ peptides, especially at lower repeat 
lengths (90, 91) though there are hints of a transition to β-sheet conformations (91) at higher 
polyQ repeat lengths. While it is possible that polyQ sequences can sample PPII helical 
conformations locally, studies using high resolution structural techniques like X-ray diffraction 
and NMR suggest that in solution polyQ sequences lack any stable structure though they might 
transiently sample secondary structural elements (80, 92). This view is also supported by 
computational studies which indicate that polyQ sequences might adopt a mixture of random-
coil, helical and β rich structures in solution (93, 94) with the caveat that results of simulations 
seem to depend on the choice of parameters (95). 
An additional level of complexity to the study of polyQ conformations arises from the 
protein context. In other words, the presence of flanking domains can influence the 
conformational preferences of polyQ. Using X-ray diffraction, Kim et al showed that the polyQ 
sequence in a maltose binding protein-htt exon 1 construct adopts conformations ranging, from 
α-helical or random coil in residues proximal to httNT, to extended in residues adjacent to the 
polyproline stretch (80). Other studies have demonstrated the ability of the polyproline sequence 
to induce PPII helical structures within polyQ  (91). Such a change in conformational 
preferences of polyQ might be of particular relevance to its aggregation propensities which are 
known to be modulated by its flanking sequences (see below).  
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Evidence for a toxic monomer conformation of polyQ :  The toxic monomer hypothesis 
suggests that polyQ expansion is linked to a toxic structural transition in the monomeric 
state (Fig 1-3). This hypothesis originated from observations of polyQ-specific 
monoclonal antibodies binding longer-polyQ repeats better than shorter repeats which 
was ascribed to the presence of a specific structural conformation at higher repeat 
lengths. Subsequent studies showed that such stronger binding of mAbs to longer polyQ 
repeats can be explained based on a “linear-lattice” mode of binding (92), at least for 
some of these antibodies. Thus, longer polyQ repeats present more binding epitopes and 
hence are bound to a greater extent by mAbs such as MW1. However, recent studies with 
the 3B5H10 antibody suggest that this antibody does bind a specific conformation in 
longer polyQ repeat constructs of htt exon-1 in a non “linear-lattice” binding mode. Thus, 
SAXS based studies of the 3B5H10-htt exon-1 complex indicate that the polyQ epitope is 
an anti-parallel β-hairpin structure (96). A greater propensity for an average β rich 
structure at higher polyQ repeat lengths has also been reported based on CD (91, 97) , 
FRET (98) and SAXS  (96) studies of different polyQ repeat peptides. The ability of 
3B5H10 antibody to bind a β strand rich monomeric conformer of polyQ coupled with 
the finding that 3B5H10 is a better predictor of neurodegeneration, based on correlative 
studies looking at neuronal lifetimes, has been used to support the argument that polyQ 
expansion is associated with the population of a toxic conformer in the monomeric state. 
Other studies in support of this argument include greater toxicity observed in the case of 
artificial htt exon-1 constructs engineered to form β hairpin structures (99) and also 
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While the presence of a specific conformer at higher polyQ repeat lengths is possible, one 
must consider the caveats with the existing evidence for this hypothesis.  It is likely that the 
putative β-strand conformation at higher polyQ repeat lengths is populated only in the presence 
of antibody. Such “conformational enrichment” has been reported in other systems (101) and is 
particularly relevant to disordered proteins that are known to have a propensity to fold when 
bound to a more structured partner (102). Of course the presence of a β-rich conformer at higher 
polyQ repeat lengths has also been observed as the average conformation (96) in the largely 
disordered monomeric ensemble (92) in the absence of the antibody. However, one would 
anticipate that given the higher propensity of longer polyQ repeats to aggregate, such a shift 
towards a β rich conformer might be explained, in part at least, by enhanced aggregation 
tendencies (103). In fact, the presence of small oligomeric species in some of these studies 
cannot entirely be discounted (96, 99). In any case, direct evidence linking a specific polyQ 
conformation to pathological events is needed to unequivocally demonstrate a toxic role for such 
species. 
1.4.2.2 Polyproline stretch. 
Unlike with other constituents of the htt N-terminal sequence, most experimental (96) 
and computational studies seem to concur that the polyPro sequence in htt adopts a PPII-helical 
conformation in solution. Functionally, this may stem from the importance of this structural 
motif to recognition by SH3 domains (77) though it might also be responsible for the inhibitory 
effect of the polyPro sequence on the aggregation of polyQ (91).  
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1.4.2.3 Solution structure of httNT. 
In the past few years, considerable attention has been given to determining the solution 
structure of the first seventeen residues in htt in part because of the crucial role that these 
residues play in determining htt’s aggregation, localization and interactions with other partners, 
in the cell. As mentioned above, the httNT segment is characterized by a mix of hydrophobic and 
hydrophilic residues prompting the hypothesis that this sequence adopts an α-helical 
conformation in solution. Earlier, circular dichroism studies of this sequence had identified 
substantial helical propensities displaying up to 50%-60% helical character (31). Supporting this 
finding, several computational simulations have also confirmed the helical propensities of this 
sequence (95, 104). On the other hand, higher resolution solution NMR studies did not find any 
stable elements of α-helix in the httNT sequence which was observed to exist as a random coil in 
solution though there were hints of transient helix conformation in some residues (31). One way 
to rationalize these seemingly disparate findings is that httNT exists as a random coil, transiently 
sampling helical states, which are stabilized under certain conditions like inter-molecular 
interactions or upon binding partners. Not surprisingly therefore, algorithms based on primary 
sequence analysis have identified httNT to belong to the larger group of MoRFs (molecular 
recognition features) which are typically compact coils in solution lacking any stable secondary 
structure but often adopt a α-helical conformation upon binding their interacting partners (31). 
Experimental support for this hypothesis comes from the X-ray diffraction studies by Kim et al 
which (80) showed that httNT  adopts a helical conformation under crystallization conditions and 
also from the concentration dependence of helicity in the httNT  sequence as assessed by circular 
dichroism (100). Overall, these findings are consistent with the idea that httNT though disordered 
at lower concentrations does have substantive helical propensities which are stabilized at high 
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concentrations. This “disorder to order” transition is particularly relevant to the aggregation of 
htt, as discussed below.  
Tetrameric assemblies of htt in solution.  A discussion of the solution structure of a protein has to 
also account for any evidence of quaternary structure. Recent studies have found evidence for the 
ability for httNT to exist in equilibrium between monomeric, tetrameric and higher order 
oligomeric forms (100). Some cellular studies with green-fluorescence protein tagged htt exon-1 
have also observed the existence of oligomeric species in the pentameric to nonameric range 
(105). While the formation of a tetramer/multimer (100) might be an early step in the 
aggregation pathway of htt (discussed below), it is also likely that htt (or its fragments) can exist 
in solution in a tetrameric state. At the very least, the formation of such multimeric species 
circumvents the energetic penalties associated with the exposure of hydrophobic residues to the 
solvent as would be expected for a disordered sequence. A closer examination of the association 
states of htt in solution could yield some interesting insights into the structural facets of HD 
pathology and will be a major area of focus in the field in the future. 
1.5 AGGREGATION OF HTT FRAGMENTS. 
1.5.1 Aggregation of htt fragments: Role in HD. 
Initially proposed as a mechanism to explain the neurodegeneration observed in HD 
(106), the case for a role of protein misfolding and/or aggregation in HD pathology was 
strengthened by the observation of neuronal intra-nuclear inclusions (NIIs) of htt fragments in tg 
HD mice (106) and subsequently in post-mortem HD brains (2). The polyQ dependence of NII 
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studies have delineated a toxic role for final aggregates. For instance, the formation of inclusion 
bodies in cells expressing htt was observed to correlate with cell death (114, 116). Similarly, the 
specific delivery of aggregates into the nucleus was observed to promote cell-death (115). 
Consistent with such a toxic role for aggregates in cellular models of HD, are observations of 
correlations between aggregate formation and appearance of HD phenotypes in a tg mouse 
model. On the other hand, there is also some evidence for a neuroprotective role for aggregates. 
For instance, studies with tg mice expressing a mutant htt N –terminal fragment that formed 
inclusions but did not give rise to any HD like phenotype argue against a toxic role of inclusions 
(117). Similarly, it has also been postulated that aggregates can play a neuroprotective role by 
simulating the autophagic clearance of mutant htt (118). As an additional level of complexity, 
there is a growing body of evidence that suggests that aggregation intermediates (like monomers 
(99, 108) or oligomers (111, 119)) and perhaps even a misfolded monomer (96) might be toxic to 
cells (Fig 1-3). In fact, as the subsequent sections will indicate, the aggregation of htt fragments 
exhibits substantial diversity in terms of aggregation intermediates, aggregation pathways and 
response to PTMs and other cellular conditions. This diversity might explain the seemingly 
paradoxical viewpoints on the role of htt aggregation in HD pathology. Nevertheless, while the 
finer details of the relationship between htt aggregation and HD pathology get worked out, it has 
now become clear that a study of htt misfolding and aggregation is crucial to our understanding 
of the disease.  
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1.5.2 Aggregation mechanisms in vitro.  
1.5.2.1 Aggregation of polyQ sequences. 
Since the polyQ stretch in htt is directly linked to the occurrence of HD, most studies 
have focused on examining the aggregation properties of simple polyQ peptides. The study of 
aggregation of the simple polyQ repeats also assumes particular significance in the light of the 
finding that under certain conditions polyQ containing htt fragments can aggregate via a pathway 
that is entirely driven by their polyQ segments (120). Most studies of polyQ aggregation 
typically incorporate a few residues (like lysines) adjacent to the polyQ stretch to overcome the 
insolubility inherent to polyQ sequences (89, 121). Using synthetic peptides of the form K2QnK2, 
the lab had earlier shown that aggregation of polyQ peptides in vitro is directly correlated to the 
polyQ length. The aggregation of these peptides proceeds through a random-coil to beta-sheet 
transition during aggregation, ending up in beta-sheet rich amyloid fibrils (122).  
Most aggregating systems are associated with a nucleation step, the rate-limiting step in 
the aggregation pathway that is concurrent with the formation of the nucleus, an unstable, 
experimentally inaccessible species on the aggregation pathway. The presence of such a 
nucleation phase in the aggregation pathway can be discerned by studying the dependence of 
aggregation rates on the concentration of the protein/peptide. A study of the concentration 
dependence of initial aggregation rates of K2QnK2 peptides identified a nucleated growth 
mechanism underlying aggregation of these peptides (122). However, there exist subtleties in the 
nucleation step in the aggregation of polyQ peptides of different lengths. Thus, while K2Q18K2 
and K2Q23K2 peptides aggregate through the formation of a tetrameric nucleus, K2Q24K2 and 
K2Q25K2 peptides aggregate through a dimeric nucleus whereas K2Q26K2 (and peptides with 
higher polyQ repeat lengths) aggregate via a monomeric nucleus (121). This relationship 
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The nucleus, by definition, is highly unstable and hence inaccessible to most 
experimental studies. It has been suggested, that the nucleus in polyQ aggregation is a transiently 
populated β-sheet structure (122). At smaller polyQ repeat lengths, multiple molecules are 
required to form a stable nucleus, hence the formation of tetrameric and dimeric nuclei. As the 
polyQ repeat length increases, the monomers can themselves form stable beta-rich structures 
(Fig 1-5.B, g).  Such a scheme is supported by studies that incorporate D-Pro-Gly sequence 
within a polyQ context, to favor the formation of β-hairpins, which showed that such peptides 
aggregate faster than a peptide of identical polyQ repeat length without the D-Pro-Gly 
interruption (123, 124). These studies also add weight to the hypothesis that anti-parallel beta 
structures might be crucially tied to the aggregation of polyQ repeat peptides (refer discussion 
below). 
Another characteristic feature of nucleation driven aggregation is that the rate of 
aggregation can be substantially accelerated by the addition of pre-formed aggregates as seeds, a 
characteristic that is also true of polyQ peptides. This property has been exploited in a biotin 
tagged polyQ recruitment assay that allows for quantification of seeding capacities of aggregates 
and provides crucial thermodynamics of polyQ aggregation (122). Thus, while the ΔGnucl. is -
12kcal/mol for a K2Q47K2 peptide (122), for an equivalent concentration of K2Q23K2 peptide this 
values is ~ -24kcal/mol (121). Two points becomes evident from such an analysis. First, an 
expansion of polyQ makes nucleation of aggregation comparatively more favorable. Second, the 
ΔGnucl (especially for higher polyQ repeats which aggregate via a monomeric nucleus, a process 
that can be compared to an unfavorable folding event) is substantially higher than those of 
typical ΔGfold of proteins ( -5 to -15 kcal/mol) (125) highlighting the ephemeralness of 
nucleation.  
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Overall, the aggregation of polyQ peptides can be described by a nucleated-
polymerization model (Fig 1-5.B). In the monomeric state, polyQ sequences exist in collapsed, 
random-coil conformations (89). The nucleus, thought to be a β-rich structure that can either be 
monomeric or multimeric depending on the polyQ repeat length (121), is in equilibrium with the 
monomer. The nucleus can also indulge in elongation steps presumably by monomer addition, 
consolidating amyloid-like features in stable assemblies. The elongation step has been described 
by invoking a “dock and lock” mechanism whereby an incoming monomer, latches onto the 
growing face of the fibril and re-arranges on the surface presenting a new growing end to 
subsequent monomer additions.  
 
Alternate mechanisms of polyQ aggregation: The nucleated growth pathway described above 
lacks any soluble, non β-sheet rich intermediates (oligomers). However, based on results from 
simulations of polyQ aggregation that suggest the formation of dimeric species (94) and 
amorphous aggregates (126) and based on the observation of oligomeric assemblies of polyQ 
peptides under certain conditions (127), it has been proposed that aggregation of these peptides 
proceeds through nucleation within such oligomeric species. The conversion of these oligomers 
into aggregates has however not been demonstrated, neither experimentally nor computationally, 
due to the rarity and transience of such an event. It is quite likely that these differences viz. 
oligomeric species between different studies stems from the differences in sample preparation 
and handling especially in the light of the fact that polyQ peptides are known to form oligomers 
under certain conditions (128). The importance of growth conditions in the aggregation of polyQ 
peptides is also driven home by the observation that aggregates of polyQ grown at -20oC display 
altered morphologies and seeding properties than those grown at 37 oC (129, 130). Temperature 
 27 
effects on polyglutamine aggregate structure and toxicity have also been observed in other 
studies (131). It is likely that similar to other aggregating systems, polyQ peptides too display 
polymorphisms in aggregate structure/property depending on growth conditions (132). In 
addition to growth conditions, sequence contexts can also affect the aggregation mechanisms and 
aggregate properties of polyQ rich peptides. Thus, a K2Q30K2 peptide with histidine insertions 
(mimicking sequences encoded by the SCA1 gene (133)) aggregates through the formation of 
oligomers at acidic pH (134). Oligomeric intermediates have also been reported in the 
aggregation of polyQ containing htt fragments (see below). Overall, these results underscore the 
complexities of polyglutamine aggregation. Of course, it is possible that inside the cell 
aggregation of polyQ sequences proceeds through either (or even both) of these mechanisms.  
1.5.2.2 Flanking sequences modulate aggregation of htt fragments. 
Sequences flanking the polyQ stretch in htt have been shown to play a crucial role in 
modulating aggregation of polyQ sequences. Initial studies investigating the effects of flanking 
sequences on polyQ aggregation focused on the role of the proline rich C terminal sequence of 
htt exon-1. Addition of a proline sequence to K2QnK2 peptides was also observed to impair  the 
kinetics of (Fig 1-3.A), and destabilize the thermodynamics of, aggregation though it did not 
change the aggregation mechanism (89). Studies with yeast models of HD showed that the 
polyproline stretch in htt exon-1 abrogates polyQ expansion induced toxicity in addition to 
altering aggregate morphologies (32). From a structural stand-point, this “auto-inhibitory” effect 
of polyproline has been explained based on its ability to induce PPII helical conformations in 
glutamines adjacent to it thereby interfering with the tendency of these sequences to form β-sheet 
rich structures (91).  
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Contrary to the inhibitory effect of the flanking proline residues, the addition of the 
seventeen residue N-terminal sequence, httNT, produced a dramatic acceleratory effect on 
aggregation of htt fragments (31, 76). Studies with peptides resembling htt exon-1fragments 
(polyQ containing htt fragments) showed that the httNT sequence accelerates aggregation (Fig 1-
4.A), apparent in the dramatic differences in the initial phases of aggregation. Thus, while polyQ 
peptides display strong concentration dependence in their initial aggregation rates, these htt 
fragments have much shallower concentration dependence (31). At the mechanistic level, this 
difference in initial aggregation is manifested through the rapid formation of oligomers (Fig 1-
4.C) which are believed to serve two crucial roles in the aggregation pathway: a. by 
concentrating polyQ segments locally, these oligomers can act as nucleating centers for the 
stochastic re-arrangement of polyQ chains into nascent amyloid-like structures and b. Oligomers 
that do not go through stochastic nucleation can act as monomer reservoirs, dissociating to 
monomers which can participate in elongation. The httNT sequence by itself is sufficient to form 
oligomers either under high concentrations (135) or after long incubations (136). These 
oligomers are predominantly helical in nature and seem to be formed through the ability of httNT 
to associate into tetramers, octamers and dodecamers in the native state (100). The hydrophobic 
residues have been hypothesized to play a crucial role in oligomerization (31, 76) while the 
polyQ stretch does not seem to be involved in the oligomer structure and remains accessible to 
binding by the polyQ specific MW1 antibody (31). Stochastic nucleation within these oligomers 
is believed to drive aggregate formation, presumably through monomer addition, forming fibril 
like structures (Fig 1-3.G) that display features characteristic of amyloid including ThT binding, 
seeding competence and β-sheet rich FTIR spectra (31) though they are morphologically 
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different from the final aggregates formed by simple polyQ peptides (Fig 1-3. H). This httNT 
mediated aggregation of polyQ containing htt fragments is also crucially linked to the glutamine 
repeat length with longer repeat lengths associated with faster aggregation kinetics (Fig 1-4.B). 
While, it has been suggested that polyQ expansion can alter monomeric conformations of polyQ 
containing htt fragments (31, 100), it is also quite likely that increasing the polyQ repeat length 
affects other stages of pathway including oligomerization, nucleation and/or elongation. While 
the point can be made that such peptide models do not accurately reflect the aggregation 
properties of htt exon-1, the lab has found that mechanistic features in play in the aggregation of 
such polyQ containing htt fragments are also largely conserved in the aggregation of chemically 
synthesized htt exon-1 (Sahoo et al, manuscript in preparation). 
The aggregation enhancing role of httNT both in vitro and in vivo (28, 76, 137) has also 
been observed in several independent studies though different aggregation mechanisms to 
explain this acceleratory role have been posited. Thus, based on the ability of the httNT sequence 
to interact with the polyQ stretch, it has been suggested that the sequence promotes an 
amyloidogenic conformation within the polyQ stretch that can grow into amyloid aggregates 
(76). The ability of the httNT sequence to accelerate the aggregation of a Q51 fragment in trans 
was cited in support of such a model (76) though similar experiments in other systems do not 
yield similar results (138).  It has also been suggested, based on some experimental (139) and 
computational (140) results, that oligomers of polyQ containing htt fragments are held together 
primarily by polyQ interactions though the results of other computational studies (95) suggest 
that initial aggregation (in as much as dimerization can be used as an indicator of aggregation) of 
polyQ containing htt fragments is mediated by httNT.  
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Cellular implications of aggregation: In the light of the crucial role that httNT plays in the 
aggregation of polyQ containing htt fragments, it can be reasoned that cellular conditions that 
selectively target this sequence can affect aggregation as well. One such trigger can be post-
translational modifications within the httNT sequence (Fig 1-1). Thus, mutation of the two Ser 
residues at positions 13 and 16 within httNT to Asp to mimic phosphorylation completely 
abrogated aggregation and neurodegeneration in a tg mice. In vitro studies of a httNT Q37P10K2 
peptide with an identical mutation showed that this mutation serves to impair aggregation 
kinetics and alter final aggregate morphology (16). In another case, phosphorylation of the lone 
threonine residue in httNT was observed to alter aggregation of htt exon-1 in vivo and reduce 
lethality in a drosophila model of HD (17). 
While, the aggregation of polyQ containing htt fragments is substantially different from 
that of polyQ-only sequences, recent evidence suggests that polyQ containing htt fragments can 
also aggregate through the nucleation growth pathway that is observed with simple polyQ 
sequences (Fig 1-4.B). However, this pathway is strongly disfavored kinetically and has thus far 
been observed only when the oligomer-driven pathway is blocked (for example with inhibitors, 
see below). It is possible that a similar situation exists inside the cell with htt exon-1 fragments 
retaining the ability to form different aggregates under different cellular conditions. For instance, 
there have been examples of osmolytes changing the final aggregation products of htt exon-1 
(141). In fact, the presence of multiple pathways of htt fragments that can be activated 
selectively under different conditions (or triggers) might underlie the observation that different 
polyQ aggregates with different toxicities (131).  
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1.5.3  Structural features of aggregates.  
Aggregates formed by both polyQ peptides and polyQ containing htt fragments display 
the characteristic β-sheet signature typified by amyloid fibrils in CD, FTIR, X-ray and ssNMR 
studies (31, 136, 142). One of the earliest structural models for aggregates proposed a β-helical 
structure for polyQ sequences (143). While, there is some support for such models, both 
experimental (144) and computational (126, 145-147), the current view seems to slant towards a 
more conventional, slab-like (142, 148)  β-structure in aggregates. While, there have been some 
reports of a parallel orientation of β-sheets in polyQ aggregates (149, 150), the consensus view 
seems to favor an anti-parallel conformation. Early evidence for an anti-parallel β-sheet 
conformation adopted by polyQ sequences in final aggregates came from studies with synthetic 
polyQ constructs rationally designed to stabilize anti-parallel conformation. Thus, synthetic 
polyQ peptides with DPro-Gly interruptions (that favor β-turn but destabilize extended strands) 
were observed to aggregate with similar kinetics and form morphologically similar aggregates as 
equivalent polyQ peptides without interruptions (123).  Subsequently, the case for an anti-
parallel arrangement of β-strands in polyQ aggregates was strengthened by the results from high-
resolution structural techniques. Both ssNMR (151) and X-ray fiber diffraction studies of final 
aggregates formed by synthetic polyQ peptides indicate an anti-parallel β-sheet aggregate 
structure (142, 148).   
The propensity of polyQ sequences to adopt anti-parallel β-sheet conformations in 
aggregates of simple polyQ peptides is also maintained in aggregates of polyQ containing htt 
fragments. Thus, ssNMR analysis of final aggregates of polyQ containing htt fragments indicated 
that the polyQ core in both “simple” polyQ peptides and in polyQ containing htt fragments are 
spectroscopically identical, most probably in an anti-parallel β-sheet conformation. Interestingly, 
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polyQ sequences in aggregates of both simple polyQ peptides (151) and polyQ containing htt-
fragments (136) indicate that glutamine residues are present in two conformations, the structural 
basis of which is not entirely understood. Surprisingly, the major portion of the httNT segment is 
present in an α-helical conformation even in the final aggregates highlighting the strong 
preference of this sequence to adopt helical conformations. The transition from the β-sheet 
conformation adopted by polyQ to the α-helical conformation occurs towards the C-terminal end 
of the httNT sequence with both S16 and F17 adopting β-sheet conformations in the final fibrils. 
The proline residues adopt a PPII helical conformation in the aggregates (96) and are probably 
not involved in the aggregate core (31). 
Given their potential role in HD pathology (see below), it becomes all the more important 
to gain structural insights into the organization of aggregation intermediates of polyQ containing 
htt fragments. While the transience of these species makes their study challenging, the use of htt 
peptides with shorter polyQ repeats has allowed us to glean some structural insights. Thus, httNT 
when incubated at high concentrations forms oligomers that display predominantly α-helical 
spectra (Fig 1-6.A). 
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1.5.4 Inhibitors of aggregation.  
In the light of the potentially toxic role that htt aggregation plays in HD pathology, 
considerable efforts have been directed towards the identification of aggregation inhibitors that 
might ameliorate disease phenotype. In addition to their potential significance as therapeutics, 
aggregation inhibitors are also useful reagents that can considerably add to our understanding of 
htt aggregation and its role in HD pathology. Based on their chemical structures, inhibitors of htt 
aggregation can be grouped into two classes: small molecule inhibitors and peptide/protein based 
inhibitors.   
1.5.4.1 Small-molecule inhibitors of aggregation.  
A wide range of small-molecule inhibitors with diverse chemical structures have thus far 
been identified as inhibitors of htt aggregation. Using an automated filter-trap assay to quantify 
aggregates, Heiser et al identified benzothioazoles as polyglutamine aggregation inhibitors 
reducing the amount of SDS insoluble (fibrillar) aggregates with IC50 values in the micromolar 
range. Some of these molecules were also identified to be potent inhibitors of aggregation in vivo 
through a cell-based assay (152) as well as reduce aggregate burden in tg HD mice (153) . A 
similar approach also led to the discovery of the polyphenol (-)-epigallocatechin-3-gallate also 
known as EGCG as an inhibitor of htt aggregation both in vitro and in vivo (154). Inhibition by 
EGCG has been suggested to be mediated through an active redirection of htt aggregation via the 
formation of off-pathway aggregates (oligomers). In addition to filter-trap based analysis of 
aggregates, fluorescence techniques have also been used in identifying other small molecule 
inhibitors of htt aggregation in vivo (155-157) though the exact mechanism of action of such 
molecules remains unknown.  Interestingly, some compounds that are effective in inhibiting htt 
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aggregation in vivo are not as effective in inhibiting the aggregation of simple polyQ sequences 
suggesting the existence of divergent aggregation mechanisms though it is also likely that these 
differences might arise out of different cellular fates of these constructs (like binding for 
instance, Table 1-1) (157). Further studies aimed at delineating the exact mechanism(s) of 
aggregation inhibition are indispensable to our goal to gain a clearer picture of htt aggregation 
and its role in HD pathology.  
1.5.4.2 Peptide/protein based inhibitors of aggregation. 
 In contrast to small-molecule inhibitors, the bases of inhibition of which are obscure in 
most cases, a large number of peptide/protein based inhibitors of htt exon-1 aggregation have 
been identified whose inhibitory actions can be explained from a structural/mechanistic 
standpoint. The target binding site of these peptide/protein inhibitors span the entire sequence of 
htt exon-1 but can broadly be grouped into the three sequence domains described above i.e the 
httNT sequence, the polyQ stretch and the C-terminal polyPro region.  
 
Inhibitors targeting polyQ sequence: Using a phage-display strategy, Nagai et al identified a 
tryptophan-rich peptide, QBP1, as an inhibitor of polyQ aggregation both in vitro (158) as well 
as in vivo (159, 160). Subsequent, structure-function studies (161) and sequence optimization 
studies (162) showed the importance of the tryptophan core in these peptides that contribute to 
the stability of the binding of these peptides (Kd ~5µM) in addition to stereospecificity of these 
interactions (161).  Even though the QBP1 peptide itself lacks any stable secondary structure 
(161) the mechanism of inhibition is believed to be based on its ability to bind a β-sheet rich 
monomer populated at high polyQ repeat lengths (Fig 1-7.A) (97).  The elongation step in polyQ 
aggregation is characterized by two successive events, binding of the incoming monomer to the 
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fibril/nuclei (dock) and subsequent re-arrangement of this monomer to present a new growth 
surface for the next round of elongation (lock). Exploiting the destabilizing effect of proline 
residues on β-sheet structures, a class of inhibitors have been designed that though capable of 
binding the growth face of a fibril (i.e docking) are incapable of the conformational 
rearrangement required to elongate the bound fibril ( i.e incapable of locking) because of the 
strategic positioning of proline residues in the middle of the β-strand at the new growth face. 
Such hybrid polyQ-polyPro inhibitors reversibly inhibit polyQ aggregation (IC50 ~1µM) both in 
vitro and in vivo (163).   
The presence of side-chains with H-bonding potential has often been cited to explain the 
high aggregation propensities of  polyQ peptides (164). Thus, it is to be expected that impairing 
the ability of the side-chains to participate in hydrogen bonds can substantially impair 
aggregation of polyQ sequences. Using peptides that have alternately N-methylated glutamine 
side-chains, Lanning et al were able to demonstrate substantial reduction of in vitro aggregation 
of polyQ rich constructs presumably by interfering with the nucleation/elongation mechanism 
(165).  
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Inhibitors targeting httNT mediated aggregation. As was described above, httNT is crucial to the 
aggregation of polyQ containing htt fragments. Thus, peptide/proteins that can bind and hence 
sequester the httNT sequence might be expected to inhibit httNT mediated aggregation. A direct 
significance of such sequestration based inhibition might be the ability of cellular chaperones to 
impair aggregation or redirect aggregation pathway by binding this sequence as has been 
reported in the case of the Hsp chaperone system (139). In fact, the httNT sequence has been 
shown to be the primary binding site of the chaperonin TRic to htt exon-1 (76). As an extension 
of this notion, the single domain VL(12.3)  intrabody, that reduces in vivo htt aggregation and 
rescues neuronal toxicity (166), was shown to bind a helical conformation of the httNT .  
The primary role of the httNT sequence in the aggregation of polyQ containing htt 
fragments is to mediate the formation of oligomers that can act as centers for stochastic 
nucleation of amyloid structure within polyQ fragments. Expectedly therefore, a class of peptide 
inhibitors have been identified that can inhibit aggregation of polyQ containing htt fragments 
based on their ability to form co-oligomers. Thus, the addition of httNT (and variants) in trans, 
inhibits aggregation of polyQ containing htt fragments presumably based on its propensity to 
form amphipathic helices within mixed oligomers (Fig 1-7.B) of the substrate and inhibitor 
(138). However, these inhibitors only delay, instead of abrogating, nucleation by reducing the 
local concentration of polyQ segments which probably explains the incomplete nature of such 
inhibition. On the other hand, a hybrid inhibitor that contains both the httNT and the polyQ-
elongation inhibitory sequence (PGQ9P1,2,3) completely blocks nucleation within these oligomers 
(Fig 1-7.C) (138).  
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Intrabodies targeting polyPro sequences. The polyproline tract has been demonstrated be crucial 
for both protein binding (Table 1-1) and for destabilizing aggregate formation both in vitro (89) 
and in vivo (32). Intrabodies targeting either the polyPro sequence or the proline-rich sequence in 
the C terminal region of htt exon-1 have been observed to have anti-aggregation and anti-toxicity 
roles in vivo which are believed to be mediated by an increased turnover of the soluble form of 
htt exon-1 (167). Such antibody mediated preferential turnover of mutant htt exon-1 over the 
wild-type presents yet another potential avenue of therapeutic intervention in HD.  
1.5.4.3 Aggregation of htt in vivo. 
High resolution electron micrographs of tissues from brains of post-mortem HD patients 
and tg HD mice often resemble fibril-like structures that are reported in the aggregation of htt 
fragments in vitro (2, 168). A more recent study that uses an amphipathic polymeric ligand to 
identify and isolate aggregates from the brains of HD mice has also been able to capture 
aggregation intermediates in addition to final fibrils which resemble oligomeric and protofibrillar 
species observed in vitro in the aggregation of htt fragments (Fig 1-4 E,F). In addition, to 
morphological similarities with fibrils grown in vitro, htt aggregates grown in vivo also display 
additional amyloid-like characteristics including Congo-red birefringence (169) and the ability to 
bind polyQ-biotin in a recruitment stain that is based on an amyloid-specific elongation 
mechanism (170). Overall, these results suggest that aggregates of htt in vivo do end up in fibril-
like structures, possibly through intermediates similar to those observed in vitro. 
In addition to such morphological assessments of aggregates, a major focus of recent 
studies has also been to look at the mechanisms and intermediates of aggregation in vivo. Using 
fluorescence and size-fractionation based techniques, a large number of studies have identified 
the presence of oligomeric species in cells ranging in sizes from  5-15 monomers (111, 171, 172) 
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to ~80 monomers (110). Interestingly, hetero-oligomers of wt and mutant htt exon-1 have been 
observed in vivo (171) consistent with in vitro studies that posit such hetero-oligomerization 
based on interactions within httNT (138). In addition to oligomeric species, larger inclusion 
bodies have also been the focus of several biophysical studies (110) (172). Such large inclusions, 
rich in β-sheet aggregates (106), are believed to form after a nucleation event (172).  As more 
studies are conducted to look into htt aggregation in vivo, one hopes that we will be able to 
clarify the finer structural aspects of these and other aggregate species and their role in mediating 
HD pathology.  
1.6 CONCLUSIONS. 
The polyQ stretch in htt is the primary locus of HD pathology. However, despite their 
relatively monotonous appearance, polyQ sequences display considerable diversity in both their 
solution and aggregation properties. While, the results from a variety of experimental and 
computational techniques have considerably improved our understanding of the solution 
properties of polyQ peptides, it is increasingly becoming clear that the aggregation of these 
seemingly monotonous sequences is not as simple as previously thought. In addition to the repeat 
length expansion effects, polyQ aggregation is also intricately tied to a horde of other factors not 
the least of which is the chemical environment surrounding these sequences. Thus, the existence 
of divergent views of aggregation mechanisms of these sequences probably stems from the 
polymorphisms inherent in polyQ aggregation. It also raises the possibility of the existence of a 
multitude of aggregation mechanisms in vivo modulated perhaps by cellular localization and the 
presence of binding partners. The development of new reagents and techniques that can 
 42 
distinguish between such subtle differences in aggregation will thus have to be a major focus of 
research in the field.  
PolyQ expansion is the shared molecular trigger in at least nine neurodegenerative 
diseases and yet there exist substantial differences in the pathologies and manifestations of these 
diseases. It is now becoming clear that these differences can be explained, at least in part, based 
on the differences in sequence contexts. A major milestone in HD research over the past decade 
has been the identification of the crucial role that sequences flanking the polyQ stretch in 
huntingtin play in modulating its aggregation and associated toxicity. In addition to directly 
modulating aggregation, these flanking sequences are also sites of crucial interactions, 
interactions that span a wide-range of cellular processes and functions. Thus, while aggregation 
can lead to a potentially toxic “gain-of-function”, it could also precipitate HD pathology through 
the loss of an essential function. It is quite likely that cellular fate of htt is ultimately decided by 
the winner of this tug-of-war between aggregation and normal cellular function.  
The use of peptide and protein models has been indispensable to our understanding of the 
biophysical and structural drivers of htt aggregation. However, it is possible, and especially so in 
the light of the observed polymorphisms in aggregation, that that the aggregation of htt in the cell 
is more complicated than that observed in vitro. While, our ability to study aggregation of htt in 
vivo has thus far been impaired by experimental constraints, the discovery of new reagents that 
can distinguish between aggregates and the application of techniques/strategies such as in vivo 
FRET, split-GFP fluorescence and AUC of cellular constituents present the possibility of 
gleaning some crucial insights into in vivo aggregation of htt and its eventual role in HD 
pathology.  
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2.0  INTRODUCTION (II): PRELIMINARY STUDIES 
2.1 BACKGROUND. 
The purpose of this chapter is to review some of the preliminary results that have aided 
the development of the hypotheses that the subsequent chapters aim to address. The work 
presented here includes some of my own results along with results that have stemmed from 
collaborations with other members of the lab (and work of other interns that I have supervised 
and directed).  
2.2 INTRODUCTION. 
Protein misfolding and aggregation has been hypothesized to play a crucial role in 
mediating the pathology of HD. While it is still unclear whether the relationship of protein 
aggregation to HD pathology is one of causality, consequence, or both, the importance of a 
detailed study of htt aggregation (and its driving forces) to our understanding of HD cannot be 
understated. The crux of this thesis has thus been to identify the biophysical driving forces and 
glean mechanistic insights into the aggregation of htt fragments.  
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Htt exon-1 is the smallest fragment of htt that has been reported to be capable of inducing 
HD pathology (173, 174). However, the size of this fragment and its propensity to aggregate 
make the study of its aggregation particularly challenging. Our method of circumventing these 
challenges is based on the use of chemically synthesized peptide mimetics of htt exon-1 (referred 
to as polyQ containing htt fragments). These peptides differ from the htt exon-1 in that they 
contain a short polyPro instead of the entire sequence C-terminal to the polyQ segment in htt 
exon-1. This approach can be rationalized on multiple grounds: 
a. We have thus far not seen any qualitative differences between the aggregation of  polyQ 
containing htt fragments and the htt exon-, either chemically synthesized (B.Sahoo et al, 
unpublished) or biosynthetic (112, 113)  
b. The size of the htt “toxic fragment” is not clearly known. While the sufficiency of htt exon-1 
for eliciting a HD phenotype is known, theoretically it is possible that shorter fragments can 
elicit a similar response as well.  
c. Unlike other methods of working with htt exon-1, the use of chemically synthesized fragments 
(when used in conjunction with the dis-aggregation protocol, Chapter 2) has the advantage of 
removing any pre-formed (seed) aggregates that might complicate analysis of aggregation.  
 
While the lab has in the past focused, and continues to focus, on examining the 
aggregation of simple polyQ peptides, the work presented in this thesis is almost entirely 
concerned with investigating the aggregation of polyQ containing htt fragments. At the outset of 
this work, this lab (along with others) had just identified a “pro-aggregation” role of the httNT 
sequence. The next few sections delineate some of the preliminary work that has contributed to 
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the overall understanding of the aggregation of polyQ containing htt fragments and that forms 
the basis to the work presented in subsequent chapters.  
2.3 RESULTS. 
2.3.1 Aggregation of polyQ containing htt fragments.  
While the polyQ stretch is directly linked to HD pathology, this stretch is also flanked by 
other sequences that might have an effect on its aggregation. Earlier, the lab had showed that the 
polyproline stretch C-terminal to the htt sequence acts an “auto-inhibitor” of aggregation though 
it does not alter the aggregation mechanism. On the other hand, studies from the lab had found 
that the addition of the httNT sequence to polyQ (or polyQ-Pro) peptides dramatically accelerates 
the rates of aggregation (31).  
Thus, the aggregation of a httNTQ37P10K2 peptide (Fig 2-1.A, ●) is substantially faster 
than an equivalent concentration of the MF-Q37P10K2 (Fig 2-1.A, ○) (120). In addition to altering 
aggregation kinetics, addition of httNT also alters the properties of final aggregates which are 
morphologically different from those of polyQ peptides (Fig 2-2 G vs. B) (31). More 
importantly, we have seen evidence for the formation of oligomeric species during aggregation 
(Fig 2-2. C, D) (31), something that is not observed in the aggregation of simple polyQ peptides 
under similar conditions (121). Finally, the aggregation rates of these polyQ containing htt 
fragments, in spite of the strong httNT effect, are also directly modulated by the length of the 
corresponding polyQ stretch (Fig 2-1.A), consistent with the reported effects of polyQ expansion 
on aggregation propensities in simple polyQ peptides (88).  
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In contrast, at higher concentrations, the CD spectrum changes to a predominantly α-
helical one (Fig 2-4.A,▬ ) (100). This transition from a random-coil to α-helical spectrum is 
most likely due to a reversible association event since dilution of a high concentration sample, 
with a predominantly helical spectrum, (Fig 2-4,▬) reverts the CD spectrum back to one that is 
predominantly random-coil (Fig 2-4,▬). Furthermore, the DLS signatures and the morphologies 
of species populated at high concentrations are consistent with oligomers (Fig 2-4.B and 2-2. D). 
An analysis of the concentration dependence of helicity indicates that the mid-point of transition 
between random-coil to α-helix occurs at ~430µM (Chapter 5). Overall, these results are 
consistent with results from the analytical ultracentrifugation studies that indicate that 
monomeric httNT is in equilibrium with tetramers, octamers and higher-order oligomeric species 
(Fig 1-2.D) (100). The characterization of the biophysical driving forces of httNT mediated 
oligomerization form a crucial aspect of the work presented here (Chapters 5,6 and 7).  
In addition to employing these low-resolution structural techniques to the study of httNT 
tetramers and other higher-order oligomers, we also tried characterizing these species by NMR 
spectroscopy. Unfortunately however, we did not observe any major difference in the 1-D NMR 
spectra of httNTQ at high concentration and a similar httNT peptide at a lower concentration 
though the httNTQ peptide did display substantial signal broadening consistent with the presence 
of oligomeric species at high concentrations (Fig 2-2.D and Fig 2-4.B). The only differences we 
observed were a shift in the methyl positions (from ~0.85ppm to ~0.71ppm) and a shift in the 
backbone amide HN peak of Leu4 (from 8.47ppm to 8.52ppm). The line broadening and the 
resonance shift exhibited by the spectrum of httNTQ is probably indicative of exchange between 
monomer and oligomers.  
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Name Sequence Alpha Helical Contenta 
NT
17
Q MATLEKLMKAFESLKSFQ 4.31
NT
17
Q #1 TMMKFQLLKSAEEKLFAS 0.69
NT
17
Q #2 MLSLKESAKMFFATKELQ 0.47
NT
17
Q #3 KQFTLEMAFLSKALSEMK 1.70
NT
17
Q #4 KLAFMLKQAELSSEKTFM 0.57
NT
17
Q #5 FAKFASEKKLESMTLMLQ 0.55
NT
17
Q #6 MLTFAEFKSMELKSQLAK 1.10
NT
17
Q #7 ASMFEAQLSKEKKMFTLL 1.58
NT
17
Q #8 ELLAKSEQAKSMLFTFMK 0.58
NT
17
Q #9 TKFSSFALLAQKEMLKME 1.29
NT
17
Q #10 ETLKMSMFLEAQFKKSAL 1.30
NT
17
Q #11 ASSQKKMKEMLAFFTLEL 2.84
NT
17
Q #12 MFSKMAKSLFLLAEKTQE 1.07
NT
17
Q #13 KLELKAASQMEFSFTMKL 0.39
NT
17
Q #14 KELKQELFFKASATLMMS 0.71
NT
17
Q #15 SAFMEKMLLLEKQFKAST 15.10
 
Table 2-1: Scrambled httNT sequences. Shown are the 15 scrambled sequences that were assessed for their abilities 
to inhibit aggregation of a httNTQ30P6K2 peptide. Also shown are the theoretical helical propensities of these 
sequences. a. Helical contents were calculated using AGADIR program. 
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(R2=0.8) between these two parameters implicates a potential role of helicity in httNT mediated 
inhibition.  
The adoption of an α-helical conformation by httNT also confers a certain degree of 
amphipathicity that stems from an optimal arrangement of polar and non-polar residues. 
Theoretically, this amphipathicity can be computed for a helical sequence by computing its 
hydrophobic moment (<µH>) (177, 178). Interestingly, a plot of <µH> versus the t1/2 of 
inhibition (Fig 2-8.B) gave a robust correlation of (R2=0.9) though this correlation drops to a R2 
of 0.7 upon normalizing the <µH> values by the actual helical propensities of these peptides, 
calculated by CD spectroscopy (Fig 2-8.C). It is possible that this drop in correlation is because 
of the experimental uncertainties in predicting helical propensities of disordered peptides and/or 
because of the inaccuracy of helical propensities in the monomeric ensemble in predicting 
inhibitory potential. Also worth noting is that in all these analyses, the httNT consistently ranks as 
the most potent sequence both in terms of amphipathic helix potential as well as inhibitory 
activity (Fig 2-8,●).   
Overall, these results in conjunction with our prior results from D-httNT and the RI-httNT, 
the propensity of the httNT sequences to interact in trans through helical interactions (80) and the 
structural details of httNT oligomers (Fig 2-3) (100) suggest that amphipathic helicity within httNT 
is crucial to inhibition. Since both aggregation and inhibition are hypothesized to proceed 
through the formation of oligomers held together by interactions within httNT, it can be argued 
that the formation of amphipathic helicity is crucial to the aggregation of polyQ containing htt 
fragments, a hypothesis that is addressed in greater detail in Chapters 4 and 5.  
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2.4 THESIS FOCUS. 
These preliminary results along with other studies from our lab and those of others have 
added considerably to our overall understanding of the aggregation pathway of polyQ containing 
htt fragments, especially the role that httNT plays in orchestrating different stages of this pathway. 
However, several aspects of httNT’s role in mediating the aggregation of polyQ containing htt 
fragments still remain unascertained. Over the next few chapters, we present our efforts in 
addressing some of these questions:  
a. Role of helicity within httNT in polyQ containing htt fragment aggregation. 
httNT’s propensity to adopt a helical conformation has received substantial attention in the 
field. While this sequence is essentially disordered (with some hints of helical structure) in the 
monomeric state (31, 100), there is a definite role for helicity within oligomers and the final 
fibrils (100, 136). Our studies assessing the inhibitory potential of httNT variants identified a role 
for amphipathic helicity in inhibition. Since both inhibition and aggregation proceed through 
oligomers that are mediated by httNT interactions, we hypothesize that amphipathic helicity in 
httNT is also crucial for the aggregation of polyQ containing htt fragments. We test this idea in 
greater detail by using scrambled versions of httNT in polyQ containing htt fragments (Chapter 4) 
and also rationally designed mutations within httNT (Chapter 5). 
 
b. Effect of polyQ expansion on httNT mediated oligomerization of polyQ containing htt 
fragments: 
PolyQ expansion is the fundamental molecular trigger of HD pathology. Thus, assessing 
the effect of polyQ expansion on the aggregation of polyQ containing htt fragments is crucial to 
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our understanding of the role that protein aggregation plays in HD. Within this context, it is 
interesting to explore the inter-dependence (if any) between polyQ expansion and the role of 
httNT in mediating aggregation. There have been some suggestions about the role of the polyQ 
sequence in modulating the conformation of httNT in the monomeric ensemble (31) and/or 
accelerating the subsequent oligomerization stage of the aggregation pathway. We explore these 
hypotheses in further detail in Chapter 7 by looking at the effect of polyQ expansion on the 
monomeric conformational ensemble as well as the energetics of oligomerization of polyQ 
containing htt fragments.  
 
c. Implications of cellular PTMs on httNT mediated aggregation of polyQ containing htt 
fragments. 
In addition to its role in driving the aggregation of polyQ containing htt fragments, the 
httNT sequence has also been implicated in several cellular processes. It is also the site of several 
post-translational modifications (PTMs) that modulate its biological activity. While PTMs have 
traditionally been examined based on their effects on cellular processes, we hypothesize that 
PTMs can affect the httNT mediated aggregation of polyQ containing htt fragments by altering 
the biophysical properties of the httNT sequence. Thus, we assessed the effects of most of the 
reported PTM’s (17) of httNT on the aggregation of poly containing htt fragments (Chapter 5). 
Also, one of these mutations, the phosphorylation of the two serine residues was studied in great 
detail in terms of its effects on different stages of aggregation in the light of the crucial role it 
plays in HD pathology (16) (Chapter 6).  
 
 
 59 
d. Structural insights into putative httNT tetramer.  
httNT mediated oligomerization proceeds through the formation of a tetrameric state. 
Given the crucial role of this putative tetramer to aggregation, we have used our experimental 
data (Chapter 5) to guide modeling efforts based on protein-protein docking to obtain a putative 
structure of the httNT tetramer.  
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3.0  EXPERIMENTAL METHODS 
3.1 PREPARATION OF MATERIAL.  
3.1.1 Peptide Synthesis and Purification. 
All of the peptides used in these studies were synthesized chemically by solid-phase synthesis 
and obtained in crude form. In most cases, the peptides were obtained from the Keck 
Biotechnology Center (http://medicine.yale.edu/keck/ssps/index.aspx) in synthesis scales of 25-
100µM. In certain cases (sequences smaller than 20 residues in length), the peptides were 
obtained from Genscript Inc or from Sigma-Aldrich (PEPscreen). All crude peptides were stored 
at -80○C for future purification.  
Crude peptides were purified using a reverse phase Agilent Zorbax C3 column as 
follows. Crude peptides were dissolved in 100% formic acid (Sigma) for ~2-3 minutes. Prior to 
injection into the reverse phase column the formic acid was diluted to ~20%. Peptides were 
purified in a Biorad Biologic Dual Flow system. The buffer systems used were water (Fisher 
Scientific, HPLC grade) + 0.05% TFA (Sigma) i.e solvent A and acetonitrile (Fisher Scientific, 
HPLC grade) + 0.05% TFA (Sigma) i.e solvent B.  Each purification run was typically preceded 
by a couple of “blank runs” where 20% formic acid was injected, in order to ensure that there 
was no residual peptide bound to the column. During the purification run, the solvents were run 
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at a flow rate of 4ml/min with a gradient system that was specific to the peptide type. Fractions 
were collected using a Biorad fraction collector with a collection volume between 0.5-0.8 ml. 
Based on the absorbance signals at 218nm, fractions corresponding to the major peak were 
identified and their masses determined by mass spectrometry (see below). Pure fractions 
(including fractions with 1-2 glutamine deletions) were then pooled, lyophilized overnight and 
stored at either -20○C or -80○C for future use.  
3.1.2 Disaggregation protocol.  
In order to ensure that the study of aggregation properties was not compromised by the presence 
of pre-formed aggregates, each peptide was subjected to a disaggregation protocol to ensure that 
the starting material for experimental studies is monomeric. This protocol consisted of dissolving 
pure lyophilized peptide in a 1:1 mixture of TFA and HFIP at a peptide concentration of 
~100µg/ml in glass scintillation vials for a period of 12-15 hours (overnight). At the end of this 
period, the solution was distributed across other glass vials (~ 5-10% of volume of vials) and the 
solvents were evaporated under a stream of nitrogen with the help of a commercially available 
manifold (Organomation N-EVAP evaporator, Fisher Scientific) leaving behind a peptide film 
on the walls of the vials. This film is then dissolved in acidic (pH 3) water (0.01% TFA) and 
centrifuged at 100,000 rpm (416640 x g) in an ultracentrifuge (Optima TLX, Beckman) for 2-3 
hours. Subsequently, 60% of the supernatant is removed and used as stock solution for use in 
experiments.  
In certain experiments with httNT and its mutants (for concentration dependence CD 
studies), in order to recover more peptide, a variant of the above protocol was used. Instead of 
dissolving in TFA/HFIP overnight, the lyophilized peptides were directly dissolved in water + 
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0.01% TFA (pH 3) and then centrifuged at 100,000 rpm for 2-3 hours (as above). No major 
changes in the CD spectra were observed with this variation of the protocol.  
3.1.3 Determination of peptide concentrations.  
The determination of peptide concentrations were done by measuring the peak area on a RP-
HPLC system. Any particular sample was first injected into the Agilent C8 column using the in-
built auto-sampler. Elution was monitored by following the absorbance signals through the 
A215nm detector channel and area under the curve calculated using in-built analysis tools for any 
particular peptide.  A standard slope was then used for each peptide to determine the amount of 
peptide injected and by extension, the concentration of peptide. Since different peptides can have 
different extinction coefficients at 215nm, the slope for each peptide was determined separately. 
This was done by first calculating the extinction coefficient for each peptide using the method of 
Kuipers and Gruppen. The calculated slope was then used to determine the concentrations of 4-5 
calibrating samples using an absorbance spectrophotometer. Aliquots of these calibrated samples 
were also simultaneously injected into the RP-HPLC to determine the slope (peak area vs 
amount of peptide injected).  
3.1.4 Isolation and quantification of aggregates. 
Certain experiments require the use of isolated aggregates. In such cases, aggregates were 
isolated by centrifugation at 14,000 rpm (20,817 x g) for 45 mins in eppendorf tubes. The 
supernatant was then separated and the pellet washed with appropriate buffer and centrifuged 
under similar conditions to remove any residual monomer. This step was repeated 1-2 times. The 
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pellet from the last wash was then re-dissolved in an appropriate buffer. In order to determine the 
concentrations of the aggregates used, an aliquot was taken and re-dissolved in formic acid 
(typically ~90% formic acid), incubated for 1-2 hours and then injected into RP-HPLC for 
concentration determination. In addition, in certain cases the concentrations of the aggregates 
were calculated by subtracting the monomer left at any point in the aggregation reaction from the 
starting concentration 
3.1.5 Mass spectrometric determination of peptide masses.  
An Agilent electrospray 1100 mass spectrometer was used to determine the masses of the 
peptides. Any particular sample was first run through the Agilent C8 reverse phase column. The 
masses were determined by using the in-built analysis module.   
3.2 EXPERIMENTAL ANALYSIS OF AGGREGATION.  
3.2.1 Sedimentation assay. 
The sedimentation assay was the primary method used to assess the aggregation propensities of 
the peptides studied in this work. The method comprised of taking aliquots from an ongoing 
reaction at any particular time and centrifuging it at 14,000 rpm on a bench top centrifuge 
(Eppendorf) for 45 minutes and then carefully isolating 50-60% of the supernatant. The 
concentration of peptide in the supernatant is then determined by injection into the RP-HPLC (as 
described above).  
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3.2.2 ThioflavinT binding. 
A characteristic feature of amyloid aggregates is their ability to bind ThioflavinT, a dye, which 
universally binds amyloid structures, binding that is poorly understood structurally. Yet, this 
ability can be utilized to follow amyloid formation and in conjunction with the sedimentation 
assay provide additional information on the aggregation properties. For example, the detection of 
aggregates through the sedimentation assay which at the same time do not bind ThoiflavinT can 
point to the presence of oligomers.   
To quantify Thioflavin T binding, an aliquot (260ul) of an ongoing reaction was taken at 
any particular time, mixed with an excess of ThioflavinT (12ul of 2.5mM stock) and the 
fluorescence measured using a Jobin Spectrofluorimeter. The instrumental parameters are as 
follows (λexc = 445 nm; excitation slit width = 2nm ;  λemm = 489nm ;  slit width = 2nm ).  
The ThioflavinT binding can be quantified were compared in two –different ways. In one 
method, the ThioflavinT binding per ug was determined for different kinds of aggregates in order 
to compare different aggregate.  In the second method, the ThioflavinT binding can be converted 
to a “% aggregation” time-course, by equating a final ThioflavinT signal to equivalent % 
aggregation value based on the sedimentation assay and then re-calibrating early time 
ThioflavinT binding signals as % aggregation values.  
3.2.3 Nucleation kinetics. 
The concentration dependence of early phase of aggregation has historically been used in the lab 
as a probe to distinguish between the nucleated growth and oligomer-mediated aggregation 
mechanisms. In this study, such analysis was employed to ascertain the effect of mutations 
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within the httNT sequence on the aggregation mechanism of htt NTF peptides. The analysis 
hinges on two aspects of aggregation: (a) the linear dependence of aggregation on t2 (time in secs 
squared) which gives the “nucleation rates” and (b) the concentration dependence of the 
nucleation rates calculated.  
As described in detail elsewhere, the integrated equation describing the earlier phases of 
aggregation kinetics is given by: 
߂ ൌ 	1 2ൗ ܬܬ∗ܥ∗ݐଶ 
where Δ is the concentration of monomers that have gone into polymers,J is the 
elongation rate of polymers, J* is the elongation rate of the nucleus, C* the concentration of the 
nucleus and t is the time.  
Making the substitutions J=k+C, J*= k+*C*, C*= Kn*Cn*, where k+ is the forward 
elongation rate constant of the monomers, c is the bulk concentration of monomers,  k+* is the 
elongation rate constant of the nucleus , C* is the concentration of the nucleus, n* is the number 
of monomers per nucleus, and Kn* is the equilibrium constant of the monomer-nucleus 
equilibrium, the equation above reduces to  
߂ ൌ 12݇ା
ଶܭ௡∗	ܿሺ௡∗ାଶሻݐଶ	
Thus a plot of Δ vs t2 gives a slope 
݈ܵ݋݌݁ ൌ 	1 2	ൗ ݇ାଶ	K௡∗	ܿሺ௡∗ାଶሻ 
for any particular starting concentration of monomers under the assumption that the 
elongation rate of the aggregates (k+) and the nucleus (k+*) are identical. Since Csol = Co –Δ 
where Csol is the concentration of soluble monomer and Co is the starting concentration, it 
follows that a plot of Csol vs t2 gives the same slope as above.  
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Also, 
	logሺݏ݈݋݌݁ሻ ൌ ሺ݊∗ ൅ 2ሻ log ܿ ൅ logሺ12 ݇ା
ଶ	ܭ௡∗ሻ 
 it follows that a plot of log (slope) vs log c yields a slope that allows the determination of 
the number of monomers in the nucleus, n*. This values of n* thus calculated allows for the 
comparison of the mechanism underlying the early stages of aggregation across different 
peptides or aggregation conditions.  
Thus, aggregation reactions of different peptides were monitored by the sedimentation 
assay as described and the drop in concentration monitored over time. The concentration vs t2 
from the initial part of reaction (20%-35%) was then fit to the equation above to get the slope. 
The logarithms of the slope thus calculated at different starting concentrations of aggregation 
were then plotted against the logarithm of the corresponding starting concentration to get the 
slope and thus the value of n*.  
 
3.2.4 Circular dichroism Spectroscopy. 
Comparison of monomers: Circular dichroism spectroscopy was used to determine the secondary 
structure of different peptides used in this study. Freshly disaggregated peptides (above) were 
typically made in 10mM Tris buffer (pH 7.4). Far-UV CD spectra were recorded using a Jasco J-
810 spectropolarimeter. Spectra were collected in either a 0.1mm (high concentrations) or 1mm 
cuvette with a resolution of either 0.5nm or 1nm using at a spectral rate of 100nm min-1. Spectra 
were collected and averaged over four scans and corrected for the appropriate buffer.  In certain 
cases, further secondary structure de-convolution was performed using the CONTIN program in 
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the CDPro analysis package (http://lamar.colostate.edu/~sreeram/CDPro) using the SP37 basis 
set (ibasis 5).  
 
Monitoring aggregate formation: Aggregate formation was monitored by making freshly 
disaggregated samples in 10mM PBS (pH 7.4) and collecting the spectra at 37○C at defined 
intervals. Spectra were collected at 1 nm resolution at a rate of 100nm min-1 and corrected for the 
buffer. Secondary structure de-convolution was performed as described above.    
3.2.5 Dynamic Light Scattering. 
All dynamic light scattering measurements (DLS) were done using the DynaPro plate reader 
(Wyatt technology) equipped with a temperature control. The DLS was typically used to follow 
the time-course of aggregation to detect any concomitant oligomer formation. All samples were 
thus filtered with a 20nm syringe filter at the start of the reaction. Then at specific time-intervals, 
a given aliquot of the reaction (~75µl) was transferred into a fresh well of a 384-well microplate 
and the scattering data was recorded. Typically, the measurements were performed at 37○C with 
an acquisition time of 5secs/scan. In each of the experiments, the most representative of all 
collected scans were selected. 
3.2.6 FTIR spectroscopy. 
FTIR of the aggregates (or aggregation intermediates) were performed at a concentration of 
~10mg ml-1. Thus, for shorter polyglutamine repeat length peptides that do not aggregate 
appreciably, the starting concentration was typically in the 1.5mM-2mM range so that enough 
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aggregate could be isolated at the end of the reaction. Aggregates were isolated by centrifugation 
at 20817 x g , washed twice with PBS to remove any residual TFA and then re-dissolved in 4µl 
PBS to get a highly concentrated sludge. Spectra were acquired by then placing this sludge 
between two polished CaF2 windows on an ABB Bomem FTIR instrument by using the in-built 
data acquisition module, BioCell (BioTools, Inc.). The data was acquired by averaging over 400 
scans, at a scan rate of 4 cm-1, at room temperature. The data was also corrected for residual 
buffer absorption. 
3.2.7 Tryptophan fluorescence of aggregates. 
In order to get some structural insights into the conformation of the httNT sequence, some of the 
eptides were synthesized with a F17W mutation. As shown earlier, this mutation does not 
appreciably alter the aggregation (neither kinetics nor the aggregation mechanism) of polyQ 
containing htt fragments (31) .  Aggregates were isolated at different time intervals as described 
above and re-dissolved in PBS. Spectra were recorded in a quartz cuvette by exciting the sample 
at 280nm and monitoring the fluorescence between 290nm and 550nm on a FluoroLog 
spectrofluorometer (Horiba). The wavelength corresponding to the maximal intensity was then 
recorded (λmax Fluor).  
3.2.8 FRET studies of peptide conformations.  
In this study, we used ratiometric FRET to determine the distance between the donor and 
acceptor fluorophores as a proxy for peptide conformations. The donor –acceptor pair used in the 
study was tryptophan (incorporated as a F17W mutation) and EDANS.  
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All fluorescent measurements are performed with a Fluorolog from Horiba Scientific. 
FRET efficiencies are calculated based on a ratio-metric approach on the basis of measured 
donor (ID) and acceptor (IA) fluorescence intensities from the protein tagged with a pair of FRET 
fluorophores.  In the traditional method of FRET efficiency measurement, one requires the 
fluorescence of the donor molecule in the presence and absence of the acceptor as well as an 
accurate determination of concentration. 
However, in ratiometric FRET method, one only requires the fluorescence of the donor 
and acceptor from the same sample(s). The major advantage of this method is the eliminate of 
error due to the measurement of concentration. Additionally, by calculating the quantum yields 
of the donor and acceptor in the protein context, this method allows one to distinguish between 
two possible contributions to measured fluorescence and hence calculated FRET distances: a. the 
actual distance, and b. the quantum yields of the fluorophores and how they may be affected by 
local structure within the protein.  This is particularly relevant in the context of polyQ containing 
htt fragments where we have observed changes in the quantum yields a tryptophan at a particular 
position in httNT depending on other sequence changes (B. Sahoo and R. Wetzel, unpublished).  
In fact, in the ratiometric FRET method, it is required that one knows the quantum yields of the 
fluorophores within the molecular context in which they are placed for the measurement (see 
below).   
The ratiometric FRET method has been used previously in many applications where the 
traditional method may not be feasible. The FRET efficiency is given by 
ܧிோா் ൌ 	 ூಲூಲାఊூವ                                             
where IA and ID are the intensities at the fluorescence-maximum of acceptor and donor 
respectively.  
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Where ߛ is a correction factor that depends on the quantum yields (Φ) of the FRET pair 
and their detection efficiencies (η). 
ߛ ൌ ఎಲథಲఎವథವ                                                   
Since we use the same spectrofluorometer to measure the fluorescence of both donor and 
acceptor, we assume the detection efficiency is same for both donor and acceptor. So the above 
equation can be modified to 
ߛ ൌ థಲథವ      
We determine the quantum yields of both the donor and acceptor using the comparative 
method  described elsewhere (reference). The quantum yield of an unknown fluorophore is given 
by 
߶ ൌ ߶ோ ቀ ௠௠ೃቁ ቀ
௡మ
௡ೃమ
ቁ                                                                
Where m is the slope of the line determined from the plot of the absorbance against the 
integrated fluorescence intensities, R is the reference fluorophore with known quantum yield, and 
n is the refractive index of the solvents. Since the samples are made in same buffer as of the 
reference, the refractive indices are same for both. So Equation 3 reduces to  
߶ ൌ ߶ோ ቀ ௠௠ೃቁ                                                                 
We have used tryptophan and EDANS as the FRET pair for all our studies. We first 
determined the quantum yields of tryptophan in the httNTQ37P10K2(F17W) and 
httNTQ37P10K2(F17W, S13D,S16D) as described in Equation 3a above and using free tryptophan 
as the standard. There was no substantial difference in the quantum yields of the Trp residues in 
these two peptides. Similarly, the quantum yields of EDANS was calculated for the 
httNTQ37P10K2(F17W) peptide using free EDANS as the standard. The quantum yields of both 
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free tryptophan and free EDANS have been determined elsewhere. Since the quantum yield of 
EDANS does not change with the protein context in htt peptides (B.Sahoo and R.W, 
unpublished), we used the quantum yield of the EDANS calculated for the httNTQ37P10K2(F17W) 
peptide for the calculations with the S13D/S16D mutant. The quantum-yields thus computed 
were then used to calculate the correction factor (Eq 2a) which were almost identical for both the 
httNTQ37P10K2(F17W) and httNTQ37P10K2(F17W/ S13D/S16D) peptides ( 4.54 and 4.39 
respectively).  
In order to compute EFRET, monomers of the httNTQ37P10K2(¥/F17W) and 
httNTQ37P10K2(¥/F17W/S13D/S16D) peptides were prepared using the disaggregation procedure 
described in phosphate buffered saline solution at concentrations of ~ 30µM. Emission spectra 
were collected between 290nm-750nm after excitation of sample at 280nm with excitation and 
emission slit-widths of 1nm and 5nm respectively. The intensities of the donor and acceptor at 
the respective maxima were then plugged into Eq 1 to compute EFRET. The EFRET values were 
then used to compute the donor-acceptor distance by using the equation  
ܧிோா் ൌ 11 ൅ ሺ ݎܴ݋ሻ଺
 
where Ro is the Forster’s radius of the EDANS –Trp pair (22A0).  
 
 
 
 72 
3.2.9 Aggregate morphologies by electron microscopy.  
Aggregate morphologies at different stages of aggregation were studied by transmission electron 
microscopy. 5µl of an on-going reaction of any particular peptide of interest was taken at defined 
time-intervals and transferred onto a freshly glow-charged carbon-coated grid, adsorbed for 3-4 
minutes, washed twice with 5µl of deionized water by blotting after which 2µl of 1% (w/v) 
uranyl acetate was added. In order for optimal staining, the uranyl acetate was removed by 
blotting within 2-3 secs and the grid was washed with deionized water again. The grids thus 
prepared were either imaged immediately or were stored for visualization later. Grids were 
imaged on a  a Tecnai T12 microscope (FEI) operating at 120kV and a magnification of 30,000. 
The microscope was equipped with an Ultrascan 1000 CCD camera (Gatan) with a post-column 
magnification of 1.4X.  
3.2.10 Trypsin sensitivity of aggregates. 
The httNT sequence has three trypsin cleavage sites at K6, K9 and K15. Thus the susceptibility of 
different aggregation intermediates (or mutants) to cleavage by trypsin can offer some insights 
into the conformation (and in certain cases dynamics) of the httNT domain in such conditions. For 
trypsin analysis, aggregates at defined time-intervals were isolated and quantified as described 
above. These aggregates were then incubated overnight at a ~25:1 ratio of peptide: trypsin 
(TRSEQZ, Worthington Biochem) in 50mM Tris pH 7.0 at 37○C. The pellet fraction was then 
isolated by centrifugation, washed with 1X Tris, dissolved in formic acid and then run on an 
Agilent 1100 LC-MS system. The A215nm signal was integrated for the cleaved and uncleaved 
peaks and the fractional cleavage was obtained by normalizing the area of the cleaved peak to the 
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total area. The masses of the cleaved fragments were noted and the cut-sites were determined by 
using the Protein Prospector tool online (http://prospector.ucsf.edu/prospector/mshome.htm).  
 
3.2.11 Accessibility of polyQ epitope to MW1 antibody.  
Antibody binding is usually used qualitatively for the detection of presence. However, within 
caveats, accessibility of epitopes to antibody can yield conformational information (albeit 
qualitative) about aggregates. In this study, the accessibility of the polyQ segment to the MW1 
antibody in the context of different mutations and/or aggregation states was probed.  
Aggregates were isolated at defined time-intervals and quantified as above. A specific 
amount of aggregate (typically between 1µg – 3µg) was transferred onto a nitro-cellulose 
membrane with the help of the Bio-Dot apparatus (Biorad. Inc.).  The blot was then blocked with 
TBST (10mM Tris-HCl, 0.1%v/v Tween-20, 150mM NaCl, 0.05% azide) containing 2.5% 
bovine serum albumin (Sigma) for 4-5 hours, washed with TBST thrice and transferred to a 
solution containing 30nM of the MW1 antibody dissolved in TBST and incubated at room –
temperature (with gentle shaking) overnight. Subsequently, the membrane was washed with 
TBST 4-5 times before being incubated with a 1:5000 dilution of a peroxidase conjugate of an 
anti-mouse IgG (Sigma, A4416), made in TBS, for 2-3 hours. At the end of this incubation, the 
blot was washed 4-5 times with TBS and visualized using an enhanced chemiluminescence 
solution (Thermo Scientific SuperSignal West Pico Chemiluminescent Substrate). For qualitative 
comparisons, every time, the polyQ accessibility of a matched concentration of the 
corresponding monomeric peptide was also analyzed.  
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3.2.12 Determination of critical concentrations. 
The critical concentration (Cr) of aggregate formation is an indicator of aggregate stability. An 
aggregation reaction of the peptide of interest was monitored until there was no change in the 
concentration of monomer. This monomer concentration at the end of the forward aggregation 
reaction was measured to obtain the critical concentration. In some cases, we also looked at the 
reversibility of aggregate formation  by taking an aliquot of the aggregation reaction at a later 
time (when the monomer concentration is at equilibrium) and diluting into 1X PBS (0.05% 
azide) such that the total peptide concentration was well-above the Cr (as measured from the 
forward reaction). This was then incubated at 37○C and the monomer concentration monitored 
by sedimentation assay as described above until equilibrium. The final Cr for any particular 
peptide was determined by taking the average of the values obtained from the forward and 
reverse reactions.  
3.2.13 DEER experiments. 
All DEER experiments were performed on a Bruker EleXsys CW/FT X-band ESR spectrometer 
using the Bruker MD5 resonator.  Temperatures were maintained using an Oxford ITC 503 
temperature controller and CF935 dynamic continuous flow cryostat.  Liquid helium was used to 
maintain temperatures at 40 K.  The samples were flash frozen by plunging the capillaries into 
liquid nitrogen cooled propane.   
 The experiments were performed using an observer /2 and  pulse of 16 and 32 ns 
respectively, and a pumping pulse of 12 ns.  The pump pulse was located at the maximum of the 
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nitroxide spectrum with the observer pulse applied at a frequency ~70 MHz higher.  The pump 
pulse began 40 ns before the echo so the zero time could accurately be determined. 
 The experimental data was analyzed using DeerAnalysis2009 in which the background 
(intermolecular signal) was subtracted by fitting to a 3D-homogeneous background model.  The 
background subtracted data was then fit using a single Gaussian distribution.   
3.3 DATA ANALYSIS. 
3.3.1 Curve Fitting. 
All curve fitting was done by using the fitting functions provided by the Sigma Plot 10.0 
software. The choice of the fitting equation was determined based on an understanding of 
aggregation phenomenon as described below.  
All aggregation kinetics of single-peptide systems (i.e aggregation reactions where only 
one peptide was present) were fit with a standard three-exponential decay equation given by : 
ݕ ൌ ݕ݋ ൅ ܽ ∗ ݁ି௕௫ 
ݓ݄݁ݎ݁	ݔ ൌ ݐ݅݉݁	݅݊	݄݋ݑݎݏ	; ݕ ൌ %	݉݋݊݋݉݁ݎ	݀ܽݐܽ 
In the case of inhibition of polyQ containing htt fragments by httNT or related analogs, the 
aggregation profiles of the substrate was described by a sigmoidal three-parameter equation 
݂ ൌ ܽ
1 ൅ ݁ିሺ௫ି௫௢ሻ௕
 
The choice of the sigmoidal function was dictated by our understanding of httNT 
inhibition of polyQ containing htt fragment aggregation which proceeds through a lag-phase as 
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described elsewhere in this thesis. The aggregation of the inhibitor was typically described by an 
exponential decay function as described above. Similarly, inhibition by the elongation inhibitor 
was modeled using the exponential decay function.  
3.3.2 FTIR deconvolution. 
FTIR spectra were collected as described above. The second-derivative of the spectra were then 
obtained by using the inbuilt PROTA software and the minima used to determine the spectral 
components. In certain cases, the relative preponderances of different secondary structural 
elements were determined by using the PeakFit program.  
 
3.4 COMPUTATIONAL METHODS. 
3.4.1 Peptide modeling. 
The initial structures for molecular dynamics simulations and/or molecular docking where 
modeled using the Sybyl7.3 program. In the case of molecular dynamics simulations, the starting 
sequence was modeled as a random coil (unless otherwise mentioned). 
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3.4.2 Theoretical structural calculations on peptides. 
Helical propensities of peptides were determined by using the AGADIR 
(http://agadir.crg.es/agadir.jsp) software that estimates helical propensities based on helix-coil 
transition theory (179-181). Calculations were performed at pH 7.4, 298K and 0.1M ionic 
strength. Hydrophobic moments (182) of different scrambled sequences in Chapter 2 were 
determined using the HeliQuest online server (http://heliquest.ipmc.cnrs.fr/) with a window-size 
of 18.  
3.4.3 Molecular Dynamics Simulation. 
All MD simulations were performed using the GROMACS software package. Starting 
conformations were either modeled using the Sybyl7.3 package or from existing crystal 
structures. Simulations were done using the GROMOS 96 force field with the SPC water model 
to mimic solvent. Excess charges were balanced using counter-ions. Post-solvation, the protein 
was energy minimized using the steepest descent algorithm with parameters as described below. 
The energy-minimized structure was then restrained and equilibrated in water for 50ps before 
setting up the simulation run was setup subsequently for a defined time length. The details of 
these runs are described below. Analysis of the trajectories was performed by using the in-built 
functions in GROMACS. Secondary structure evolution over time was done using the DSSP 
executable and the inbuilt do_dssp function. A detailed tutorial of the simulation setup and 
parameters can be accessed at http://www-personal.umich.edu/~amadi/fwspidr_tutor.pdf.  
 
 78 
3.4.4 Modeling tetramer structure. 
The workflow adopted in the modeling of tetramer structure is shown in Figure 3-1. Briefly, the 
starting helical conformation of httNT was obtained from a previously reported crystal structure 
(80). This was then supplied to the online ClusPro server 
(http://nrc.bu.edu/cluster/cluspro_v1.cgi) (183, 184) to generate tetramer models. Briefly, chain 
A (residues 371-387) of the pdb structure (3IO4.pdb) were supplied to the online ClusPro server 
following which tetrameric models were generated by using the default parameters (DOT, 
distance cut-offs of 5A○). The DOT rigid body docking algorithm produces 20,000 
conformations which is then reduced to 2000 based on electrostatic and desolvation energies 
(1500 structures with stable electrostatics and 500 with stable desolvation). These 2000 
structures are then clustered using the ClusPro algorithm that groups neighbors below the 
selected clustering radius into clusters that are ranked based on the size of such neighbors. Each 
cluster center (the conformation with the maximum number of neighbors) is then CHARMM 
(185) minimized. A detailed description of the procedure is described elsewhere (186). Of the ten 
(default number of clusters) tetrameric models, we did an initial screen that comprised of 
calculating the side-chain solvent accessibilities by using the WHATIF webserver 
(http://swift.cmbi.ru.nl/servers/html/index.html) (187) to identify structures where the major 
hydrophobic residues were buried. Single-point alanine mutations (in addition to the K6, 9,15R) 
were then modeled across each of the four chains in these structures using the Sybyl software 
(ver 7.3) and the side-chains were locally minimized. The energy of the complex was then 
calculated by using the FastContact Server (http://structure.pitt.edu/servers/fastcontact/) (188) by 
summing the contributions of the desolvation and electrostatic components of the associations 
between Chains B,C and Chains A,D of the tetramer.  
  
Figure 3-1: Workflow for httNT tetramer modeling
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4.0   IMPORTANCE OF AMPHIPATHIC HELICITY IN AGGREGATION OF 
POLYQ CONTAINING HTT FRAGMENTS (I): STUDIES WITH SCRAMBLED 
SEQUENCES  
4.1 OVERVIEW.  
 
Using different scrambled versions of the httNT sequence in polyQ containing htt 
fragments, we demonstrate that amphiphathic helix-formation underlies the httNT mediated 
aggregation of htt exon-1fragments. Our results suggest that amphipathic helix formation is 
necessary for initial oligomerization which mediates the observed rate acceleration in 
aggregation upon adding the httNT sequence to polyQ peptides. In addition, the httNT sequence 
seems to have a dual-role in polyQ containing htt fragment aggregation, acting on both the 
oligomerization and subsequent nucleation/elongation phases. Overall, these results add to the 
emerging picture about the role that httNT plays in the aggregation of polyQ containing htt 
fragments and lay the ground-work for a subsequent chapter that details the sequence-
determinants of this role.  
 A
sequence
the forma
in the p
aggregati
has been 
Figure 4-1
formation 
inhibition 
(B) mediat
incomplete
nucleation 
 
s has been 
 to polyQ p
tion of olig
olyQ segme
on mechani
suggested to
: Mechanism
of oligomers 
of aggregation
ed by the httNT
 since oligom
steps of the pa
described in
eptides dram
omeric spec
nt (31, 10
sm is chara
 have subst
 of httNT inhib
(A). This abil
 of polyQ con
 sequences in 
ers that have 
thway.  
4.2 IN
 previous c
atically alte
ies that act a
0). The htt
cterized by 
antial helica
ition.  httNT se
ity to mediate
taining htt fra
the inhibitor (
a lesser numb
81 
TRODUCT
hapters, the
rs the mech
s sites for s
NT sequenc
a mix of hy
l propensity
quence in poly
 oligomerizat
gments presum
blue) and the s
er of the inhi
ION.  
 addition of
anism of ag
tochastic nu
e that lies 
drophobic a
 (29, 31, 104
Q cotnaining 
ion is also be
ably through
ubstrate (gree
bitor molecule
 the sevent
gregation, p
cleation of a
at the core
nd hydroph
).  
htt fragments 
lieved to lie 
the formation 
n). The inhibit
s can proceed
een residue 
rimarily thr
myloid stru
 of this al
ilic residue
(green) mediat
at the core of
of mixed olig
ion is believed
 through stoc
httNT 
ough 
cture 
tered 
s and 
 
es the 
 httNT 
omers 
 to be 
hastic 
 82 
Thus, within oligomers and final fibrils of polyQ containing htt fragments, the httNT 
sequence adopts a helical conformation (135, 136) though the sequence is essentially disordered 
within the monomer. The exact role that this putative helicity plays in the aggregation of htt 
fragments (and on which stage of aggregation) remains to be ascertained. Earlier, we had showed 
that the inhibition of polyQ containing htt fragment aggregation by httNT (and sequence variants 
thereof) seems linked to their ability to form amphipathic helices (Chapter 3). Thus, scrambled 
versions of httNT that have a high tendency to form amphipathic helices (based on their 
hydrophobic moments, <µH>) act as good inhibitors, presumably by presenting a hydrophobic 
interaction surface in co-oligomers with the aggregating substrate. This could also explain the 
inhibitory activity of the all-D and the retro-inverso versions of httNT (Chapter 3). Since 
aggregation inhibition by httNT is believed to occur through the formation of co-oligomers that 
require an amphiphathic helical conformation within httNT, it can be hypothesized that the 
aggregation of polyQ containing htt fragments that occurs through httNT mediated 
oligomerization has similar requirements for amphipathic helicity within httNT (Fig 4-1).  
In order to directly test the role of amphipathic helicity within httNT in the aggregation of 
polyQ containing htt fragments, we decided to replace the httNT sequence in httNTQ30P6K2 
peptides with three of the different scrambled versions of the httNT sequence (shttNT), described 
previously. The three scrambled sequences were so chosen as to factor in both their tendency to 
form amyloid (evinced by their propensity to aggregate at low concentrations) and their ability to 
inhibit, in trans, the aggregation of a control httNTQ30P6K2 substrate (Chapter 3). Based on these 
parameters, we chose three sequences: i. a sequence that has low amyloid propensity and is an 
effective inhibitor, shtt(Olig)+ ii. a sequence that has low amyloid propensity but is not an effective 
inhibitor, shtt(Olig)- and iii. a sequence that has a high amyloid propensity though not an effective 
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inhibitor of httNTQ30P6K2 aggregation, shtt(Amyl)+ (Table 4-1). We then investigated in detail the 
aggregation properties of model httNTQ30P6K2 analogs containing these three different scrambled 
sequences.  
 
Peptide Sequence t1/2 (hrs) <µH> % helix (theoretical) 
httNTQ MATLEKLMKAFESLKSFQ 90 0.398 4.27 
shtt(Olig)+ ASSQKKMKEMLAFFTLEL 80 0.287 2.97 
shtt(Olig)- FAKFASEKKLESMTLMLQ 18 0.092 0.56 
shtt(Amyl)+ SAFMEKMLLLEKQFKAST 9 0.282 15.1 
 
Table 4-1: Details of scrambled sequences.  Shown are the control httNT sequence and its three scrambled variants 
chosen in this study along with other properties such as inhibitory activity (t1/2, hrs), hydrophobic moments (<µH>) 
and theoretical helical propensities of these peptides. The choice of nomenclature is dictated by the underlying 
rationale. Thus, the scrambled httNT sequence that is a good inhibitor is presumed to form co-oligomers with the 
substrate and hence is designated shtt(Olig)+ while the peptide that does not inhibit cannot form such co-oligomers and 
is called shtt(Olig)-. The peptide with a high tendency to form amyloid fibrils is termed shtt(Amyl)+ 
 
Overall, the results of the studies described in this chapter indicate that the aggregation of 
polyQ containing htt fragments is driven primarily by the ability of the httNT sequence to adopt 
amphipathic helical conformations that are crucial for the initial oligomerization of htt 
fragments. 
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other higher-order oligomers (Chapter 2). We thus wanted to assess whether the three scrambled 
sequences display a similar propensity to form helical oligomers by investigating the 
concentration dependence of their CD spectra. Unfortunately however, all our efforts to prepare 
samples of these peptides at high concentrations were futile probably due to loss of material due 
to aggregation (see below).  Nevertheless, an analysis of the CD spectrum and de-convolution of 
the individual contributions of different secondary structural sub-types to the spectrum confirms 
our previous results. Thus, of the three shttNT peptides, the shtt(Olig)+ peptide displayed maximal 
helical propensity (~16%) while the shtt(Olig)- peptide had the least helical propensity (~5%). 
Interestingly, the shtt(Amyl)+ sequence exhibited substantial helical propensity, almost matching 
that of the shtt(Olig)+ peptide, consistent with the high helical propensity predicted for this 
sequence by secondary structure prediction algorithms (Table 4-1). It must be noted that though 
the relative helical propensities of the shtt(Olig)+ and the shtt(Olig)- peptides found here are similar to 
the values determined before, the absolute numbers are slightly different. This difference most 
likely stems from the difference in sampling conditions (use of different cuvettes) and/or from 
the inaccuracy of de-convolution algorithms in predicting the relative percentages of different 
structures in disordered peptides. Overall, these results suggest that both the shtt(Olig)+ and 
shtt(Amyl)+ sequences have an amphipathic helical potential that matches that of the httNT sequence 
(Fig 4-2.B) in the monomeric state whereas the shtt(Olig)+ has negligible amphipathic helical 
potential.  
Our lab had previously demonstrated that httNT when incubated at high concentrations 
forms sedimentable oligomers which display a characteristic helical FTIR spectrum (136) (Fig 4-
3.A). We thus wanted to investigate whether any of these scrambled peptides when incubated at 
high concentrations form similar helical oligomers. We were thus disappointed to find that at 
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structure
 
 
Figure 4-3
▬), shtt(Oli
into contrib
the observ
color schem
cm-1 and 1
 
H
individua
displays 
concentra
centrations,
s (peaks at 1
: FTIR spectr
g)- (B, ▬) and 
utions from in
ed spectra in a
e is same as d
690 cm-1 to β-s
owever, spe
l structural
a pronounc
tions (Fig 4
 all the thre
620 cm-1 an
a of shttNT pe
shtt(Amyl)+ (D, 
dividual struc
ll cases (χ2>0
etailed above
heet, 1635-16
ctral decon
 elements t
ed helical c
-3.B, ~28%
e scramble
d 1695 cm-1
ptides. Aggre
▬) peptides in
tural subtypes
.999). Contribu
. For deconvol
40cm-1 to rand
volution of
hrows up s
omponent in
)  while sim
86 
d peptides 
) (Fig 4-3. B
gates isolated 
cubated at hig
 (dashed lines)
tions from di
ution, we assig
om coil and 16
 the FTIR 
ome interes
 the FTIR 
ilar analysi
aggregate to
-D and E).
by centrifugat
h concentratio
. The theoretic
fferent structu
ned peak at ~
65-1675 cm-1
spectra to p
ting facts. 
spectrum o
s on the shtt
 form β-sh
ion from WT (
ns. All spectr
al fit (dotted l
ral sub-types a
1650cm-1 to α-
 to turns (189)
arse out co
Thus, the 
f aggregate
(Olig)- and sh
eet rich fib
A, ▬), shtt(Oli
a were deconv
ine) was ident
re shown in E
helix, peaks a
.  
ntributions 
shtt(Olig)+ pe
s formed at 
tt(Amyl)+  pep
rillar 
 
g)+ (C, 
oluted 
ical to 
. The 
t 1620 
from 
ptide 
high 
tides 
 87 
displays substantially lower helicity values (~12%-13%).  In comparison, the httNTQ3 peptide 
forms helical oligomers that by the same deconvolution analysis are 50% helical. Of course, 
based on these data it is not possible to ascertain whether these different structural subtypes 
originate from a structurally homogeneous or heterogeneous mix of aggregates. Nevertheless, 
these data do suggest that amongst the three scrambled peptides, the shtt(Olig)+ sequence has the 
maximal tendency to adopt helical conformations, an observation consistent with the CD results 
and its inhibitory effect on aggregation of polyQ containing htt fragments.  
 
4.3.2 Studies with shttNTQ30P6K2 peptides.  
Each of the three scrambled sequences chosen in this study has different biophysical 
properties viz. amphipathic helix forming propensity, inhibitory activity and tendency to 
aggregate (Table 1). We were thus interested in examining how the addition of these scrambled 
httNT variants to a Q30P6K2 peptide affects aggregation so as to better understand the role of the 
httNT sequence in mediating aggregation of polyQ containing htt fragments.  
4.3.2.1 Structural characterization of the monomeric ensemble of shttNTQ30P6K2. 
One of the hypotheses to explain the enhanced aggregation of longer htt fragments 
invokes the presence of a toxic monomeric conformation (96, 131) at longer polyQ lengths. 
While in our system we have thus far not discovered any evidence of such a toxic monomeric 
conformation with polyQ containing htt fragments, it is theoretically possible that the addition of 
shttNT sequences might preferentially stabilize any particular conformation within the monomer. 
We thus set out to look at the CD spectrum of the monomeric ensemble of the shttNTQ30P6K2 
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These differences in the aggregation properties of the scrambled peptides become all the 
more apparent in an analysis of the early-phase of aggregation. Thus, while the shtt(Amyl)+Q30P6K2 
and shtt(Olig)-Q30P6K2 peptide hardly aggregate within the first 20hrs, both the WT and the 
shtt(Olig)+Q30P6K2 peptides display a sharp drop in monomer concentrations within the first 5 hrs 
suggesting these two peptides might behave similarly during the early phases of aggregation.  
A characteristic feature of all amyloid aggregates is their ability to bind the ThioflavinT 
(ThT) dye. Thus, monitoring ThT binding of aggregates during the course of aggregation can 
provide insights into the aggregation that can complement information obtained from 
sedimentation analysis. As shown in Fig 4-5.B, we did not observe any substantial differences in 
the ThT binding of aggregates formed by the shttNTQ30P6K2.peptides suggesting that the relative 
rates of formation of β-rich fibrillar aggregate, the binding target of ThT (190), are similar across 
the three scrambled peptides though substantially slower than that of the WT httNTQ30P6K2 
peptide. However, an analysis of the initial aggregation, as observed by ThT binding, does throw 
up some differences. Thus, a plot of % aggregation calculated from sedimentation assay vs that 
calculated from ThT binding shows that in the initial phase, the ThT based value lags behind the 
one calculated through the sedimentation assay for the WT (●) and the shtt(Olig)+Q30P6K2 (●) 
peptides but not for the shtt(Olig)-Q30P6K2 (▲) and shtt(Amyl)+Q30P6K2 (♦). In the case of the 
httNTQ30P6K2 peptide, this property is believed to originate from the formation of non β-sheet 
oligomeric structures during the early-phases of aggregation which do not bind ThT (31). It is 
possible that a similar mechanism is in play in the case of the shtt (Olig)+Q30P6K2 peptide as well.  
Overall, these results suggest that both the WT and the shtt(Olig)+Q30P6K2 peptides 
aggregate similarly, at least during the early phases of aggregation while the shtt(Olig)-Q30P6K2 and 
the shtt(Amyl)+Q30P6K2 peptides aggregate similar (mechanistically) to a K2Q30P6K2 peptide. 
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morphologies of the aggregates isolated at intermediate stages of aggregation. Thus, the 
shtt(Olig)+Q30P6K2 peptide aggregates through the formation of oligomers (Fig 4-6.J) and proto-
fibrillar intermediates (Fig 4-6.K). On the other hand, the earliest aggregates of the shtt(Olig)-
Q30P6K2 peptide resembled fibrillar (Fig 4-6.G) structures morphologically. The early aggregates 
of the shtt(Amyl)+Q30P6K2 peptide were a mix of amorphous aggregates (Fig 6A) and dark-staining 
protofibrillar intermediates (Fig 4-6.B). While it is tempting to speculate about aggregation 
mechanisms based on morphologies, especially in the context of shtt(Olig)+Q30P6K2 and shtt(Olig)-
Q30P6K2 peptides, doing so can be misleading since aggregates with similar morphologies have 
been shown to have completely different properties (120). 
4.3.2.3 Concentration dependence of initial aggregation rates of shttNTQ30P6K2. 
As was described in Chapter 1, one of the fundamental differences in the aggregation of 
polyQ peptides and that of polyQ containing htt fragments lies in the difference in the 
concentration dependence of the initial rates of aggregation, originating from differences in 
aggregation mechanisms. Since our analysis of the aggregation kinetics (Fig 4-5. A,B) uncovered 
differences in the early phases of aggregation between shtt(Olig)+Q30P6K2 and the other two 
scrambled peptides, we decided to explore whether such differences were also apparent in the 
concentration dependence of the initial aggregation rates of these peptides. Thus, a log-log plot 
(Fig 4-5.D) of the starting concentrations vs initial aggregation rates for the shtt(Olig)+Q30P6K2 (●) 
peptide gave a slope of 1.15 almost identical to the slope of 1.2 reported earlier (31) for the 
control httNTQ30P6K2 peptides (●). On the other hand, both the shtt(Olig)-Q30P6K2 (▲) and the 
shtt(Amyl)+Q30P6K2 (♦) peptides gave almost identical slopes of ~3 similar to that observed in the 
case of simple polyQ peptides (122). Overall, these results are consistent with our results from 
the study of the aggregation kinetics of these peptides in suggesting that during the early phases 
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of aggregation, the shtt(Olig)+Q30P6K2 peptide aggregates similar to polyQ containing htt 
fragments, while the shtt(Olig)-Q30P6K2 and shtt(Amyl)+Q30P6K2 peptides aggregate similar to simple 
polyQ peptides. 
4.3.2.4 Characterization of the early aggregation phase of shttNTQ30P6K2. 
The difference in the concentration dependence of the initial rates of aggregation between 
polyQ peptides and polyQ containing htt fragments is believed to be indicative of the different 
aggregation mechanisms of these peptides. Thus, polyQ containing htt fragments that show a 
shallow concentration dependence of initial aggregation rates aggregate through oligomeric 
intermediates. In contrast, simple polyQ peptides that display strong concentration dependence in 
their initial rates of aggregation do not form any oligomeric intermediates under similar 
conditions (121). We thus wanted to see whether the different concentration dependencies of the 
shttNTQ30P6K2 peptides are also reflected in other indicators of aggregation mechanisms.  
The DLS (dynamic light scattering) technique is particularly useful in identifying large 
scattering species that are populated during aggregation. Earlier, we had successfully used this 
technique in demonstrating that the early phases of aggregation of polyQ peptides lack any 
oligomeric species (121). Hence, we decided to apply this technique to the characterization of 
early aggregates formed by shttNTQ30P6K2 peptides. 
The aggregation of httNTQ30P6K2 peptides was observed to proceed through the rapid 
formation of larger-scattering species (Fig 4-7.A) with the average size of these species 
increasing within an hour from 40Å to 300Å (Fig 4-7.C). Similarly, the early phases of 
shtt(Olig)+Q30P6K2 aggregation were also characterized by the rapid formation of large, highly 
scattering species (Fig 4-7.B) with progressively increasing sizes (Fig 4-7.D). It is worth pointing 
 94 
out that within this timeframe (60-90mins), aggregates of both these peptides do not display any 
ThT binding (Fig 4-5.D) consistent with the non β-sheet nature of these aggregates. 
In contrast, the initial phases of both the shtt(Olig)-Q30P6K2 and the shtt(Amyl)+Q30P6K2  do 
not exhibit formation of any large-scattering species (Fig 4-7.E and 4-7.F), behavior that is  
similar to what has been reported with simple polyQ peptides (121). Eventually, upon 
completion of ~35%-45% of aggregation, both shtt(Olig)-Q30P6K2 and the shtt(Amyl)+Q30P6K2 form 
larger scattering species with average radii of 100 Å -200Å respectively (Fig 4-7.G and 4-7.H). 
Based on the ThT binding of aggregates formed at an equivalent point in the aggregation 
reaction, it is likely that these scattering species (formed by shtt(Olig)-Q30P6K2 and the 
shtt(Amyl)+Q30P6K2 ) are nascent β-sheet rich fibrils.  
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As an additional probe of amyloid nucleation mechanisms, we also assessed the ability of 
the httNT peptide to inhibit the aggregation of the shttNTQ30P6K2. Earlier, we had shown that the 
addition of the httNT sequence (with or without a few glutamine residues) inhibits the aggregation 
of polyQ containing htt fragments based on their ability to form mixed oligomers (Fig 4-1.B). 
Thus, we reasoned that shttNTQ30P6K2 peptides that can form oligomers should display inhibition 
by the httNT peptide.  
As was reported earlier, adding the httNT peptide to httNTQ30P6K2 peptide in a 1:1 ratio (or 
greater) substantially reduces the rate of aggregation, increasing the t1/2 of aggregation by ~ten-
fold (Fig 4-8.A,B, ○). Similarly, addition of httNT was also observed to inhibit the aggregation of 
shtt(Olig)+Q30P6K2 (Fig 4-8.A, ○) though the degree of inhibition was substantially lower than 
observed in the case of the WT httNTQ30P6K2 (increasing t1/2 by ~2.5 fold). More importantly, the 
aggregation of shtt(Olig)+Q30P6K2 peptide in the inhibition reaction proceeds through an initial lag-
phase, similar to that observed with the WT httNTQ30P6K2 peptide (○), consistent with the 
hypothesis that httNT reversibly inhibits homo-oligomerization of these peptides.  
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On the other hand, the addition of httNT did not have any effect on the aggregation of the 
shtt(Amyl)+Q30P6K2 peptide (Fig 4-8.B, ◊) which aggregates similar to the uninhibited control (Fig 
4-8.B,♦). Expectedly, we did not see any difference between the aggregations of the httNT in this 
mixed reaction (Fig 4-8.C, ◊) or by itself (Fig 4-8.C, ▲), consistent with its inability to interact 
with the shtt(Amyl)+Q30P6K2. Interestingly the aggregation of the shtt(Olig)-Q30P6K2 peptide was 
slightly accelerated upon addition of the httNT peptide (Fig 4-8.B, Δ) in comparison with the 
uninhibited control (Fig 4-8.B,▲) especially during the early-phases of aggregation. The 
involvement of httNT in this rate acceleration of aggregation is also suggested by the drop in the 
httNT concentration in the mixed reaction (Fig 4-8.C,Δ ).  
Overall, both the DLS and inhibition studies demonstrate that the 
shtt(Olig)+Q30P6K2peptide aggregates via the formation of oligomers, similar to the WT 
httNTQ30P6K2 peptide while the shtt(Amyl)+Q30P6K2 and shtt(Olig)-Q30P6K2 peptides like simple 
polyQ peptides, do not aggregate through the formation of oligomers.  
4.3.2.5 Low-resolution structural characterization of shttNTQ30P6K2 aggregates.  
Next, we moved to structurally characterizing aggregates isolated at different times in the 
aggregation reactions of shttNTQ30P6K2 peptides. First, we looked at the accessibilities of the 
polyQ segments, in isolated aggregates, to the polyQ specific monoclonal antibody MW1 (92). 
Earlier, we had demonstrated that the polyQ stretch in oligomers of the WT httNTQ30P6K2 peptide 
is accessible to MW1 binding though this accessibility is lost in the final fibrils (31). 
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4.4 DISCUSSION.  
The httNT sequence is highly conserved across species (27) consistent with the crucial role that 
this sequence plays in a wide-range of cellular processes (28, 29). This sequence has also been 
shown to take the lead in mediating the aggregation of polyQ containing htt fragments (31, 76) 
through the formation of oligomeric species that accelerate nucleation of the polyQ segments. In 
this work, we have tried to understand in greater detail the role that the httNT sequence plays in 
the aggregation of polyQ containing htt fragments. 
Our studies of the abilities of scrambled variants of the httNT sequence to inhibit 
aggregation of polyQ containing htt fragments, led us to hypothesize that the adoption of 
amphipathic helical structures by httNT is crucially linked to the initial oligomerization of these 
peptides. We further tested this hypothesis by replacing the httNT sequence within polyQ 
containing htt fragments by three of the scrambled variants studied in Chapter 2. These 
sequences were chosen based on their different properties (Table 4-1). Thus, while the shtt (Olig)+  
sequence inhibited the aggregation of httNTQ30P6K2 peptides, the  shtt(Amyl)+ and shtt(Olig)- 
sequences did not. In addition, both the shtt (Olig)+  and shtt(Amyl)+ sequences display similar 
amphipathic helix forming propensities which are similar to that of the httNT sequence but 
substantially higher than that of the shtt(Olig)- sequence. Finally, the tendency to form amyloid 
structures at low concentrations acts as another differentiating feature between these sequences 
with only the shtt(Amyl)+ sequence capable of aggregating into amyloid structures at low 
concentrations. These helical propensities are also reflected in the structures of the aggregates 
formed by these sequences at high concentrations (Fig 4-3.E) with aggregates of shtt(Olig)+  
sequence displaying maximal helical propensity of these three sequences. Thus, despite our 
inability to directly isolate helical oligomers, these results in conjunction with the inhibitory 
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activity of these peptides (Table 1) suggest that of the three peptides only shtt(Olig)+ is capable of 
forming amphipathic helical oligomers.  
Consistent with its amphipathic helical propensity, the shtt(Olig)+ sequence within the 
context of a httNTQ30P6K2 peptide was observed to aggregate the fastest amongst all the three 
shttNTQ30P6K2 peptides (Fig 4-5.A), with its initial aggregation kinetics almost matching that of 
the WT httNTQ30P6K2 peptide (Fig 4-5.C). This equivalence in initial aggregation of the WT 
httNTQ30P6K2 and the shtt(Olig)+Q30P6K2 peptides are also reflected in the similarly shallow 
concentration dependencies of their initial aggregation rates (Fig 4-5.D). While it is theoretically 
possible that the pro-acceleratory role of the shtt(Olig)+ sequence is mediated by a change in the 
monomeric conformation, CD measurements of the average structure argue against this (Fig 4-
4.A,B). Rather, the effects of the shtt(Olig)+ sequence on aggregation are almost entirely mediated 
during the oligomerization phase. Thus, both the WT httNTQ30P6K2 and the shtt(Olig)+Q30P6K2 
peptides aggregate via the rapid formation of oligomers (Fig 5I) that have typical DLS profiles 
(Fig 6A and Fig 6B) . This shared tendency to form oligomers also explains the inhibition of the 
httNTQ30P6K2 and the shtt(Olig)+Q30P6K2 peptides by httNT (Fig 4-7.A), presumably through co-
oligomerization of the substrate and inhibitor (Fig 4-7.C). Furthermore, the substantial exposure 
of the polyQ segment in these initial oligomers (Fig 4-9.A and 4-9.B) suggests that the shtt(Olig)+ 
sequence, primarily mediates the formation of these oligomers.  
The low propensity of the shtt(Olig)- sequence to form amphipathic helices (Fig 4-2.B) and 
its inability to inhibit the aggregation of httNTQ30P6K2 (Table 4.1) make it an excellent negative 
control in testing the hypothesis that amphipathic helicity is crucial to aggregation of polyQ 
containing htt fragments. Overall, the shtt(Olig)-Q30P6K2 peptide behaved as expected, aggregating 
much slower than the httNTQ30P6K2 peptide and displaying an initial lag-phase in its aggregation 
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that is similar to that observed in simple polyQ peptides (Fig 4-5.A). Also, the initial aggregation 
rates of this peptide were found to scale linearly with the peptide concentration, almost identical 
to the relationship observed in polyQ peptides. More importantly, we did not observe any 
indication of this peptide forming oligomeric structures during the initial phase of aggregation 
(Fig 4-6.E).  
The propensity of the shtt(Amyl)+ peptide to form amphipathic helices (Fig 4-2.B)  coupled 
with its high tendency to aggregate and its inability to inhibit aggregation of polyQ containing htt 
fragments, made this sequence particularly interesting . Thus, it could be hypothesized that the 
addition of this sequence to a Q30P6K2 peptide would drive aggregation through an oligomer 
driven mechanism similar to that observed in httNTQ30P6K2 peptides, mediated by its amphipathic 
helical propensities. On the other hand, the high tendency of this peptide to aggregate into β-
sheet rich fibrils could mean that population of amphipathic helical oligomers of 
shtt(Amyl)+Q30P6K2 is not favored. Our results indicate the latter to be the case. Thus, aggregation 
of the shtt(Amyl)+Q30P6K2 was observed to be substantially slower than httNTQ30P6K2 proceeding 
through an initial lag-phase similar to the ones observed with the shtt(Olig)-Q30P6K2 and 
K2Q30P6K2 peptides. Furthermore, the concentration dependencies of initial aggregation and the 
lack of any oligomeric species during the lag-phases of aggregation are consistent with an 
aggregation mechanism that is similar to that of polyQ peptides. Even though these data 
demonstrate the lack of any oligomers mediated by amphipathic helical interactions, it is still 
possible that nucleation of amyloid formation involves elements of the shtt(Amyl)+ sequence.   
Overall, these results suggest that the major role of the httNT sequence lies in the 
mediation of oligomerization, driven by its propensity to adopt amphipathic helical 
conformations. This property of httNT also underlies the rapid initial aggregation that is observed 
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in polyQ containing htt fragments. However, is the mediation of amphipathic helical oligomers 
the only role of the httNT sequence? Our results with the scrambled httNT sequences seem to 
suggest otherwise.  ssNMR studies of final fibrils showed that the C-terminal region of the httNT 
sequence (Ser16, Phe17) adopts the β-sheet conformation that characterize the polyQ segments 
(136) suggesting that at least part of the httNT sequence plays a role in nucleation/elongation 
stages of the aggregation pathway (Chapter 1). Our results with the shtt (Olig)+Q30P6K2 peptide 
provide some additional insights. Thus, this peptide is similar to the WT sequence in terms of its 
tendency to form amphipathic helices, its ability to aggregate via oligomeric intermediates and 
its concentration dependencies of its initial aggregation. Yet, the formation of β-sheet aggregates 
is substantially slower in the case of this sequence than the WT. Similarly, the shtt (Olig)+ 
sequence is substantially more accessible to cleavage by trypsin (Fig A-6 and Table A-1) than 
the WT sequence (31). These results suggest that mimicking the amphipathic helical propensities 
of the httNT sequence is not sufficient to match the aggregation observed with polyQ containing 
htt fragments. Thus, it would appear possible that another (probably secondary) role of httNT lies 
in its ability to engage in β-sheet structures especially in the polyQ proximal region of this 
sequence. Of course, it must be stressed that this argument in its current form is mostly 
speculative and needs to be experimentally validated. For instance, differential stabilities of 
oligomers formed by the httNT sequence and the shtt (Olig)+ sequence could explain the differences 
in kinetics of formation of β-sheet aggregates observed in these peptides. 
In conclusion, our work with the scrambled httNT sequences ascribes a crucial role for 
amphipathic helicity within httNT in the oligomerization of polyQ containing htt fragments. In the 
subsequent chapter, we have adopted a mutational analysis approach to confirm and to determine 
the major residues within httNT that are crucial to this “pro-aggregation” role of httNT.  
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5.0  IMPORTANCE OF AMPHIPATHIC HELICITY IN AGGREGATION OF 
POLYQ CONTAINING HTT FRAGMENTS (II): A MUTATIONAL ANALYSIS. 
5.1 OVERVIEW. 
Using a combination of single point alanine mutations and other functionally important 
mutations, we show that amphipathic helix formation is the major driving force in the 
oligomerization of polyQ containing htt fragments, controlling the kinetics and thermodynamics 
of oligomer formation. This ampiphilicity driven oligomerization underlies the differences in the 
aggregation mechanism (concentration dependence) between polyQ containing htt fragments and 
polyQ-only (simple polyQ) sequences. Within this context we also assessed the effects of some 
of the reported post-translational modifications (PTMs) of httNT on aggregation.  These results 
provide an additional dimension to the analysis of the role that PTMs play in HD pathology. 
Finally, we have used the mutational data described here in modeling in silico a putative 
structure of the httNT mediated tetramer that is populated during aggregation. We anticipate the 
structure provided here to be a useful tool in guiding future experiments and to be a starting point 
for pharmacophore screening studies to identify chemical targets that can block tetramer 
formation.  
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5.2 INTRODUCTION. 
The addition of the httNT sequence to a polyQ (or a polyQ-polyPro) peptide was observed 
to a. accelerate the kinetics of aggregation and b. alter the aggregation mechanism from a 
nucleated-growth (with a monomeric nucleus) mechanism to one that is driven by stochastic 
nucleation within an oligomeric pool. Such httNT mediated oligomerization proceeds through the 
formation of tetrameric, octameric and dodecameric species in equilibrium with each other (100). 
While in the monomeric state the httNT sequence adopts a random-coil structure (31), within 
oligomers this sequence is almost entirely helical and a major portion of the httNT sequence 
remains helical (136) even in the final fibrils highlighting the preference of this sequence to 
adopt a helical conformation (Fig 5-1).  
A number of experimental and computational studies have identified a crucial role for 
httNT helicity in mediating the aggregation of polyQ containing htt fragments (31, 76, 95, 100). 
However, the role of the different parts of the httNT sequence and the exact role of helicity (and 
by extension amphipathicity) in the different stages of polyQ containing htt fragment aggregation 
remains to be ascertained. This is crucial not only to our understanding of the aggregation 
pathway but might also hold potential for the discovery of active molecules that inhibit 
aggregation.  
The httNT sequence is not only crucial to the aggregation of polyQ containing htt 
fragments but also has several crucial cellular roles. For instance, the httNT sequence has been 
implicated as the site of several post-translational modifications (PTMs) in vivo with crucial 
implications in HD pathology (16, 17, 37) . It can be reasoned that PTMs within httNT can also 
affect the aggregation of polyQ containing htt fragments as has been described for the 
phosphorylation of serines at positions 13 and 16 in httNT (Chapter 6). Given the potential 
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We have used a series of single point alanine and other functional mutations in assessing 
the importance of amphipathicity in the aggregation of polyQ containing htt fragments. Within 
this context, we have also determined the effects of some of the reported PTMs of httNT on 
aggregation kinetics and aggregate morphology. We have also used the data from our mutational 
analysis of polyQ containing htt fragments’ oligomerization and aggregation in guiding in silico 
based modeling of the httNT mediated tetramer populated during aggregation and obtained a 
putative structure which could be a useful tool in future pharmacophore screening experiments.  
 
5.3 RESULTS. 
5.3.1 Effect of PTMs on aggregation. 
 In order to look at the effect of post-translational modifications on the aggregation of 
polyQ containing htt fragments, we used mutations that have been shown to chemically mimic a 
particular PTM. Thus, in order to mimic acetylation, we mutated lysines to glutamine while 
arginine mutations were used to mimic the modification –resistant state. Similarly, threonine was 
mutated to aspartate to mimic phosphorylation or alanine to mimic the alternate state. These 
studies were performed in the httNTQ37P10K2 (F17W) background which exhibits aggregation 
properties similar to the huntingtin exon-1 (B.Sahoo et al, unpublished). The use of chemically 
synthesized peptides allows us to not only to study modification-mimicking mutations (similar to 
ones studied by cell biologists) but also look at the effect of the actual chemical modifications on 
aggregation properties.  
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were almost identical, displaying a characteristic network of amyloid fibril structures that we 
observe in our htt exon-1 models.  We also confirmed that the acetylation of the N-terminus of 
the newly generated peptide upon methionine cleavage does not affect the aggregation kinetics 
(Fig 5-2.A, ▲) nor the final aggregate morphologies of polyQ containing htt fragments by EM 
(Fig 5-3.C). As an additional probe of aggregate morphology we looked at the ability of the final 
aggregates of these peptides to bind ThT, a property that can distinguish the aggregates formed 
by polyQ containing htt fragments and simple polyQ sequences. The ThT binding ability of the 
N-Ac Ala2 peptide was slightly greater than that of the WT though the difference is not as 
pronounced as that between the WT httNTQ37P10K2 peptide and a K2Q31K2 peptide (Fig 5-2.D). 
Since there is not much difference in the aggregation behavior of the des-Met peptide and that of 
the WT, we chose to maintain Met 1 in all our subsequent studies of PTMs.  
Phosphorylation of the two serine residues has been shown to alter the aggregation of 
polyQ containing htt fragments (16). We thus assessed whether phosphorylation of the lone 
threonine residue, Thr3, has any effects on the aggregation kinetics of a httNTQ37P10K2 peptide. 
The T3D mutation had previously been shown to reduce lethality and neurodegeneration in a 
drosophila model of HD (17). We did not observe any significant difference in the aggregation 
kinetics of the phosphomimetic T3D (Fig 5-2.B, ●) nor a peptide with phosphothreonine (pT3) 
(Fig 5-2.B, ■) compared to the WT. Similarly, the final aggregates formed by these peptides 
were similar to the WT peptide in terms of their ThT binding ability (Fig 5-2.D) and EM 
morphologies (Fig 5-3). As an additional control, we also examined the aggregation behavior of 
the non-modifiable T3A mutation but found no significant difference in the aggregation kinetics 
(Fig 5-2, ■), aggregate morphologies (Fig 5-3) nor ThT binding (Fig 5-2.D). In contrast, 
mutating the serine residues at positions 13 and 16 to aspartate or phosphoserine not only impairs 
 aggregati
that the 
possibly 
Figure 5-3
variants- W
and S13p/S
 
N
htt fragm
faster tha
aggregate
proceede
on kinetics 
location of 
due to differ
: Effect of PT
T (A), des-M
16p (J). All im
ext we exam
ents. We sta
n the WT, 
s that are s
d to investi
but also alte
these modif
ent effects o
Ms on aggre
et (B), N-Ac A
ages were tak
ined the ef
rted by look
consistent w
imilar to the
gate the ef
rs aggregat
ications wit
n biophysic
gate morphol
la2 (C), pT3 
en at the same
fect of lysin
ing at the e
ith the incr
 WT in term
fect of the 
110 
e morpholog
hin httNT se
al propertie
ogies. Final ag
(D), T3D (E),
 magnification
e acetylation
ffect of K6Q
ease in hyd
s of their 
K6, 9,15R
ies (Fig 5-
gment can 
s.  
gregate morph
 K6Q (F), K (
 with the scale
 on the agg
 mutation (F
rophobicity 
ThT binding
mutation th
3.H-J, Chap
have differe
ologies of dif
6, 9, 15) R (G
 bar (i) repres
regation of p
ig 2c, ▲) w
and loss of
 and morph
at mimics 
ter 6) sugge
nt conseque
ferent httNTQ3
), S13D/S16D
enting 50nm.
olyQ conta
hich aggre
 charge, for
ology. Nex
the modific
sting 
nces 
 
7P10K2 
 (H-I) 
ining 
gated 
ming 
t, we 
ation 
 111 
resistant states of lysine. Since lysine and arginine are both charged residues, we expected the 
aggregation kinetics of the K6, 9,15R mutation to be similar to that of the WT. We were thus 
surprised to observe that this mutation accelerated aggregation (Fig 5-2.C, ▲), as much as if not 
faster than, the K6Q mutation even though the final aggregate products are similar to the WT and 
K6Q peptides (Fig 5-3 and Fig 5-2.D) in morphology and ThT binding. Interestingly, a single 
point K-R mutation has also been observed to increase aggregation in vivo (156). Earlier, we had 
shown that mutations within httNT that alter hydrophobicity alter aggregation kinetics (31). 
However, the data discussed above suggest that in addition to changes in hydrophobicity, the 
position of these mutations within httNT also plays a role in aggregation. For instance, mutations 
that increase or decrease hydrophobicity of Thr3 do not seem to affect kinetics of aggregation by 
much whereas a single mutation at Lys6 that increases hydrophobicity slightly, increases 
aggregation substantially. One hypothesis for this sequence dependence of hydrophobicity is that 
mutations that affect aggregation do so by affecting amphipathicity (rather than net 
hydrophobicity) which is a property that is tied to httNT’s helical propensities. It is also possible 
that different parts of the helix might make different contributions to helical packing. 
As described already in chapter 3, httNT displays a concentration dependent transition 
from a random coil conformation to an entirely helical conformation (presumably through the 
formation of tetramers and other species). Thus, mutations that change ampiphilicity should also 
change this concentration dependence of helicity within httNT, evinced by a change in the mid-
point concentration of the random coil to helix transition in CD spectra. In order to test this 
hypothesis, we decided to look at the effect of the K6, 9,15R mutation on the concentration 
dependence of httNT helicity. Our choice of this mutation was dictated by its drastic effect on the 
aggregation kinetics and the overall conservative nature of this mutation. Consistent with the 
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in httNT to alanine in the httNTQ37P10K2 peptide background and assessed the effects of the 
mutations on aggregation kinetics and aggregate morphology.  
The httNT sequence has three neutral, polar residues: the lone threonine residue at position 
3 and the two serine residues at positions 13 and 16. Sedimentation analysis of aggregation 
indicates that the S16A (Fig 5-5.A, -○-) and the T3A (Fig 5-5.A, -■-) mutants aggregate similar 
to the WT (Fig 5-5.A, ●) sequence, aggregating to 50% within 4hrs and 3hrs respectively. On the 
other hand, the S13A mutant (Fig 5-5.A, -▲-) aggregates slightly faster than the WT sequence 
(t1/2= 2.5hrs). An examination of the morphologies of the final aggregates formed by these 
mutants reveals the characteristic meshwork of fibril-like structures that characterize the WT 
sequence (Fig 5-3.A). Similarly, the ThT binding ability of the final aggregates of these mutants 
is similar to those of the WT (Fig 5-5.D). 
Next we looked at the role of the charged residues (glutamate at positions 5 and 12 and 
lysines at positions 6, 9 and 15) in modulating polyQ containing htt fragment aggregation. We 
did not observe any major changes in the aggregation kinetics nor aggregate morphologies upon 
mutating glutamates at positions 5 (Fig 5-5.B, ● and Fig 5-6) and 12 (Fig 5-5.B, ○ and Fig 5-6) 
nor the lysines at position 9 (Fig 5-5.B, ▲ and Fig 5-6) or 15 (Fig 5-5.B, ■ and Fig 5-6). On the 
other hand, mutating the lysine at position 6 to alanine substantially enhances aggregation 
kinetics (Fig 5-5.B, ●), aggregating to 50% within 1.8 hrs though there is no visible change in 
the morphologies of the final aggregate products (Fig 5-6). The ThT binding abilities of the final 
aggregates of all mutations at charged residues were found to be more or less similar to those of 
the WT.   
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of this triple mutant are actually faster than the WT in their study which is consistent with the 
results presented here.  
By far, the most dramatic effects on aggregation kinetics were observed upon mutating 
the hydrophobic residues into alanine which in each case reduced the kinetics of aggregate 
formation. In fact, a pattern can be identified in the effects of hydrophobic residues on 
aggregation. Thus, the inhibitory effect of mutating the hydrophobic residues to alanine increases 
gradually from M1A ( Fig 5-5.C  --○--)  to L4A ( Fig 5-5.C   --○--)   through L7A ( Fig 5-5.C   -
●-)  and M8A ( Fig 5-5.C   -●-) , before peaking at F11A ( Fig 5-5.C   -●-)  and L14A ( Fig 5-
5.C   -▲- and inset )   and then dropping back to near WT level with the F17A mutation ( Fig 5-
5.C   --○--). Interestingly, the aggregation kinetics of a triple alanine mutant M8A/F11A/F17A 
(Fig 5c, ▲, AAA in E ) are almost identical to those of the F11A and L14A mutations and just 
marginally slower than the L7A, M8A mutants, suggesting that disruption of hydrophobic 
interactions at any of these positions is sufficient to reduce aggregation rates to similar extents.  
 Figure 5-6
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making these mutations (based on a determination of the hydrophobic moments, <µH>). A plot 
of the <µH> vs t1/2 of aggregation of all alanine mutants did not display any correlation (R2 =0.3) 
(Fig 5-7.B, ▬) though a plot of the <µH> vs t1/2 of aggregation of just the hydrophobic mutations 
gave a correlation (R2=0.6) (Fig 5-7.B, ▬) that almost matches that between t1/2 and net 
hydrophobicity.  Based on the analysis described above and the results from the PTMs, a picture 
begins to emerge that suggests that amphipathicity (arising out of a helical httNT sequence) within 
httNT drives the aggregation of polyQ containing htt fragments with the hydrophobic residues as 
the major drivers. We thus decided to explore in details how amphipathicity might affect the 
different stages of the aggregation pathway shown in Figure 1.  
5.3.2.2 Ampiphilicity in the monomeric ensemble. 
It is possible that the effects of the alanine mutations described here on aggregation are 
exerted via a change in the monomer conformation. In order to test this, we first assessed the 
effect of some of these mutations on the monomeric conformational ensemble. Thus, after 
disaggregation, peptides were filtered through a 20nm syringe filter before CD sampling to 
ensure that the results of the analysis are not complicated by the presence of oligomeric species 
(Fig 5-8). Except for the K9A (- -) peptide which had slightly more helical character, all the 
peptides surveyed displayed typically random coil spectra with some hint of helical propensity as 
has been reported before. This point is also reinforced by looking at the ratios of mean residue 
ellipticities at 222nm and 208 nm (Fig 5-8, insets) which is often used to characterize helicity 
(for a helical peptide, this ratio is ~0.86 or greater). Even though we looked at only nine of the 
fifteen Ala mutants, the mutations studied here span the region from Leu4-Phe11 that was 
observed to be helical in ss NMR studies of final aggregates and that can be argued to constitute 
the  “helical core” of the httNT sequence.  In the monomeric state, polyQ containing htt fragments 
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assess the effect of alanine mutants on the initial oligomer formation. As shown in Fig 5-9, at 
high concentrations (>~600µM), the httNT sequence displays a predominantly helical spectra 
(▬). Thus, we first started by looking at the effect of the point alanine mutations on the helicity 
of httNT at high concentrations. We found that mutating the hydrophobic residues to alanine 
completely abrogated the formation of helical oligomers of httNT with these mutants exhibiting 
typical random coil spectra even at the highest concentrations studied with the exception of 
F17A which displays substantial helicity at concentrations higher than 1mM (Fig 5-10.C). These 
results are consistent with the notion that the hydrophobic residues form the interaction interface 
within the oligomers and hence mutating the hydrophobic residues destabilizes the association of 
httNT into helical assemblies.  
All of the other mutations (Fig 5-9.A and 5-9.B) gave typically helical spectra under 
similar concentrations with the exception of the K9A mutation which yielded a seemingly helical 
spectrum with lower mean residue ellipticity values. It should be noted though that all our efforts 
to obtain higher concentrations of this mutant were futile because of considerable peptide loss in 
the preparatory centrifugation step, presumably as larger aggregates/oligomer.   
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robust R2of 0.92 if the K9A mutation is not considered. Regardless of this nuance, the strong 
correlation suggests that the effects of alanine mutations on the aggregation of polyQ containing 
htt fragments are exerted primarily through httNT oligomerization. 
In order to parse out subtle differences in the oligomerization ability of these different 
alanine mutants, we also decided to look at the concentration dependence of helicity of the 
alanine mutants (Appendix A, Fig A-3). To this end, we calculated the concentration (C1/2helix) at 
which the mid-point of the helical transition is reached for some of these mutations by plotting 
the ratio of molar ellipticities at 222nm and 208nm versus the concentration.  The C1/2helix 
provides us with some information regarding the comparative thermodynamics of 
oligomerization across these different mutations. As mentioned above, for the hydrophobic 
mutants even the highest concentrations gave characteristic random coil spectra and hence the 
C1/2helix was assigned a value greater than the highest concentration studied. Amongst the other 
mutations, only the charged mutations K6A and E12A had any substantial effect on the helicity 
of httNT, with both of these mutations stabilizing helicity by reducing the C1/2helix.  A plot of the 
C1/2helix (Table 5-1) vs. the t1/2 of aggregation gave a correlation of R2=0.9 when fit to a sigmoidal 
function (Appendix A) similar to the results obtained in Fig 5-9.D 
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Peptide C1/2helix [µM] Peptide C1/2helix [µM] 
WT 432µM K9A n.d 
M1A >1012 µM F11A >1490 µM 
T3A 460 µM E12A 382 µM 
L4A >740 µM S13A 614 µM 
E5A 437 µM L14A 1246 µM 
K6A 330 µM K15A 638 µM 
L7A >1105 µM S16A 525 µM 
M8A >1015 µM F17A 871 µM 
 
Table 5-1: Mid-point concentrations of coil-helix transition of httNT mutants. Data used in the calculation of 
mid-points is shown in Appendix A. 
 
In addition to CD studies of the effects of alanine mutations on httNT mediated 
oligomerization, we also looked at the effect of a couple of hydrophobic mutations, L4A and 
M8A, on the oligomerization kinetics and oligomer structure of httNTQ3 peptides (Appendix A, 
Fig A-1). Consistent with the results described above, mutating these hydrophobic residues to 
alanine was observed to disfavor oligomerization.  
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httNTQ37P10K2 sequence displays the same transition from helical oligomer to ordered β-sheet 
aggregates. The early aggregates of M8A are helical oligomers (Fig 5-10.B, --) that over time 
mature into β-sheet aggregates (Fig 5-10.B, ▬) with ordered Gln side chains. Furthermore, both 
the WT (Fig 5-10.A, ●) and the M8A (Fig 5-10.A, ●) peptides aggregate to almost the same 
extent suggesting that there is not much difference in the net efficiency of nucleation/elongation 
between these peptides. Thus, it seems unlikely that alanine mutants that impair oligomerization 
and by extension aggregation, aggregate via any alternate pathway. The observation that the 
M8A mutation is incapable of helical oligomer formation in a httNT background but can do so in 
a httNT-Q8 K2 peptide points to a potential effect of glutamines on the thermodynamics of httNT 
mediated oligomerization, a hypothesis that is tested in detail in Chapter 7. 
5.3.2.5 Studies of the helix disrupting M8P mutation.  
The M8P mutation has been shown to almost entirely abrogate helical propensities in a 
httNT sequence (29). Furthermore, the M8P mutation in a 1-171 htt fragment with 128 glutamines 
was observed to be substantially more toxic than the control despite the lack of large inclusions 
in the cells as were observed with the WT. Other studies have also found that the M8P mutation 
in cells expressing htt exon-1 to completely disrupt aggregation (156).We thus decided to utilize 
the M8P mutation in our studies of polyQ containing htt fragments’ aggregation.  
5.3.2.6 M8P mutation impairs formation of httNT oligomers.  
We first looked at the effects of the M8P mutation on the ability of a httNTQ3 construct to 
form helical oligomers. Thus, while pelleted oligomers of WT httNT-Q3 display a predominantly 
α-helical FTIR spectrum (Appendix A, Fig A-1, ▬), the M8P mutant grown under similar 
conditions formed oligomers (Fig A-1,- - -) that show a broad FTIR Amide I spectra with a 
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mean position of 1640cm-1 which is characteristic of random coil structures. While the 
broadness of the Amide I peak could indicate the presence of different structural subtypes within 
the oligomers, overall the data suggests that the M8P mutant, unlike the WT, does not form 
helical oligomers.   
5.3.2.7 M8P mutation impairs aggregation. 
 Next, we examined the effect of the M8P mutation on the aggregation of a httNTQ37P10K2 
peptide (Fig 5-11). We observed the M8P mutant (●) to aggregate considerably slower than the 
WT peptide (●). The aggregation kinetics of the M8A mutation (○) in the same peptide 
background (Fig 5-5) is intermediate between that of the WT and the M8P mutation suggesting 
that a good portion of the inhibitory effects of the M8P mutation can be explained based on a 
general reduction in side-chain hydrophobicity. The rest of the rate differences between WT and 
M8P is most likely attributable to the loss of the backbone conformation. Even though the 
aggregation rate is impaired in the M8P mutation, it is still much faster than an equivalent 
concentration of a MF-Q37P10K2 peptide (○) that lacks the majority of the httNT peptide 
suggesting that despite the loss of helicity (upon mutating the Met to Pro), the net hydrophobicity 
of the httNT segment still plays a role in polyQ containing htt fragment aggregation. Interestingly, 
the morphology of the final aggregates of the M8P mutation are typically shorter than mature 
fibrils (Fig 5-11.C-F), and look more like intermediate aggregates observed on the polyQ 
containing htt fragment aggregation pathway suggesting that the properties of these aggregates 
might be different than those of the WT. As a positive control, we also looked at the aggregation 
of a peptide with a proline residue inserted between the httNT and the Q37P10K2 domains (referred 
to here as the Q0P mutant). The addition of this mutation does not affect aggregation as both the 
Q0P (●) and the WT (●) peptide have similar aggregation profiles. The final aggregates of the 
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Q0P mutant (Fig 5-11.G) resemble those of the WT (Fig 5-3.A), displaying the characteristic 
meshwork of long, and amyloid-like fibrils.  
5.3.2.8 M8P alters initial aggregation rates.  
As was described before, one of the major differences between the aggregation of simple 
polyQ (or polyQ-polyPro) sequences and that polyQ containing htt fragments lies in the 
concentration dependence of initial aggregation. One explanation for this difference could be that 
this difference is linked to the helicity in the httNT which is responsible for oligomerization. 
Thus, the M8P mutation which impairs helicity and oligomerization might be expected to exhibit 
a concentration dependence that is more in-line with that of simple polyQ peptide. We thus 
looked at the concentration dependence of the initial aggregation rates (refer experimental 
methods for a detailed analysis of the model) of the WT, Q0P and M8P mutants in the 
httNTQ37P10K2 background (Fig 5-11.B). Both the WT (●) and the Q0P (●) display log-log slopes 
of ~1 as has been reported for polyQ containing htt fragments (31). On the other hand, the M8P 
mutant (●) gave a slope of 3.46 consistent with the concentration dependence of a K2Q37P10K2 
peptide that has been reported to give a slope of 3 (122) and the shtt(Amyl)+Q30P6K2 peptide 
(Chapter 4) that has a slope of 3.3 (Fig 5-11.B, ♦). Thus, while the M8P mutation stimulates 
aggregation compared to the MFQ37P10K2 peptide (Fig 5-11), this peptide nonetheless undergoes 
nucleation of aggregation by a mechanism that does not involve httNT mediated oligomerization 
similar to the shtt (Amyl)+Q30P6K2.  
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The critical concentration of aggregation is another useful parameter to compare the 
relative stabilities of different aggregates. By definition, the critical concentration is the 
concentration of monomer in equilibrium with the aggregates towards the end of an aggregation 
reaction. In other words, the higher the critical concentration, the greater the instability of the 
aggregates.  We thus measured the critical concentrations of aggregation for the WT and the 
M8P mutant (Fig 5-12.B).While the WT httNTQ37P10K2 aggregates to a critical concentration of 
~0.3-0.4µM (▬), the M8P mutation was observed to aggregate to ~1.5µM (▬). Based on the 
calculated critical concentration, the destabilization in the free energy of elongation upon 
mutation, ΔΔGM8Pelong would be ~ 1 kcal/mol.  It is worth mentioning that other mutations within 
httNT have been known to destabilize aggregation to a greater extent (Chapter 6).  
 
5.3.3 Modeling a httNT tetramer structure 
As was described earlier, the oligomerization of polyQ containing htt fragments proceeds 
through the formation of a tetrameric species held together by interactions within httNT. A 
structure of this tetrameric species would not only facilitate a better understanding of the disease 
but could also have drug-screening potential as a viable target. We thus decided to utilize the 
experimental data that we had obtained from the different mutations described in this chapter in 
conjunction with protein-protein docking to model the httNT tetrameric species. Our goal in this 
study was to obtain a preliminary structure that can form the basis to future experiments.  
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This was then submitted to ClusPro and 10 docking models were obtained.  Next, we 
calculated the side-chain exposure of each residue in all models (Fig 5-13.A-C). Since the 
hydrophobic residues are known to be involved in the formation of the tetramer, the argument 
can be made that models that have the hydrophobic side-chains most buried are probably the best 
representations of the tetrameric structure.  
Thus, we calculated the average side-chain accessibility of the hydrophobic residues in 
the “helical core” within httNT (Fig 5-13.D) across all the ten models to identify models 7 and 10 
as the two best representations. The major difference between these two models is that while 
model 7 had the four helices arranged in a parallel fashion (Fig 5-14.B), model 10 had them in an 
anti-parallel configuration (Fig 5-14.A).  
Next, we made in silico mutations at each position within httNT across all the four chains 
in the tetrameric structures obtained from model 7 and model 10. Each of these structures thus 
obtained were then minimized locally at the site of the mutation and the energy of the complex 
determined by summing the electrostatics and de-solvation energy components obtained from the 
FastContact analysis and this energy term was used to calculate the ΔEtotmut for each mutant. In 
addition to the point alanine mutants, we also repeated the above procedure for the K (6, 9, 15) R 
mutant. To test whether the tetramers from model 7/model 10 had any relevance to our 
experimental system, we computed a. the correlation between the ΔEtotmut and the t1/2 of 
aggregation and b. the correlation between ΔEtotmut t and the ratio of mean residue ellipticities at 
222nm/208 nm (Fig 5-15).  
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Since the t1/2 of aggregation can also be influenced by other mechanistic features of 
polyQ containing htt fragments’ aggregation, in addition to tetramer formation (viz. stochastic 
nucleation, fibril stabilities etc.), one can rationalize such a weak correlation. However, this 
analysis clearly suggests that model 10 is a more accurate representation of the tetramer structure 
than model 7. It is imperative to point out that the structures reported here are preliminary and 
will have to be refined for a more accurate model. The refinement strategy would include getting 
distance constraints and/or adding more mutations to the dataset. Notwithstanding these 
limitations of accuracy, the structure of the tetramer proposed here should still be useful for 
guiding experimental design and for in silico drug screening. In fact, testing the pharmacophores 
identified using the structure above, for their ability to impair aggregation in vitro would be an 
additional test of the accuracy of the structure.  
 
5.4 DISCUSSION. 
The goal of this study was to identify the driving forces and the sequence determinants 
underlying the httNT mediated aggregation pathway of polyQ containing htt fragments.  To this 
end, we designed a series of mutations within httNT and assessed their effects on the different 
stages of polyQ containing htt fragment aggregation. First, we assessed the effects of some of the 
PTMs in httNT on the kinetics of aggregation and the morphologies of the final aggregates. 
Amongst the PTMs surveyed, we did not find any major effects on polyQ containing htt 
fragments’ aggregation though there were subtle effects on the aggregation kinetics which 
correlated with a change in hydrophobicity. The results of our alanine scan mutagenesis studies 
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of the httNT sequence identified the hydrophobic residues in the region between Leu 4-Leu 14 to 
be the major drivers of aggregation. Mutating any of the hydrophobic residues within this region 
to alanine substantially impaired aggregation kinetics (Fig 5-5.C) though it did not abrogate 
aggregation nor alter drastically the morphology of the aggregates. On the other hand, mutating 
the polar or charged residues did not alter the aggregation kinetics by much except in the case of 
the K6A mutation which substantially accelerated aggregation (Fig 5-5.A and 5-5.B). While 
superficially the results described here might suggest that average hydrophobicity is the major 
driving force of polyQ containing htt fragment aggregation, the sequence-position dependence of 
the aggregation rates of chemically identical mutations suggests otherwise. Thus peptides M1A 
and M8A, F11A and F17A and K6A and K9A/K15A while being similar in terms of net 
hydrophobicity have substantially different aggregation kinetics.  
The role of helicity within the httNT sequence in mediating polyQ containing htt fragment 
aggregation has received considerable attention. The observation that httNT retains its helical 
character in the oligomers and in the final fibrils formed during/after polyQ containing htt 
fragments’ aggregation underscore the importance of helicity in httNT mediated aggregation.  It 
also provides an explanation for the sequence dependent effect of the hydrophobic residues on 
polyQ containing htt fragment aggregation based on α-helix amphipathicity. In other words, 
helicity within httNT creates a hydrophobic face that promotes interactions between httNT and 
subsequent aggregation. 
The role of amphipathic helicity in mediating the aggregation of polyQ containing htt 
fragments was found to be most crucial in the oligomerization stage of the pathway (Fig 5-9).  
Thus all alanine mutations of hydrophobic residues were observed to destabilize the 
thermodynamics of oligomer formation. Amongst the other alanine mutants, only K6A showed 
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any significant effect, stabilizing the formation of helical oligomers (Table 1) consistent with its 
effects on the aggregation of the httNTQ37P10K2 peptide.  A correlation between the ratios of 
molar ellipticities at 222nm and 208nm (proxy for helicity) and the t1/2 of aggregation in the 
httNTQ37P10K2 background, gave a R2 of 0.8 suggesting that the effects of the alanine mutations 
on aggregation are driven primarily by their effects on oligomerization.  
Our results from the alanine scan mutagenesis studies also make another subtle point 
regarding the structural differences between oligomers and fibrils. ssNMR studies of final 
aggregates of polyQ containing htt fragments (136) showed that Leu 14 is typically disordered 
lying between the helical segment of httNT from the β-sheet portion of the rest of the peptide. 
Yet, this residue plays a crucial role in oligomerization as evinced by impairment of helical 
oligomer formation and the reduced aggregation rates in the httNTQ37P10K2 peptide. Taken 
together these results suggest that stochastic nucleation within the oligomers is accompanied by 
structural re-arrangements within httNT, similar to the conformational re-arrangement model 
proposed in other aggregating systems (192) though in this case such re-arrangements 
presumably follow amyloid nucleation elsewhere within the aggregate.   
The major quantitative difference between the aggregation mechanisms of simple polyQ 
peptides and htt fragment peptides is observed in the concentration dependence of the initial 
aggregation rates. Here we demonstrated that helicity within httNT that drives oligomerization 
underlies this lack of concentration dependence. Thus the helix-breaking M8P mutation that 
disrupts oligomerization (Appendix A) shows a concentration dependence of initial aggregation 
kinetics that is more similar to that of a K2Q37P10K2 peptide than the control httNTQ37P10K2 
peptide. However, the M8P mutant still aggregates though the final aggregates are different in 
their properties than those formed by WT peptide. For instance, the aggregates seem to be much 
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smaller in size (Fig 5-11) and exhibit greater susceptibility to protease cleavage and are less 
stable than WT aggregates (Fig 5-12). In the light of these results, it is tempting to speculate that 
the greater toxicity observed (29) and the lack of inclusion bodies in cells expressing a M8P 
version of a pathogenic htt fragment might be linked to the observed alteration of aggregation 
properties by this mutation.  
Overall, the results presented here implicate amphipathic helicity within the httNT 
sequence as the primary driving force in aggregation of polyQ containing htt fragments and are 
consistent with those from our studies with the scrambled analogs of htt fragment peptides 
(Chapter 3). However, net hydrophobicity might still play a role, albeit a sub-ordinate one, the 
aggregation of polyQ containing htt fragments. Thus, despite a concentration dependence of 
initial aggregation that is similar to polyQ peptides, the M8P mutation still aggregates 
substantially faster than an equivalent concentration of a MF-Q37P10K2 peptide (Fig 5-11.A).  
In addition to clarifying the biophysical driving forces underlying httNT mediated 
aggregation, the results described here also have significant implications on the role and fate of 
htt fragments in vivo. httNT is the site of several PTMs and at least some of these mutations seem 
to enhance the rates of aggregation presumably by promoting oligomerization of httNT. Thus, in 
addition to the normal assumption that PTMs affect protein behavior by altering cellular 
localization, trafficking and/or degradation, our results suggest that at least some of the PTMs 
might also significantly alter biophysical properties.  The results presented here on the effects of 
some reported PTMs on polyQ containing htt fragment aggregation will thus be crucial to our 
understanding of the cellular and pathological role of PTMs within httNT.  
We have also used the data from the mutants described here in constructing a preliminary 
model of the httNT tetramer which seems to be the fundamental unit of polyQ containing htt 
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fragment oligomers (100). The structural model described here will not only guide future 
experiments but can also be used for in silico identification of compounds that can destabilize 
tetramer formation and hence by extension httNT mediated aggregation. Such compounds would 
greatly enhance our understanding of the role that aggregation plays in HD pathology (especially 
the relative importance of the httNT mediated aggregation pathway) and might have therapeutic 
implications.  
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6.0  EFFECT OF SERINE PHOSPHORYLATION ON AGGREGATION OF POLYQ 
CONTAINING HTT FRAGMENTS. 
6.1 OVERVEW. 
The phosphorylation of the serine residues at positions 13 and 16 within httNT was 
suggested to have a neuroprotective role in tg mice models of HD. We thus assessed the effects 
of phosphorylation at the serine residues on the aggregation of polyQ containing htt fragments. 
Our results indicate that phosphorylation of serine residues alters different facets of the 
aggregation of polyQ containing htt fragments though it does not alter the mechanism of 
aggregation. Thus, the introduction of negatively charged Ser replacements significantly 
impaired the assembly of the α-helical translating to impairment of aggregation rates.  In addition 
to impaired aggregation, serine phosphorylation also seems to alter aggregate properties evinced 
by differences in aggregate morphology and aggregate stabilities. Overall, these results might 
provide some crucial insights into the current understanding of the role that phosphorylation at 
serines 13 and 16 plays in HD pathology.  
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6.2 INTRODUCTION.  
The httNT sequence is the site of several post-translational modifications (Fig 1-1), some 
of which have been observed to alter aggregation kinetics based on changes in the biophysical 
properties of the httNT sequence (Chapter 5). One such modification, phosphorylation of the two 
serine residues at positions 13 and 16 is particularly relevant primarily because of its ability to 
completely abrogate disease phenotype in a tg mouse model of HD. Thus, expression of fl-htt in 
BACHD mice harboring the S13D/S16D mutations was observed to be neuroprotective, 
preventing the development of neuronal and behavioral deficits as is characteristic with the 
control mice. More interestingly however, SD mice lacked any detectable aggregates in contrast 
to the control mice raising the possibility that impairment of aggregation might be a possible 
mechanism of phosphorylation mediated neuroprotection. While some subsequent studies have 
suggested that the effects of serine phosphorylation might be mediated, in part at least, through 
altered cellular localization (193, 194), the S13D/S16D mutation was not observed to 
appreciably alter cellular localization in tg mice reflective most likely of divergent mechanisms 
in different HD models. Notwithstanding these observations, the finding that phosphorylation of 
serine residues can affect aggregation underscores the need for a detailed assessment of this 
modification on the aggregation of polyQ containing htt fragments. Here, we have assessed the 
effects of serine phosphorylation on the different stages of the aggregation of polyQ containing 
htt fragments by using both phosphomimetic Ser-Asp mutations and Ser-phosphoSer mutations.  
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probably stems from an increase in hydrophobicity (amphipathicity) upon mutating serine to 
alanine residues. Next, we looked at the aggregation of each of the single Ser-Asp mutants to 
determine whether there was position dependence of the aggregation impairing effects of the 
S13, 16D mutations. We found that while the S13D mutant (Δ) aggregates with almost identical 
kinetics as the WT, the S16D mutant (◊) is similar to the S13D/S16D mutant in its aggregation 
suggesting that the serine 16 probably contributes to a greater extent to the kinetic effect of 
S13D/S16D mutation.  
Although the Ser->Asp mutation has proved a remarkably good mimic of phosphorylated 
serine in a variety of biological settings, we were concerned about whether this is necessarily 
true for any physicochemical impact on htt aggregation. We therefore investigated the 
aggregation of httNT Q37P10K2 (F17W) peptides with phospho-Ser residues built into the peptides 
at positions 13 and/or 16 during chemical synthesis.  We found that the doubly phosphorylated 
S13pS/S16pS peptide (●) exhibits substantially reduced aggregation compared not only to the 
WT peptide (●), but also to the S13D/S16D mutant (●) (Fig. 2A).  Furthermore, overall 
aggregation rates of the single phosphoryl-Ser peptides S13pS (Δ) and S16pS (◊) are also slower 
than the WT rate (●) and similar to S13D/S16D rate (●) indicative perhaps of a link between net-
charge and aggregation kinetics.  
6.3.2 Serine phosphorylation alters aggregate morphologies.  
Having ascertained that substituting the serine residues in httNT with aspartates or 
phosphoserines impairs aggregation, we proceeded to examine the morphologies of the final 
aggregates formed by these mutants. As demonstrated before, the final aggregates of the WT 
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This alteration in final aggregate morphologies was also observed in the case of the 
S13pS/S16pS mutant (G-I) which, similar to the S13D/S16D mutant, forms aggregates that 
resemble protofibrillar species with some evidence of altered staining compared to the WT (G). 
We also looked at the aggregate morphologies of the single Asp and/or phosphoserine mutants 
and observed mostly protofibrillar species with some evidence for fibrils (16). Overall, these 
results suggest that the incorporation of negatively charged residues at positions 13 and 16 seems 
to alter aggregate morphologies considerably.  
Next, we looked at the morphologies of aggregates isolated at early time-points of both 
the S13D/S16D and the S13pS/S16pS mutants to determine whether this difference in aggregate 
morphologies is also maintained at such early times. We observed that in contrast to the WT 
which exhibits intermediate aggregates (Fig 6-2.B) with morphologies substantially different 
from final aggregates (Fig. 6-2.A), early aggregates of peptides with both Ser residues replaced 
with Asp (Fig. 6-2. P-Q) or phosphoSer (Fig. 6-2.R-S) generally are no different from final 
aggregates.  
Overall, the results from our study of aggregation kinetics and of aggregate morphologies 
suggest that the mutation of the serine residues to Asp or phosphoSer not only impairs 
aggregation kinetics but also alters aggregate morphologies. We were thus interested in 
exploring the mechanisms by which phosphorylation at serines alters aggregation behavior. To 
this end, we started by looking at the effects of serine phosphorylation on different stages of the 
aggregation pathway (Fig 1-4.B).  
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As an additional test of serine phosphorylation on the monomeric ensemble, we also 
looked at the compactness of the httNT sequence in these mutants by measuring the FRET 
distance between residues -1 and 17 in the WT (Fig 6-3.B,▬) and the S13D/S16D (Fig 6-3.B,▬) 
mutants in the httNTQ37P10K2 context. Based on the -1-17 distance in these mutants, the httNT 
compactness appears to be similar in both these peptides.  
While, it is possible that there are subtle differences between these peptides in their 
propensities for structural subtypes that constitute the disordered monomeric ensemble, overall 
these results are consistent with the lack of any appreciable effect of serine phosphorylation on 
the average conformation of the monomeric ensemble in polyQ containing htt fragments.  
6.3.4 Kinetic impairment by serine phosphorylation is mediated at the oligomeric level.  
The aggregation enhancing role of httNT in the aggregation of polyQ containing htt 
fragments, stems from its ability to form oligomers that can serve as sites for stochastic 
nucleation (Chapter 4, 5). Since mutation of serines 13 and 16 to either Asp or phosphoSer was 
observed to reduce the rates of aggregation, we next explored whether serine phosphorylation 
affects httNT mediated oligomerization.  
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Overall, these studies with shorter polyQ repeat length htt peptides indicate that the 
kinetic impairment of aggregation resulting from the introduction of negative charges at serine 
residues is mediated at the oligomeric level. However, oligomers of S13D/S16D, once formed, 
retain the ability to act as sites of stochastic nucleation.  
6.3.5 Mechanistic effects of serine phosphorylation.  
Our studies with the short polyQ versions of htt fragments gave us some insights into the 
effects of serine phosphorylation on the aggregation of polyQ containing htt fragments. 
However, it is possible that these shorter polyQ repeat peptides do not accurately describe the 
mechanistic details in play in the aggregation of longer polyQ containing htt fragments. Thus, we 
proceeded to assess whether the results from these shorter peptides were also true in the case of 
longer polyQ containing htt fragments. Since, the rapid aggregation kinetics of these peptides 
makes it challenging to isolate and spectroscopically study aggregation intermediates, we had to 
utilize other probes to assess the effects of serine phosphorylation on aggregation mechanisms.  
First, we looked at the concentration dependence of the initial aggregation kinetics of the 
S13D/S16D mutant in a httNTQ37P10K2 background. Thus, as has been described earlier, the WT 
httNTQ37P10K2 peptide displays a shallow concentration dependence with a log-log slope of ~1 
while simple polyQ peptides lacking the httNT sequence display slopes of ~3. We found that the 
slope of an analogous log-log plot for the S13D/S16D mutant of httNTQ37P10K2 is ~ 1.3 
consistent with an httNT-mediated nucleation mechanism. 
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peptides (163).  Consistent with past results in the lab, we find that PGQ9P1,2,3K8 gives no 
detectible inhibition of spontaneous aggregation of WT httNTQ37P10K2. However, there is a 
measurable reduction in the aggregation of the S13D/S16D mutant. The meaning of the PGQ9P1, 
2,3K8 inhibition of the Ser-modified peptide is not entirely clear, but it does raise the possibility of 
a defective nucleation/elongation step in the case of the S13D/S16D mutant compared to the 
WT.  
 Overall, these mechanistic probes support the view that Ser modifications in httNT do not 
alter the fundamental, httNT-mediated nucleation mechanism of polyQ containing htt N-terminal 
fragments. The modest reductions in overall aggregation rate observed with the S13D/S16D 
mutant and reported here for the phosphoryl-Ser peptides (Fig. 6-1), appear to be primarily due 
to less favorable formation of the α-helix-rich oligomeric intermediates that are the springboard 
for amyloid nucleation. 
6.3.6 Serine phosphorylation does not change the secondary structure of the final fibrils.  
The final aggregate morphologies of the S13D/S16D mutant as well as those of the 
S13pS/S16pS mutant are considerably different from those of the WT (Fig 6-2). One possible 
explanation for these differences in aggregate morphologies is that the structure of the polyQ 
containing htt fragment in these aggregates is different. To test this hypothesis, we decided to use 
ssNMR techniques to look at the secondary structure of the httNT segment in the httNTQ37P10K2 
(S13D/S16D).  
Previously we had reported solid state NMR data on mature amyloid fibrils of 
httNTQ30P10K2 peptides that confirmed the expected β-structure in many of the polyQ Gln 
residues while surprisingly showing that residues 4-11 of the httNT reside in stable α-helix  
 Figure 6-7
compared 
peptides, w
associated 
 
(136). W
Leu14 a
secondar
and Ala1
peptide a
structure 
WT httNT
which ar
profile.  
aggregate
aggregate
: ssNMR stud
to random co
ith secondary
with two confo
e carried ou
nd Gln18 l
y structure t
0 residues o
ggregates.  
in aggregat
, a specifica
e β-conform
Thus, in sp
s are indi
s, at least a
ies of S13D/S
il positions (δ
 structures in
rmations, bot
t a similar 
abeled. The
hat is rema
f S13D/S16
Likewise, L
es of both p
lly-labeled 
ations.  Th
ite of signi
stinguishabl
t the labele
16D mutant.
Δ) for differen
ferred from th
h β.    
analysis on 
 results (F
rkably simil
D exhibit t
eu14 exhib
eptides.  Fi
Gln18 is fou
e S13D/S16
ficant differ
e at the le
d residues.  
153 
 Graphical rep
t labeled pos
ose values.  S
the S13D/S
ig 6-7) sho
ar to that of
he same kin
its the abse
nally, as in 
nd in two c
D aggregate
ences in EM
vel of sec
This is con
resentation of
itions in aggr
plit bars for 
16D mutant
w that the 
 the WT ht
d of strong
nce of any
the previou
hemically d
s exhibit an
 morpholo
ondary stru
sistent with 
 the 13C chem
egates from W
Gln18 indicat
 with residu
S13D/S16D
tNT peptide.
 α-helix as 
 strongly fa
sly reported
istinct envir
 essentially
gy, the S13
cture from
the other d
 
ical shift diffe
T and S13D
e two environ
es Lys6, A
 fibrils ha
  Thus, the 
found in the
vored secon
 aggregates
onments, bo
 identical sp
D/S16D pe
 the WT 
ata in sugge
rences 
/S16D 
ments 
la10, 
ve a 
Lys6 
 WT 
dary 
 with 
th of 
lit β 
ptide 
httNT 
sting 
 154 
that serine phosphorylation does not alter the overall aggregation mechanism of polyQ 
containing htt fragments.  
6.3.7 Serine phosphorylation alters stability of aggregates.  
In contrast to these ssNMR results, other tests detect some important differences in 
aggregate structure and stability introduced by serine modifications. We exposed final aggregates 
of various httNTQ37P10K2 peptides to trypsin proteolysis - a sensitive, if low resolution, probe of 
amyloid structure. We found that mature WT aggregates are relatively stable to cleavage within 
the httNT segment, with only about 10% of the peptides being cleaved (Fig. 6-8.A).  In contrast, 
about 30% of the peptides in S13D/S16D aggregates, and nearly 50% of the peptides in 
S13pS/S16pS aggregates, are cleaved by trypsin exposure under the same conditions. 
Interestingly, the single phosphoryl-Ser mutants, S13pS and S16pS, are both about 30% cleaved, 
the same level as the S13D/S16D aggregates. Thus, the sensitivity of these modified Ser 
aggregates to trypsin cleavage rank very similarly to their relative formation rates (Fig 6-8.A).   
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Thus, the aggregation reaction of a httNTQ37P10K2 with a WT httNT sequence reaches equilibrium 
after about 50 hrs, with no further change up to 200 hrs, for a Cr in the 0.3 µM range (Fig. 6-8.B, 
-●-).  In comparison, the corresponding S13D/S16D peptide aggregation reaction reaches a 
plateau in monomer concentration after about 100 hrs, with no further change out to 1400 hrs 
(Fig. 6-8.B, ♦).  This plateau is in the 2.5 – 3.0 µM range, almost 10-fold higher (i.e., less stable) 
than the WT. A similar monomer concentration of 2 µM is reached when S13D/S16D aggregates 
are diluted and given the opportunity to dissociate to toward equilibrium (Fig. 6-8.B inset), 
showing the robustness of the measurement as a feature of a dynamic equilibrium.  The 
S13pS/S16pS peptide requires about 200 hrs to reach equilibrium where it indicates a Cr value in 
the 4.5 – 6.0 µM range (Fig. 5C, ▲).  Based on these values, we calculated the aggregation 
destabilization (ΔΔGag) (31) from placing negative charges at the serines to be ~1.3-1.4 kcal/mol 
for the S13D/S16D mutation and ~1.7-1.8 kcal/mol for the S13pS/S16pS peptide.   
 
6.4 DISCUSSION.  
Protein phosphorylation and de-phosphorylation play an enormous role in cell regulation 
and cell pathway dysfunction linked to disease. In the context of the htt protein, phosphorylation 
has been implicated in modulating several cellular processes (16, 36, 195). Particularly, 
phosphorylation of serines 13 and 16 has been shown to enhance the degradation of htt by the 
proteasome in cell models (37) and abrogate aggregation of htt in tg HD mice (16). Here, we 
have aimed to investigate the biophysical basis of serine phosphorylation on the aggregation of 
htt peptides.  
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Our studies indicate a significant impact of the replacement of Ser13 and Ser16 with 
negatively charged groups on the rates of spontaneous aggregation of htt N-terminal fragments.  
Thus, both the S13D/S16D mutations and the S13pS/S16pS mutations reduce the aggregation 
rates of httNTQ37P10K2 peptides considerably with the degree of impairment depending on the 
net-charge of the peptide.  
In principle, there are a number of mechanistic steps that might be targeted by httNT 
sequence changes to explain observed aggregation rate reductions; these include monomer 
conformation, oligomer formation, amyloid nucleation and amyloid elongation.  We found that 
the S13D/S16D mutation does not appreciably affect the ensemble monomeric conformation of 
the httNTQ37P10K2 peptides based on CD and FRET results. In contrast, Truant and colleagues 
described CD experiments showing significant reductions of α-helix in httNT peptides modified 
on the Ser residues which they interpreted as evidence for altered monomer conformations (29). 
The different results may be due to sample disaggregation procedures, peptide sequence 
background used, or peptide concentrations used. The httNT Ser modifications do not appear to 
alter the reliance of these peptides on httNT mediated oligomer formation as a basis of polyQ 
amyloid nucleation, nor is there any evidence for a difference in the efficiencies of nucleation 
and elongation after formation of α-helix-rich oligomers. However, we found that httNT segments 
containing the S13D/S16D mutations assemble less readily into these α-helix-rich oligomers 
(Fig. 6-4.B).  Thus, the most likely source of diminished spontaneous aggregation rates is a 
reduced ability to form the α-helix-rich tetramers and higher aggregates that serve as the species 
within which polyQ amyloid structure is nucleated (135). 
Consistent with the CD results that suggest that a role for httNT α-helix formation in the 
amyloid nucleation mechanism is retained in Ser modified peptides, ss NMR shows that central 
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8.B).  These dramatic effects have strong implications for the ability of the cell to manage 
aggregation.  The Cr values of 2-6 µM for httNTQ37P10K2 amyloid-like aggregates with Asp or 
phosphoryl-Ser residues at positions 13 and 16 mean that peptide solutions below these 
concentrations have no thermodynamic driving force to aggregate at all.  Of course the crowded 
environment might drive Cr values lower, but even so the ~10 fold difference in WT vs. Ser-
modified htt fragment stabilities is likely to be maintained and would be expected to reduce the 
tendency of the mutated peptides to aggregate.  The increased susceptibility of httNT to trypsin in 
the Ser-modified aggregates suggests a greater accessibility of the httNT segment to many 
modifying enzymes. For instance, htt fragments have been shown to be ubiquitinylated at the N-
terminus (19) and it would not be surprising if the ubiquitinylating enzymes responsible for 
flagging misfolded and aggregated proteins for destruction at the proteasome were found to more 
efficiently modify S13D/S16D and S13pS/S16pS aggregates compared with WT aggregates 
based on the enhanced httNT accessibility observed in the trypsin experiments (Fig. 6-8.A).   
Mutations of Ser or Thr residues to Asp or Glu residues have long been seen as viable, 
ribosomally accessible mimics of phosphorylated residues, in spite of the dramatically different 
sizes and pKas of carboxylic acid and phosphoric acid moieties.  Our results suggest that Asp 
mutations are also reasonable mimics of the effects of phosphorylation of Ser residues on htt N-
terminal fragment aggregation.  While the tendency of these acidic groups to have negative 
effects on β-sheet rich amyloid formation is not surprising, their ability to reduce the formation 
of httNT α-helix-rich oligomers is somewhat puzzling.  The helical wheel diagram of httNT (Fig 6-
9) shows a strong amphipathic nature, and recent results suggest that the hydrophobic face of this 
helix plays a major role in oligomer stabilization (R. Mishra and R. Wetzel, Ms. in preparation).  
However, Ser13 and Ser16 are on the hydrophilic face of the α-helix, which would be then 
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predicted to be solvent exposed and relatively unfazed by the introduction of negatively charged 
groups.  It is possible that this hydrophilic face is involved in packing of α-helical tetramers into 
higher order oligomers that might be required for amyloid nucleation.   
Many substrates for phosphorylation are intrinsically disordered proteins, and the 
mechanisms by which phosphorylation imparts cellular effects has a strong protein folding 
component. Our results suggest a feasible pathway by which protein phosphorylation might 
impact protein misfolding and aggregation by modulating the long term viability of such aberrant 
species.  The data provide a consistent mechanism to explain the lack of aggregate accumulation, 
and potentially the lack of toxicity, of S13D/S16D htt in a mouse model of HD. 
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7.0  EFFECT OF POLYQ EXPANSION ON AGGREGATION OF POLYQ 
CONTAINING HTT FRAGMENTS.  
7.1 OVERVIEW. 
Since polyQ expansion is the fundamental trigger in HD pathology, we explore in detail 
the relationship between polyQ expansion and aggregation of polyQ containing htt fragments. 
We have looked at the effects of polyQ expansion on aggregation rates, the conformational 
ensemble in the monomeric state of polyQ containing htt fragments and on the thermodynamics 
of oligomerization. We did not find any substantial effect of polyQ expansion on the monomeric 
conformational ensemble. However, our preliminary observations do indicate that polyQ 
expansion stabilizes oligomerization which might underlie the acceleration of aggregation that is 
observed. Overall, these results are expected to be crucial in adding to our existing understanding 
of the role that polyQ expansion plays in aggregation and in guiding future experiments  
7.2 INTRODUCTION.  
Polyglutamine expansion is the fundamental trigger in Huntington’s disease thereby making it 
one of the ten CAG repeat diseases. While the cellular and pathological manifestations of polyQ 
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Over the next few sections, we highlight some of the preliminary results in our efforts to 
identify the mechanistic details of such polyQ expansion induced rate enhancement.  
7.3.2 polyQ expansion does not alter monomeric conformation.  
Earlier FRET based studies in the lab has suggested that expansion of polyQ within htt 
peptides alters the conformation of the leader httNT sequence from a compact coil at lower polyQ 
repeats to an extended coil at higher polyQ repeats. However, a caveat with these studies is that 
they did not account for any sequence dependent changes in quantum yield of the donor 
(acceptor). Thus, when these same experiments were performed using a ratiometric FRET 
(Chapter 3) approach that does not require the donor-only control, there was no substantial 
difference in the conformation of the httNT sequence in htt fragments of different polyQ repeat 
lengths (Fig 7-1 .B) (B.Sahoo et al, unpublished results). To explore the polyQ length 
dependence of monomeric conformational ensemble in greater detail, we decided to use double 
electron-electron resonance (DEER), an EPR based technique that uses the relaxation of two spin 
probes to obtain a mutual distance distribution. Thus, we attached the MTSL spin probe to 
cysteines mutated into the httNT sequence at positions 1 and 17 in polyQ containing htt fragments 
with 1, 30 or 37 glutamine repeats. Since the DEER experiments are performed at low 
temperatures (80K), any aggregation of the samples during sampling is expected to be minimal. 
Nevertheless, we decided to first ensure that this is actually true, especially in the cases of the 
peptides with 30 and 37 polyQ repeats. 
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httNT, httNTQ30P10K2 and httNTQ37P10K2 peptides based on the 1-17 distance distribution (Fig 7-
2.B,C). Both the httNTQ30P10K2 (▬)  and the httNTQ37P10 K2 (▬) peptides display a broadened 
distance distribution with an average distance of ~25A0 consistent with the notion that in the 
monomeric state polyQ containing htt fragments are disordered and can transiently sample 
multiple conformations. Also shown is the distance distribution between labeled residues in a 
globular protein (▬) which is much narrower than observed in the htt fragments. Interestingly, 
the average distances calculated by this method match the expected distance between the Cβ 
atoms of Met 1 and Phe 17 when httNT is an α-helical conformation (Fig 7-2.D). Overall, these 
results are consistent with previously reported CD studies in suggesting that in the monomeric 
ensemble polyQ containing htt fragments display a heterogeneous conformational ensemble with 
some hints of helical structure (100).   
Unfortunately however, our efforts to look at the intra-molecular distance distribution in 
httNTQ under the same conditions (1X PBS) turned out to be futile since under the same 
conditions, the relaxation rates of the spin labels were too rapid for DEER measurements. 
However, we were able to collect some data in the presence of  10-15% glycerol that suggest 
httNTQ exists in a compact conformation with a 1-17 distance of ~16 A0. It is not clear whether 
this calculated distance is representative of the physiological conformation and short of repeating 
the other experiments in the same conditions as those used in httNT sample, there is no way of 
confirming whether there is actually a conformational transition in the httNT monomeric 
ensemble with polyQ expansion. Nevertheless, the results from the httNTQ30P10K2 and 
httNTQ37P10K2 peptides suggest that the monomeric ensemble of longer polyQ containing htt 
fragments is essentially disordered.  
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Earlier, Pande and co-workers using replica-exchange based simulation strategies had showed 
that httNT adopts helical conformations in aqueous solutions (104). Within the relatively shorter 
time-scales of these simulations (Fig 7-3), we did not observe any stable secondary structure in 
httNT across the three peptides of different polyQ lengths that were studied. The slightly 
enhanced helicity in httNT in the httNTQ20P10K2 is not maintained in the httNTQ37P10K2 peptide 
hinting that under these simulation conditions (i.e. not allowing for oligomerization) polyQ 
expansion does not seem to alter the conformational preferences of httNT. However, our studies 
of the aggregation of htt peptides with different polyQ repeat lengths suggest that polyQ 
expansion does alter initial aggregation rates (Fig 7-1.A, initial 20%). Since the effects do not 
seem to be mediated at the monomeric level, we next sought to ascertain whether polyQ 
expansion might affect oligomerization of polyQ containing htt fragments. 
7.3.3 polyQ expansion stabilizes oligomerization. 
We have shown in earlier chapters that the oligomerization of polyQ containing htt fragments is 
mediated by httNT. Thus, CD studies of httNT identified a concentration dependent transition from 
random-coil to α-helical spectra indicative most likely of oligomerization, with the mid-point of 
this transition at ~ 400-500µM. Since polyQ expansion is associated with an acceleration of 
aggregation rates (Fig 7-1) and given the intricate link between oligomerization and aggregation 
rates (Chapter 5), we next explored whether polyQ expansion can affect stability of httNT 
mediated oligomerization.  
 Figure 7-4
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course the time to 15% aggregation is also expected to be modulated by other aggregation events 
aside from oligomerization (viz. nucleation and elongation).  
Next, we wanted to ascertain whether polyQ expansion might also affect other stages of 
the aggregation pathway independent of its effects on oligomerization.  Expectedly, the time to 
50% aggregation of any peptide should be modulated by contributions from both oligomerization 
and other downstream stages of aggregation. Thus, it can be reasoned that if the correlation 
between the C1/2 of helicity for different polyQ length htt peptides and the time to 50% 
aggregation (that reflects nucleation processes) is comparable to that between C1/2 of helicity and 
the time to 15% aggregation (that reflects, presumably, oligomerization) then the effects of 
polyQ expansion on aggregation can be explained, in the major part at least, on the basis of its 
effect on oligomerization. Such an analysis (Fig 7-5.B, ▬) however gave a poor correlation with 
a R2 of 0.5 suggesting that polyQ expansion exhibits independent effects on both oligomer 
formation and stochastic nucleation efficiency( and/or elongation) in htt fragments . However, 
one must consider that the sample size in these analyses is too small to conclusively prove this 
point. Rather, the purpose of this exercise is to set the hypothesis for future studies that aim to 
delineate the role of polyQ expansion on nucleation and/or elongation efficiencies.  
7.4 DISCUSSION. 
 Polyglutamine expansion is the fundamental molecular event that precipitates HD. 
While, repeat length expansion has been linked to several cellular processes, the increase in 
aggregation kinetics in vitro and aggregate burden in vivo is of particular interest to us. Early 
studies with simple polyQ peptides showed that aggregation propensities are directly tied to the 
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size of the polyQ stretch. Subsequently, this polyQ dependence of aggregation was also observed 
in the aggregation of polyQ containing htt fragments ((31), Fig 7-1). It is possible for the pro-
aggregation effects of polyQ expansion to be mediated at any of the different stages of the 
aggregation pathway i.e by altering the monomeric conformational ensemble, by stabilizing 
oligomerization, by favoring nucleation within oligomers, by increasing the stabilities of the final 
fibrils. Here, we have looked at the effects of polyQ expansion on the average monomeric 
conformation and on httNT mediated oligomerization.  
A case for a conformational transition to a β-rich structure within the monomeric 
ensemble at higher polyQ repeat lengths has been made based on antibody binding and bulk 
spectroscopic techniques (96, 99, 108, 131). CD results from our group (31, 100) and those of 
others (103) do not show the existence of any stable β-sheet conformation in the monomeric 
ensemble of polyQ containing proteins of any repeat length. The focus of this current work has 
therefore been to primarily look at the conformation of httNT in the monomeric ensemble of htt 
fragments with different polyQ repeats. Earlier, FRET based studies from the lab had shown that 
with an increase in the polyQ repeat length, the httNT conformation switches from a compact to 
an extended state. However, using a more careful FRET approach to measuring the distance 
between residues at -1 and 17 in the httNT sequence, we did not notice any major difference in the 
conformation of the httNT sequence in htt fragments with 3 or 37 glutamine repeats. As an 
additional probe of httNT conformation at different polyQ repeat lengths we also looked at the 
distance distribution between residues 1 and 17 using EPR based DEER techniques. Consistent 
with our CD results, htt fragments of different polyQ repeat lengths are essentially disordered in 
their monomeric ensemble, evinced by the spread of the 1-17 distance distributions. Also, at 
higher polyQ repeat lengths the average distance is ~25A○ as would be expected for the httNT 
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sequence in an α-helical conformation consistent with the increase in helical propensities 
reported for the monomer at higher polyQ repeats (100). While, there was an observed difference 
in the average 1-17 distance in httNT and httNTQ37P10K2 this is most likely due to difference in the 
measurement conditions. Overall, these results suggest that polyQ expansion does not 
appreciably alter the monomeric ensemble of htt segments which are still predominantly 
disordered.  
Based on our work detailed in Chapters 4 and 5, the primary role of httNT in the 
aggregation of polyQ containing htt fragments is mediated through oligomerization. While 
oligomerization is believed to be primarily mediated through interactions between httNT, it is still 
possible that polyQ expansion can affect httNT mediated oligomerization. The preliminary results 
shown here indicate that polyQ expansion stabilizes httNT mediated oligomer formation based on 
the reduction in the C1/2 of helicity with increasing glutamine repeats. This observation is also 
consistent with the increase in the rates of oligomerization observed upon increasing polyQ 
length in htt fragments (100). At this stage, the structural/mechanistic details of polyQ 
stabilization of oligomers are not clear. It is possible that polyQ stabilizes helicity, a fundamental 
facet of polyQ containing htt fragments’ aggregation. For instance, the crystal structure of a htt 
exon-1 fragment suggests that the polyQ stretch adjacent to httNT can adopt a helical sequence 
(80). However, our results with the httNT-P-Q37P10K2 peptide (Chapter 5) that aggregates similar 
to the WT control argue against such stabilization. Alternately, stabilization of these oligomers 
could also possibly be mediated through inter-molecular interactions between polyQ segments 
from different monomers within tetramers.  
While, we have not yet looked at the effects of polyQ expansion on stochastic nucleation 
within the oligomers, it is entirely possible (and in fact likely) that there is an intricate link 
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between the two. In fact, a cursory examination of the aggregation kinetics of htt fragments with 
different length polyQ repeats suggests this to be the case. Thus, the aggregation of 
httNTQ37P10K2 (Fig 7-1, ♦) is substantially faster than httNTQ23P10K2 (Fig 7-1, ) even though 
these peptides are not substantially different in their oligomerization stabilities (Fig 7-4.B). This 
observation suggests that the differences in kinetics probably stem from polyQ repeat length 
effects on the subsequent nucleation event. This would not be surprising given the role of repeat 
length in nucleation of simple polyQ peptides (121). While the transience of the nucleation event 
makes it intractable to most bulk biophysical techniques, it is hoped that the use of single-
molecule techniques such as fluorescence correlation spectroscopy or total internal reflection 
based fluorescence microscopy might allow us to investigate this particular hypothesis.  
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8.0  CONCLUSION?. 
8.1 THESIS CONTRIBUTIONS. 
Work from the lab, at the outset of this work, had just highlighted the crucial role that the first 
seventeen residues of huntingtin (httNT) play in the aggregation of polyQ containing htt 
fragments. The major focus of the work presented in this thesis has been to elucidate in detail the 
mechanistic and structural details of httNT mediated aggregation.  
8.1.1 Amphipathic helicity drives httNT mediated aggregation  
Using a combinatorial approach relying on rationally designed mutations and structural 
and biochemical techniques we have identified that the adoption of a helical conformation by 
httNT is crucial to oligomerization and by extension the aggregation of polyQ containing htt 
fragments (Chapters 4 and 5). A particularly distinctive feature of the httNT sequence is the 
presence of hydrophobic residues that are uniformly distributed throughout the sequence. Our 
results show that net hydrophobicity cannot solely explain the aggregation enhancing role of 
httNT. Rather, it is the ability of httNT to adopt an amphipathic helical conformation within 
oligomers that can present a hydrophobic interaction surface that stabilizes oligomers and 
promotes stochastic nucleation of amyloid structure. However, as the results of our work with the 
scrambled httNT sequences (Chapter 4) suggest, in addition to the role that httNT plays in 
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mediating initial oligomerization there is some evidence for a secondary role in mediating 
stochastic nucleation consistent with at least part of this sequence adopting a β-sheet 
conformation in final aggregates formed by polyQ containing htt fragments.  
8.1.2 Delineating the effects of PTMs on httNT mediated aggregation  
In addition to its role in modulating the aggregation of polyQ containing htt fragments, 
the httNT sequence is also the site of several post-translational modifications. The results of our 
studies with some of these modifications suggest that in addition to the cellular roles they can 
also modulate aggregation of polyQ containing htt fragments. Particularly the phosphorylation of 
serines 13 and 16 which abrogates HD pathology substantially impairs the aggregation kinetics 
and aggregate stability highlighting the importance of acknowledging the effect of post-
translational modifications on biophysical properties of the target sequence.  
8.1.3 Putative httNT tetrameric structure 
Oligomers of polyQ containing htt fragments have been widely cited as being the toxic 
species in HD pathology though this still remains controversial. A structural insight into the 
organization of such oligomers is not only crucial for our understanding of their role in HD 
pathology but also for designing aggregation inhibiting strategies. Here, we have described a 
preliminary model of the putative httNT tetrameric structure that is populated during aggregation. 
While this structure does not account for the role of polyQ segments on oligomer formation, it 
still provides a theoretical framework for the design of experiments aimed at elucidating 
structure of these oligomers. In addition, it could also possibly pave the way for in silico 
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screening experiment aimed at identifying inhibitors of oligomerization which might not only 
have potential therapeutic relevance but also provides us with reagents that can directly test the 
role of aggregation in disease pathology in cellular or animal models of HD. 
8.1.4 Exploring the effect of polyQ expansion on httNT mediated oligomerization. 
While the httNT sequence is the primary driver in the oligomerization of polyQ containing 
htt fragments, the polyQ segment does not play an entirely passive role in this process. Thus, at 
least some portion of the effect of polyQ expansion on the aggregation of htt fragments stems 
from its ability to stabilize oligomerization (Chapter 7). It is unclear at this stage as to how polyQ 
expansion structurally stabilizes oligomers and this will remain the focus of future studies.  
8.2 FUTURE DIRECTIONS?  
Overall, these results have contributed to an emerging picture that unmasks the role of 
httNT in the oligomerization stage of the aggregation pathway. Yet, there are several aspects to 
the aggregation of polyQ containing htt fragments that remain to be ascertained. Thus far we 
have not been able to get many insights into the process of stochastic nucleation of polyQ 
amyloid structure that is believed to occur within these oligomers. The transience of this event 
makes it pretty inaccessible to most, if not all, bulk techniques and the only insights that we have 
gleaned are based on analyses of events that are linked to this process. However, single-molecule 
techniques such as TIRFM and FCS-FRET can shed some light on this aspect of the aggregation 
pathway and particularly the role that polyQ expansion plays in this process. Finally, since the 
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ultimate goal of these studies is to clarify the role of aggregation in the context of HD pathology, 
the study of htt aggregation in vivo is indispensable. This is one direction that the lab has 
currently set its focus towards, guided by the results from our in vitro studies.  
 
 
 
 
 
 
 178 
APPENDIX A: SUPPLEMENTARY DATA. 
A.1 EFFECT OF HYDROPHOBIC ALA MUTANTS ON HTTNT-Q3 PEPTIDES. 
The httNT-Q3 peptide when incubated for ~1000 hours forms oligomers that can be visualized by 
EM and pelleted and studied by FTIR (at high starting concentrations). Using the sedimentation 
assay, we looked at the ability of the M8A, L4A and M8P mutants on the aggregation kinetics 
and aggregate (oligomer) structure of httNT-Q3 peptides. We found that all of these mutants 
hardly aggregate at low concentrations. Even when incubated at high concentrations (~1mM) for 
~1000 hrs, these mutants yield very small amount of pelletable oligomers that exhibit 
predominantly random coil spectra. In contrast, the WT httNTQ3 peptide forms predominantly 
helical oligomers.  
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(Inset) FTIR spectra of oligomers isolated from these peptides (Same color scheme). (C) Aggregation of httNTQ8K2 
(F17W)  peptides. WT (●) and S13A/S16A (●) followed by sedimentation assay. Also shown are the peak positions 
of the maxima in the fluorescence emissions spectra of Trp 17 in aggregates of WT (○) and S13A/S16A (○) isolated 
at different times. (B) FTIR spectra of aggregates of httNTQ8K2 S13A/S16A isolated after 68 hrs (▬), 240 hrs (▬) 
and 720 hrs (▬).  
 
We found that the monomeric conformation of this mutant showed slightly more helicity than the 
WT (Fig A-5.A). We also looked at effect of this mutation on the aggregation of the httNTQ3 
peptide. Overall, we found that the WT and the S13A/S16A aggregate with similar kinetics to 
form predominantly helical oligomers (Fig A-5.B).  Next, we explored whether the S13A/S16A 
mutation affects the stochastic nucleation within oligomers by looking at the aggregation of the 
httNTQ8K2 (S13A/S16A). To our surprise, this peptide did not aggregate appreciably at low 
concentrations (Fig A-5.C). FTIR spectra of aggregates isolated at high concentrations showed 
that while the httNTQ8K2 (S13A/S16A) forms helical oligomers, stochastic nucleation within 
these oligomers seems impaired evinced by the lack of β-sheet rich aggregate formation, as 
observed with the WT peptide (Fig A-5.D). One possible explanation of this result is that the 
S13A/S16A stabilization of oligomerization interferes with nucleation which is probably 
associated with at least part of the httNT sequence (including S16) adopting a β strand 
conformation. Since in the httNTQ37P10K2 context the S13A/S16A mutant aggregates substantially 
more to form amyloid fibrils, it is likely that these counter-intuitive results are a feature of the 
peptide context used.  
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We found that the aggregates formed by all the three peptides showed greater 
susceptibility to trypsin cleavage than that observed for the final aggregates of polyQ containing 
htt fragments ( (31),Chapter 6). Of the three shttNTQ30P6K2 peptides, the shtt(Amyl)+Q30P6K2 and 
(Fig A-6.A/B, ▬)  and the shtt(Olig)- Q30P6K2  (Fig A-6.A/B, ▬) peptides showed the least 
susceptibility to trypsin (~20% cleavage). 
Also, the major sites of cleavage in both these peptides were in the early portion of the 
sequence (Table A-1). On the other hand, final aggregates of both the shtt(Olig)+Q30P6K2 (Fig A-
6.A/B, ▬) peptide were cleaved substantially by trypsin (~50%) with the sites of cleavage 
located in different regions of the leader shttNT sequence. Overall, these results indicate that 
amongst the shttNT sequences, the shtt(Amyl)+ sequence has the highest tendency to be incorporated 
into fibril structures while the shtt(Olig)+ has the least propensity to do so.  
Peptide Fragment Masses (Cut-site) % abundance 
shtt(Amyl)+Q30P6K2            6090 (Lys 6) 100 
shtt(Olig)+Q30P6K2 6155 (Lys5)           62 
6027 (Lys 6)           31 
5768 (Lys 8)            7 
shtt(Olig)-Q30P6K2 6310 (Lys 3) 58 
5746 (Lys 8) 42 
 
Table A-1: Fragments obtained after trypsinization of shttNTQ30P6K2 aggregates. Masses of cleaved fragments 
alongwith corresponding cut-sites within the shttNT sequence. The % abundance of cleaved fragments for any 
particular peptide were calculated by normalizing the individual relative abundances of these fragments to the sum-
total of all relative abundances of the cleaved fragments for that peptide.  
 187 
BIBLIOGRAPHY 
1. A novel gene containing a trinucleotide repeat that is expanded and unstable on 
Huntington's disease chromosomes. The Huntington's Disease Collaborative Research 
Group. Cell. 1993;72(6):971-83. 
2. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, et al. Aggregation 
of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. 
Science. 1997;277(5334):1990-3. 
3. Kozlowski P, de Mezer M, Krzyzosiak WJ. Trinucleotide repeats in human genome and 
exome. Nucleic Acids Res. 2010;38(12):4027-39. PMCID: 2896521. 
4. Mirkin SM. Expandable DNA repeats and human disease. Nature. 2007;447(7147):932-
40. 
5. Wojciechowska M, Krzyzosiak WJ. CAG repeat RNA as an auxiliary toxic agent in 
polyglutamine disorders. RNA Biol. 2011;8(4):565-71. PMCID: 3225975. 
6. Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, et al. Non-ATG-
initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A. 
2011;108(1):260-5. PMCID: 3017129. 
7. Krzyzosiak WJ, Sobczak K, Wojciechowska M, Fiszer A, Mykowska A, Kozlowski P. 
Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. 
Nucleic Acids Res. 2012;40(1):11-26. PMCID: 3245940. 
8. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, et al. Targeted 
disruption of the Huntington's disease gene results in embryonic lethality and behavioral 
and morphological changes in heterozygotes. Cell. 1995;81(5):811-23. 
9. Boxall R, Porteous DJ, Thomson PA. DISC1 and Huntington's disease--overlapping 
pathways of vulnerability to neurological disorder? PLoS One. 2011;6(1):e16263. 
PMCID: 3027647. 
10. Costa MC, Magalhaes P, Guimaraes L, Maciel P, Sequeiros J, Sousa A. The CAG repeat 
at the Huntington disease gene in the Portuguese population: insights into its dynamics 
and to the origin of the mutation. J Hum Genet. 2006;51(3):189-95. 
 188 
11. Barron LH, Warner JP, Porteous M, Holloway S, Simpson S, Davidson R, et al. A study 
of the Huntington's disease associated trinucleotide repeat in the Scottish population. J 
Med Genet. 1993;30(12):1003-7. PMCID: 1016632. 
12. Tartari M, Gissi C, Lo Sardo V, Zuccato C, Picardi E, Pesole G, et al. Phylogenetic 
comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea 
urchin. Mol Biol Evol. 2008;25(2):330-8. 
13. Clabough EB, Zeitlin SO. Deletion of the triplet repeat encoding polyglutamine within 
the mouse Huntington's disease gene results in subtle behavioral/motor phenotypes in 
vivo and elevated levels of ATP with cellular senescence in vitro. Hum Mol Genet. 
2006;15(4):607-23. 
14. Schilling B, Gafni J, Torcassi C, Cong X, Row RH, LaFevre-Bernt MA, et al. Huntingtin 
phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and 
toxicity. J Biol Chem. 2006;281(33):23686-97. 
15. Matsumoto G, Wada K, Okuno M, Kurosawa M, Nukina N. Serine 403 phosphorylation 
of p62/SQSTM1 regulates selective autophagic clearance of ubiquitinated proteins. Mol 
Cell. 2011;44(2):279-89. 
16. Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, et al. Serines 13 and 16 
are critical determinants of full-length human mutant huntingtin induced disease 
pathogenesis in HD mice. Neuron. 2009;64(6):828-40. PMCID: 2807408. 
17. Aiken CT, Steffan JS, Guerrero CM, Khashwji H, Lukacsovich T, Simmons D, et al. 
Phosphorylation of threonine 3: implications for Huntingtin aggregation and 
neurotoxicity. J Biol Chem. 2009;284(43):29427-36. PMCID: 2785575. 
18. Cong X, Held JM, DeGiacomo F, Bonner A, Chen JM, Schilling B, et al. Mass 
spectrometric identification of novel lysine acetylation sites in huntingtin. Mol Cell 
Proteomics. 2011;10(10):M111 009829. PMCID: 3205870. 
19. Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, et al. SUMO 
modification of Huntingtin and Huntington's disease pathology. Science. 
2004;304(5667):100-4. 
20. Yanai A, Huang K, Kang R, Singaraja RR, Arstikaitis P, Gan L, et al. Palmitoylation of 
huntingtin by HIP14 is essential for its trafficking and function. Nat Neurosci. 
2006;9(6):824-31. PMCID: 2279235. 
21. Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, Ellerby LM. Inhibition of 
calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase 
fragments in the nucleus. J Biol Chem. 2004;279(19):20211-20. 
22. Kim YJ, Yi Y, Sapp E, Wang Y, Cuiffo B, Kegel KB, et al. Caspase 3-cleaved N-
terminal fragments of wild-type and mutant huntingtin are present in normal and 
 189 
Huntington's disease brains, associate with membranes, and undergo calpain-dependent 
proteolysis. Proc Natl Acad Sci U S A. 2001;98(22):12784-9. PMCID: 60131. 
23. Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R, et al. 
Caspase cleavage of gene products associated with triplet expansion disorders generates 
truncated fragments containing the polyglutamine tract. J Biol Chem. 
1998;273(15):9158-67. 
24. Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, et al. Inhibiting 
caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and 
nonneuronal cells. J Biol Chem. 2000;275(26):19831-8. 
25. Zhang Y, Leavitt BR, van Raamsdonk JM, Dragatsis I, Goldowitz D, MacDonald ME, et 
al. Huntingtin inhibits caspase-3 activation. EMBO J. 2006;25(24):5896-906. PMCID: 
1698892. 
26. Southwell AL, Bugg CW, Kaltenbach LS, Dunn D, Butland S, Weiss A, et al. 
Perturbation with intrabodies reveals that calpain cleavage is required for degradation of 
huntingtin exon 1. PLoS One. 2011;6(1):e16676. PMCID: 3031625. 
27. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical 
targets in Huntington's disease. Physiol Rev. 2010;90(3):905-81. 
28. Rockabrand E, Slepko N, Pantalone A, Nukala VN, Kazantsev A, Marsh JL, et al. The 
first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and 
effects on calcium homeostasis. Hum Mol Genet. 2007;16(1):61-77. 
29. Atwal RS, Xia J, Pinchev D, Taylor J, Epand RM, Truant R. Huntingtin has a membrane 
association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. 
Hum Mol Genet. 2007;16(21):2600-15. 
30. Cornett J, Smith L, Friedman M, Shin JY, Li XJ, Li SH. Context-dependent 
dysregulation of transcription by mutant huntingtin. J Biol Chem. 2006;281(47):36198-
204. 
31. Thakur AK, Jayaraman M, Mishra R, Thakur M, Chellgren VM, Byeon IJ, et al. 
Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex 
aggregation mechanism. Nat Struct Mol Biol. 2009;16(4):380-9. PMCID: 2706102. 
32. Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S. Flanking sequences profoundly 
alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A. 2006;103(29):11045-50. 
PMCID: 1544171. 
33. Andrade MA, Bork P. HEAT repeats in the Huntington's disease protein. Nat Genet. 
1995;11(2):115-6. 
 190 
34. Takano H, Gusella JF. The predominantly HEAT-like motif structure of huntingtin and 
its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family 
transcription factor. BMC Neurosci. 2002;3:15. PMCID: 137586. 
35. Kalchman MA, Graham RK, Xia G, Koide HB, Hodgson JG, Graham KC, et al. 
Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J 
Biol Chem. 1996;271(32):19385-94. 
36. Luo S, Vacher C, Davies JE, Rubinsztein DC. Cdk5 phosphorylation of huntingtin 
reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J Cell Biol. 
2005;169(4):647-56. PMCID: 2171695. 
37. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, et al. IKK 
phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. 
J Cell Biol. 2009;187(7):1083-99. PMCID: 2806289. 
38. Jeong H, Then F, Melia TJ, Jr., Mazzulli JR, Cui L, Savas JN, et al. Acetylation targets 
mutant huntingtin to autophagosomes for degradation. Cell. 2009;137(1):60-72. PMCID: 
2940108. 
39. Li W, Serpell LC, Carter WJ, Rubinsztein DC, Huntington JA. Expression and 
characterization of full-length human huntingtin, an elongated HEAT repeat protein. J 
Biol Chem. 2006;281(23):15916-22. 
40. Wellington CL, Hayden MR. Of molecular interactions, mice and mechanisms: new 
insights into Huntington's disease. Curr Opin Neurol. 1997;10(4):291-8. 
41. Heng MY, Detloff PJ, Albin RL. Rodent genetic models of Huntington disease. 
Neurobiol Dis. 2008;32(1):1-9. 
42. Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, et al. Specific 
caspase interactions and amplification are involved in selective neuronal vulnerability in 
Huntington's disease. Cell Death Differ. 2004;11(4):424-38. 
43. Lunkes A, Lindenberg KS, Ben-Haiem L, Weber C, Devys D, Landwehrmeyer GB, et al. 
Proteases acting on mutant huntingtin generate cleaved products that differentially build 
up cytoplasmic and nuclear inclusions. Mol Cell. 2002;10(2):259-69. 
44. Ratovitski T, Chighladze E, Waldron E, Hirschhorn RR, Ross CA. Cysteine proteases 
bleomycin hydrolase and cathepsin Z mediate N-terminal proteolysis and toxicity of 
mutant huntingtin. J Biol Chem. 2011;286(14):12578-89. PMCID: 3069459. 
45. Kegel KB, Sapp E, Alexander J, Reeves P, Bleckmann D, Sobin L, et al. Huntingtin 
cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors. Mol 
Neurodegener. 2010;5:58. PMCID: 3018386. 
 191 
46. Kim YJ, Sapp E, Cuiffo BG, Sobin L, Yoder J, Kegel KB, et al. Lysosomal proteases are 
involved in generation of N-terminal huntingtin fragments. Neurobiol Dis. 
2006;22(2):346-56. 
47. Harjes P, Wanker EE. The hunt for huntingtin function: interaction partners tell many 
different stories. Trends Biochem Sci. 2003;28(8):425-33. 
48. Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 
2000;23(9):387-92. 
49. Miller JP, Hughes RE. Protein Interactions and Target Discovery in Huntington's 
Disease. 2011. 
50. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, et al. Sp1 and 
TAFII130 transcriptional activity disrupted in early Huntington's disease. Science. 
2002;296(5576):2238-43. 
51. Boutell JM, Thomas P, Neal JW, Weston VJ, Duce J, Harper PS, et al. Aberrant 
interactions of transcriptional repressor proteins with the Huntington's disease gene 
product, huntingtin. Hum Mol Genet. 1999;8(9):1647-55. 
52. Holbert S, Denghien I, Kiechle T, Rosenblatt A, Wellington C, Hayden MR, et al. The 
Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic 
and genetic evidence for a role in Huntington's disease pathogenesis. Proc Natl Acad Sci 
U S A. 2001;98(4):1811-6. PMCID: 29339. 
53. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, et al. 
The Huntington's disease protein interacts with p53 and CREB-binding protein and 
represses transcription. Proc Natl Acad Sci U S A. 2000;97(12):6763-8. PMCID: 18731. 
54. Kegel KB, Meloni AR, Yi Y, Kim YJ, Doyle E, Cuiffo BG, et al. Huntingtin is present in 
the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and 
represses transcription. J Biol Chem. 2002;277(9):7466-76. 
55. Faber PW, Barnes GT, Srinidhi J, Chen J, Gusella JF, MacDonald ME. Huntingtin 
interacts with a family of WW domain proteins. Hum Mol Genet. 1998;7(9):1463-74. 
56. Li SH, Cheng AL, Zhou H, Lam S, Rao M, Li H, et al. Interaction of Huntington disease 
protein with transcriptional activator Sp1. Mol Cell Biol. 2002;22(5):1277-87. PMCID: 
134707. 
57. Huang CC, Faber PW, Persichetti F, Mittal V, Vonsattel JP, MacDonald ME, et al. 
Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of 
normal polyglutamine proteins. Somat Cell Mol Genet. 1998;24(4):217-33. 
58. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, et al. Huntingtin 
interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal 
genes. Nat Genet. 2003;35(1):76-83. 
 192 
59. Kalchman MA, Koide HB, McCutcheon K, Graham RK, Nichol K, Nishiyama K, et al. 
HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated 
huntingtin in the brain. Nat Genet. 1997;16(1):44-53. 
60. Singaraja RR, Hadano S, Metzler M, Givan S, Wellington CL, Warby S, et al. HIP14, a 
novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and 
endocytosis. Hum Mol Genet. 2002;11(23):2815-28. 
61. Modregger J, DiProspero NA, Charles V, Tagle DA, Plomann M. PACSIN 1 interacts 
with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's 
disease brains. Hum Mol Genet. 2002;11(21):2547-58. 
62. Sittler A, Walter S, Wedemeyer N, Hasenbank R, Scherzinger E, Eickhoff H, et al. 
SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of 
polygln-containing protein aggregates. Mol Cell. 1998;2(4):427-36. 
63. Li XJ, Li SH, Sharp AH, Nucifora FC, Jr., Schilling G, Lanahan A, et al. A huntingtin-
associated protein enriched in brain with implications for pathology. Nature. 
1995;378(6555):398-402. 
64. Sun Y, Savanenin A, Reddy PH, Liu YF. Polyglutamine-expanded huntingtin promotes 
sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol 
Chem. 2001;276(27):24713-8. 
65. Bao J, Sharp AH, Wagster MV, Becher M, Schilling G, Ross CA, et al. Expansion of 
polyglutamine repeat in huntingtin leads to abnormal protein interactions involving 
calmodulin. Proc Natl Acad Sci U S A. 1996;93(10):5037-42. PMCID: 39402. 
66. Holbert S, Dedeoglu A, Humbert S, Saudou F, Ferrante RJ, Neri C. Cdc42-interacting 
protein 4 binds to huntingtin: neuropathologic and biological evidence for a role in 
Huntington's disease. Proc Natl Acad Sci U S A. 2003;100(5):2712-7. PMCID: 151406. 
67. Liu YF, Deth RC, Devys D. SH3 domain-dependent association of huntingtin with 
epidermal growth factor receptor signaling complexes. J Biol Chem. 1997;272(13):8121-
4. 
68. Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, et al. Huntingtin and 
huntingtin-associated protein 1 influence neuronal calcium signaling mediated by 
inositol-(1,4,5) triphosphate receptor type 1. Neuron. 2003;39(2):227-39. PMCID: 
3220623. 
69. Zucchelli S, Marcuzzi F, Codrich M, Agostoni E, Vilotti S, Biagioli M, et al. Tumor 
necrosis factor receptor-associated factor 6 (TRAF6) associates with huntingtin protein 
and promotes its atypical ubiquitination to enhance aggregate formation. J Biol Chem. 
2011;286(28):25108-17. PMCID: 3137084. 
70. Liu YF, Dorow D, Marshall J. Activation of MLK2-mediated signaling cascades by 
polyglutamine-expanded huntingtin. J Biol Chem. 2000;275(25):19035-40. 
 193 
71. Boutell JM, Wood JD, Harper PS, Jones AL. Huntingtin interacts with cystathionine 
beta-synthase. Hum Mol Genet. 1998;7(3):371-8. 
72. Burke JR, Enghild JJ, Martin ME, Jou YS, Myers RM, Roses AD, et al. Huntingtin and 
DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med. 1996;2(3):347-
50. 
73. Subramaniam S, Sixt KM, Barrow R, Snyder SH. Rhes, a striatal specific protein, 
mediates mutant-huntingtin cytotoxicity. Science. 2009;324(5932):1327-30. PMCID: 
2745286. 
74. Yang H, Liu C, Zhong Y, Luo S, Monteiro MJ, Fang S. Huntingtin interacts with the cue 
domain of gp78 and inhibits gp78 binding to ubiquitin and p97/VCP. PLoS One. 
2010;5(1):e8905. PMCID: 2811200. 
75. Cornett J, Cao F, Wang CE, Ross CA, Bates GP, Li SH, et al. Polyglutamine expansion 
of huntingtin impairs its nuclear export. Nat Genet. 2005;37(2):198-204. 
76. Tam S, Spiess C, Auyeung W, Joachimiak L, Chen B, Poirier MA, et al. The chaperonin 
TRiC blocks a huntingtin sequence element that promotes the conformational switch to 
aggregation. Nat Struct Mol Biol. 2009;16(12):1279-85. PMCID: 2788664. 
77. Yu H, Chen JK, Feng S, Dalgarno DC, Brauer AW, Schreiber SL. Structural basis for the 
binding of proline-rich peptides to SH3 domains. Cell. 1994;76(5):933-45. 
78. Gerber HP, Seipel K, Georgiev O, Hofferer M, Hug M, Rusconi S, et al. Transcriptional 
activation modulated by homopolymeric glutamine and proline stretches. Science. 
1994;263(5148):808-11. 
79. Schaefer MH, Wanker EE, Andrade-Navarro MA. Evolution and function of 
CAG/polyglutamine repeats in protein-protein interaction networks. Nucleic Acids Res. 
2012. 
80. Kim MW, Chelliah Y, Kim SW, Otwinowski Z, Bezprozvanny I. Secondary structure of 
Huntingtin amino-terminal region. Structure. 2009;17(9):1205-12. PMCID: 2863341. 
81. Chun W, Lesort M, Tucholski J, Faber PW, MacDonald ME, Ross CA, et al. Tissue 
transglutaminase selectively modifies proteins associated with truncated mutant 
huntingtin in intact cells. Neurobiol Dis. 2001;8(3):391-404. 
82. Davranche A, Aviolat H, Zeder-Lutz G, Busso D, Altschuh D, Trottier Y, et al. 
Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself 
triggers aberrant interactions. Hum Mol Genet. 2011;20(14):2795-806. 
83. Suopanki J, Gotz C, Lutsch G, Schiller J, Harjes P, Herrmann A, et al. Interaction of 
huntingtin fragments with brain membranes--clues to early dysfunction in Huntington's 
disease. J Neurochem. 2006;96(3):870-84. 
 194 
84. Groves MR, Hanlon N, Turowski P, Hemmings BA, Barford D. The structure of the 
protein phosphatase 2A PR65/A subunit reveals the conformation of its 15 tandemly 
repeated HEAT motifs. Cell. 1999;96(1):99-110. 
85. Palidwor GA, Shcherbinin S, Huska MR, Rasko T, Stelzl U, Arumughan A, et al. 
Detection of alpha-rod protein repeats using a neural network and application to 
huntingtin. PLoS Comput Biol. 2009;5(3):e1000304. PMCID: 2647740. 
86. Crick SL, Jayaraman M, Frieden C, Wetzel R, Pappu RV. Fluorescence correlation 
spectroscopy shows that monomeric polyglutamine molecules form collapsed structures 
in aqueous solutions. Proc Natl Acad Sci U S A. 2006;103(45):16764-9. PMCID: 
1629004. 
87. Dougan L, Li J, Badilla CL, Berne BJ, Fernandez JM. Single homopolypeptide chains 
collapse into mechanically rigid conformations. Proc Natl Acad Sci U S A. 
2009;106(31):12605-10. PMCID: 2722357. 
88. Chen S, Ferrone FA, Wetzel R. Huntington's disease age-of-onset linked to 
polyglutamine aggregation nucleation. Proc Natl Acad Sci U S A. 2002;99(18):11884-9. 
PMCID: 129363. 
89. Bhattacharyya A, Thakur AK, Chellgren VM, Thiagarajan G, Williams AD, Chellgren 
BW, et al. Oligoproline effects on polyglutamine conformation and aggregation. J Mol 
Biol. 2006;355(3):524-35. 
90. Chellgren BW, Miller AF, Creamer TP. Evidence for polyproline II helical structure in 
short polyglutamine tracts. J Mol Biol. 2006;361(2):362-71. 
91. Darnell G, Orgel JP, Pahl R, Meredith SC. Flanking polyproline sequences inhibit beta-
sheet structure in polyglutamine segments by inducing PPII-like helix structure. J Mol 
Biol. 2007;374(3):688-704. 
92. Bennett MJ, Huey-Tubman KE, Herr AB, West AP, Jr., Ross SA, Bjorkman PJ. A linear 
lattice model for polyglutamine in CAG-expansion diseases. Proc Natl Acad Sci U S A. 
2002;99(18):11634-9. PMCID: 129321. 
93. Vitalis A, Wang X, Pappu RV. Quantitative characterization of intrinsic disorder in 
polyglutamine: insights from analysis based on polymer theories. Biophys J. 
2007;93(6):1923-37. PMCID: 1959550. 
94. Vitalis A, Wang X, Pappu RV. Atomistic simulations of the effects of polyglutamine 
chain length and solvent quality on conformational equilibria and spontaneous 
homodimerization. J Mol Biol. 2008;384(1):279-97. PMCID: 2847503. 
95. Dlugosz M, Trylska J. Secondary structures of native and pathogenic huntingtin N-
terminal fragments. J Phys Chem B. 2011;115(40):11597-608. 
 195 
96. Peters-Libeu C, Miller J, Rutenber E, Newhouse Y, Krishnan P, Cheung K, et al. 
Disease-Associated Polyglutamine Stretches in Monomeric Huntingtin Adopt a Compact 
Structure. J Mol Biol. 2012. 
97. Nagai Y, Inui T, Popiel HA, Fujikake N, Hasegawa K, Urade Y, et al. A toxic 
monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol. 
2007;14(4):332-40. 
98. Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, et al. Cellular 
toxicity of polyglutamine expansion proteins: mechanism of transcription factor 
deactivation. Mol Cell. 2004;15(1):95-105. 
99. Zhang QC, Yeh TL, Leyva A, Frank LG, Miller J, Kim YE, et al. A compact beta model 
of huntingtin toxicity. J Biol Chem. 2011;286(10):8188-96. PMCID: 3048705. 
100. Jayaraman M, Kodali R, Sahoo B, Thakur AK, Mayasundari A, Mishra R, et al. Slow 
amyloid nucleation via alpha-helix-rich oligomeric intermediates in short polyglutamine-
containing huntingtin fragments. J Mol Biol. 2012;415(5):881-99. 
101. Pejchal R, Gach JS, Brunel FM, Cardoso RM, Stanfield RL, Dawson PE, et al. A 
conformational switch in human immunodeficiency virus gp41 revealed by the structures 
of overlapping epitopes recognized by neutralizing antibodies. J Virol. 
2009;83(17):8451-62. PMCID: 2738203. 
102. Dyson HJ, Wright PE. Coupling of folding and binding for unstructured proteins. Curr 
Opin Struct Biol. 2002;12(1):54-60. 
103. Bulone D, Masino L, Thomas DJ, San Biagio PL, Pastore A. The interplay between 
PolyQ and protein context delays aggregation by forming a reservoir of protofibrils. 
PLoS One. 2006;1:e111. PMCID: 1762411. 
104. Kelley NW, Huang X, Tam S, Spiess C, Frydman J, Pande VS. The predicted structure of 
the headpiece of the Huntingtin protein and its implications on Huntingtin aggregation. J 
Mol Biol. 2009;388(5):919-27. PMCID: 2677131. 
105. Takahashi Y, Okamoto Y, Popiel HA, Fujikake N, Toda T, Kinjo M, et al. Detection of 
polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy. J Biol 
Chem. 2007;282(33):24039-48. 
106. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation 
of neuronal intranuclear inclusions underlies the neurological dysfunction in mice 
transgenic for the HD mutation. Cell. 1997;90(3):537-48. 
107. Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL, et al. Intranuclear 
neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: 
correlation between the density of inclusions and IT15 CAG triplet repeat length. 
Neurobiol Dis. 1998;4(6):387-97. 
 196 
108. Miller J, Arrasate M, Brooks E, Libeu CP, Legleiter J, Hatters D, et al. Identifying 
polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol. 
2011;7(12):925-34. PMCID: 3271120. 
109. Sathasivam K, Lane A, Legleiter J, Warley A, Woodman B, Finkbeiner S, et al. Identical 
oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse 
models of Huntington's disease. Hum Mol Genet. 2010;19(1):65-78. PMCID: 2792149. 
110. Olshina MA, Angley LM, Ramdzan YM, Tang J, Bailey MF, Hill AF, et al. Tracking 
mutant huntingtin aggregation kinetics in cells reveals three major populations that 
include an invariant oligomer pool. J Biol Chem. 2010;285(28):21807-16. PMCID: 
2898425. 
111. Takahashi T, Kikuchi S, Katada S, Nagai Y, Nishizawa M, Onodera O. Soluble 
polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum 
Mol Genet. 2008;17(3):345-56. 
112. Poirier MA, Li H, Macosko J, Cai S, Amzel M, Ross CA. Huntingtin spheroids and 
protofibrils as precursors in polyglutamine fibrilization. J Biol Chem. 
2002;277(43):41032-7. 
113. Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, et al. Self-
assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: 
implications for Huntington's disease pathology. Proc Natl Acad Sci U S A. 
1999;96(8):4604-9. PMCID: 16379. 
114. Ho LW, Brown R, Maxwell M, Wyttenbach A, Rubinsztein DC. Wild type Huntingtin 
reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of 
Huntington's disease. J Med Genet. 2001;38(7):450-2. PMCID: 1757193. 
115. Yang W, Dunlap JR, Andrews RB, Wetzel R. Aggregated polyglutamine peptides 
delivered to nuclei are toxic to mammalian cells. Hum Mol Genet. 2002;11(23):2905-17. 
116. Hackam AS, Singaraja R, Wellington CL, Metzler M, McCutcheon K, Zhang T, et al. 
The influence of huntingtin protein size on nuclear localization and cellular toxicity. J 
Cell Biol. 1998;141(5):1097-105. PMCID: 2137174. 
117. Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, et al. Absence of 
behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal 
huntingtin inclusions. Proc Natl Acad Sci U S A. 2005;102(32):11402-7. PMCID: 
1183566. 
118. Ventruti A, Cuervo AM. Autophagy and neurodegeneration. Curr Neurol Neurosci Rep. 
2007;7(5):443-51. 
119. Sanchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine 
neurodegenerative disorders. Nature. 2003;421(6921):373-9. 
 197 
120. Jayaraman M, Mishra R, Kodali R, Thakur AK, Koharudin LM, Gronenborn AM, et al. 
Kinetically competing huntingtin aggregation pathways control amyloid polymorphism 
and properties. Biochemistry. 2012;51(13):2706-16. 
121. Kar K, Jayaraman M, Sahoo B, Kodali R, Wetzel R. Critical nucleus size for disease-
related polyglutamine aggregation is repeat-length dependent. Nat Struct Mol Biol. 
2011;18(3):328-36. PMCID: 3075957. 
122. Bhattacharyya AM, Thakur AK, Wetzel R. polyglutamine aggregation nucleation: 
thermodynamics of a highly unfavorable protein folding reaction. Proc Natl Acad Sci U S 
A. 2005;102(43):15400-5. PMCID: 1266079. 
123. Thakur AK, Wetzel R. Mutational analysis of the structural organization of 
polyglutamine aggregates. Proc Natl Acad Sci U S A. 2002;99(26):17014-9. PMCID: 
139261. 
124. Walters RH, Murphy RM. Aggregation kinetics of interrupted polyglutamine peptides. J 
Mol Biol. 2011;412(3):505-19. PMCID: 3170924. 
125. Pfeil W. The problem of the stability globular proteins. Mol Cell Biochem. 1981;40(1):3-
28. 
126. Marchut AJ, Hall CK. Effects of chain length on the aggregation of model polyglutamine 
peptides: molecular dynamics simulations. Proteins. 2007;66(1):96-109. 
127. Lee CC, Walters RH, Murphy RM. Reconsidering the mechanism of polyglutamine 
peptide aggregation. Biochemistry. 2007;46(44):12810-20. 
128. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and 
membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid 
oligomers. J Biol Chem. 2005;280(17):17294-300. 
129. Chen S, Berthelier V, Hamilton JB, O'Nuallain B, Wetzel R. Amyloid-like features of 
polyglutamine aggregates and their assembly kinetics. Biochemistry. 2002;41(23):7391-
9. 
130. Chen S, Berthelier V, Yang W, Wetzel R. Polyglutamine aggregation behavior in vitro 
supports a recruitment mechanism of cytotoxicity. J Mol Biol. 2001;311(1):173-82. 
131. Nekooki-Machida Y, Kurosawa M, Nukina N, Ito K, Oda T, Tanaka M. Distinct 
conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different 
cytotoxicity. Proc Natl Acad Sci U S A. 2009;106(24):9679-84. PMCID: 2689308. 
132. Kodali R, Wetzel R. Polymorphism in the intermediates and products of amyloid 
assembly. Curr Opin Struct Biol. 2007;17(1):48-57. 
 198 
133. Orr HT, Chung MY, Banfi S, Kwiatkowski TJ, Jr., Servadio A, Beaudet AL, et al. 
Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat 
Genet. 1993;4(3):221-6. 
134. Jayaraman M, Kodali R, Wetzel R. The impact of ataxin-1-like histidine insertions on 
polyglutamine aggregation. Protein Eng Des Sel. 2009;22(8):469-78. PMCID: 2719497. 
135. Jayaraman M, Kodali R, Sahoo B, Thakur AK, Mayasundari A, Mishra R, et al. Slow 
Amyloid Nucleation via alpha-Helix-Rich Oligomeric Intermediates in Short 
Polyglutamine-Containing Huntingtin Fragments. J Mol Biol. 2011. 
136. Sivanandam VN, Jayaraman M, Hoop CL, Kodali R, Wetzel R, van der Wel PC. The 
aggregation-enhancing huntingtin N-terminus is helical in amyloid fibrils. J Am Chem 
Soc. 2011;133(12):4558-66. PMCID: 3109494. 
137. Tam S, Geller R, Spiess C, Frydman J. The chaperonin TRiC controls polyglutamine 
aggregation and toxicity through subunit-specific interactions. Nat Cell Biol. 
2006;8(10):1155-62. PMCID: 2829982. 
138. Mishra R, Jayaraman M, Roland BP, Landrum E, Fullam T, Kodali R, et al. Inhibiting the 
Nucleation of Amyloid Structure in a Huntingtin Fragment by Targeting alpha-Helix-
Rich Oligomeric Intermediates. J Mol Biol. 2011. 
139. Wacker JL, Zareie MH, Fong H, Sarikaya M, Muchowski PJ. Hsp70 and Hsp40 attenuate 
formation of spherical and annular polyglutamine oligomers by partitioning monomer. 
Nat Struct Mol Biol. 2004;11(12):1215-22. 
140. Williamson TE, Vitalis A, Crick SL, Pappu RV. Modulation of polyglutamine 
conformations and dimer formation by the N-terminus of huntingtin. J Mol Biol. 
2010;396(5):1295-309. PMCID: 2832287. 
141. Borwankar T, Rothlein C, Zhang G, Techen A, Dosche C, Ignatova Z. Natural osmolytes 
remodel the aggregation pathway of mutant huntingtin exon 1. Biochemistry. 
2011;50(12):2048-60. 
142. Sikorski P, Atkins E. New model for crystalline polyglutamine assemblies and their 
connection with amyloid fibrils. Biomacromolecules. 2005;6(1):425-32. 
143. Perutz MF, Finch JT, Berriman J, Lesk A. Amyloid fibers are water-filled nanotubes. 
Proc Natl Acad Sci U S A. 2002;99(8):5591-5. PMCID: 122814. 
144. Stanley CB, Perevozchikova T, Berthelier V. Structural formation of huntingtin exon 1 
aggregates probed by small-angle neutron scattering. Biophys J. 2011;100(10):2504-12. 
PMCID: 3093554. 
145. Khare SD, Ding F, Gwanmesia KN, Dokholyan NV. Molecular origin of polyglutamine 
aggregation in neurodegenerative diseases. PLoS Comput Biol. 2005;1(3):230-5. 
PMCID: 1193989. 
 199 
146. Ogawa H, Nakano M, Watanabe H, Starikov EB, Rothstein SM, Tanaka S. Molecular 
dynamics simulation study on the structural stabilities of polyglutamine peptides. Comput 
Biol Chem. 2008;32(2):102-10. 
147. Stork M, Giese A, Kretzschmar HA, Tavan P. Molecular dynamics simulations indicate a 
possible role of parallel beta-helices in seeded aggregation of poly-Gln. Biophys J. 
2005;88(4):2442-51. PMCID: 1305343. 
148. Sharma D, Shinchuk LM, Inouye H, Wetzel R, Kirschner DA. Polyglutamine 
homopolymers having 8-45 residues form slablike beta-crystallite assemblies. Proteins. 
2005;61(2):398-411. 
149. Bevivino AE, Loll PJ. An expanded glutamine repeat destabilizes native ataxin-3 
structure and mediates formation of parallel beta -fibrils. Proc Natl Acad Sci U S A. 
2001;98(21):11955-60. PMCID: 59749. 
150. Kajava AV, Baxa U, Wickner RB, Steven AC. A model for Ure2p prion filaments and 
other amyloids: the parallel superpleated beta-structure. Proc Natl Acad Sci U S A. 
2004;101(21):7885-90. PMCID: 419526. 
151. Schneider R, Schumacher MC, Mueller H, Nand D, Klaukien V, Heise H, et al. Structural 
characterization of polyglutamine fibrils by solid-state NMR spectroscopy. J Mol Biol. 
2011;412(1):121-36. 
152. Heiser V, Engemann S, Brocker W, Dunkel I, Boeddrich A, Waelter S, et al. 
Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of 
Huntington's disease by using an automated filter retardation assay. Proc Natl Acad Sci U 
S A. 2002;99 Suppl 4:16400-6. PMCID: 139900. 
153. Hockly E, Tse J, Barker AL, Moolman DL, Beunard JL, Revington AP, et al. Evaluation 
of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for 
Huntington's disease. Neurobiol Dis. 2006;21(1):228-36. 
154. Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, et al. 
Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding 
and reduces toxicity in Huntington's disease models. Hum Mol Genet. 2006;15(18):2743-
51. 
155. Rinderspacher A, Cremona ML, Liu Y, Deng SX, Xie Y, Gong G, et al. Potent inhibitors 
of Huntingtin protein aggregation in a cell-based assay. Bioorg Med Chem Lett. 
2009;19(6):1715-7. PMCID: 2710884. 
156. Fuentealba RA, Marasa J, Diamond MI, Piwnica-Worms D, Weihl CC. An aggregation 
sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate 
inhibitors. Hum Mol Genet. 2012;21(3):664-80. PMCID: 3259017. 
 200 
157. Desai UA, Pallos J, Ma AA, Stockwell BR, Thompson LM, Marsh JL, et al. Biologically 
active molecules that reduce polyglutamine aggregation and toxicity. Hum Mol Genet. 
2006;15(13):2114-24. 
158. Nagai Y, Tucker T, Ren H, Kenan DJ, Henderson BS, Keene JD, et al. Inhibition of 
polyglutamine protein aggregation and cell death by novel peptides identified by phage 
display screening. J Biol Chem. 2000;275(14):10437-42. 
159. Nagai Y, Fujikake N, Ohno K, Higashiyama H, Popiel HA, Rahadian J, et al. Prevention 
of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 
in Drosophila. Hum Mol Genet. 2003;12(11):1253-9. 
160. Popiel HA, Nagai Y, Fujikake N, Toda T. Protein transduction domain-mediated delivery 
of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo. Mol Ther. 
2007;15(2):303-9. 
161. Tomita K, Popiel HA, Nagai Y, Toda T, Yoshimitsu Y, Ohno H, et al. Structure-activity 
relationship study on polyglutamine binding peptide QBP1. Bioorg Med Chem. 
2009;17(3):1259-63. 
162. Ren H, Nagai Y, Tucker T, Strittmatter WJ, Burke JR. Amino acid sequence 
requirements of peptides that inhibit polyglutamine-protein aggregation and cell death. 
Biochem Biophys Res Commun. 2001;288(3):703-10. 
163. Thakur AK, Yang W, Wetzel R. Inhibition of polyglutamine aggregate cytotoxicity by a 
structure-based elongation inhibitor. FASEB J. 2004;18(7):923-5. 
164. Starikov EB, Lehrach H, Wanker EE. Folding of oligoglutamines: a theoretical approach 
based upon thermodynamics and molecular mechanics. J Biomol Struct Dyn. 
1999;17(3):409-27. 
165. Lanning JD, Hawk AJ, Derryberry J, Meredith SC. Chaperone-like N-methyl peptide 
inhibitors of polyglutamine aggregation. Biochemistry. 2010;49(33):7108-18. PMCID: 
2965777. 
166. Colby DW, Chu Y, Cassady JP, Duennwald M, Zazulak H, Webster JM, et al. Potent 
inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-
domain intracellular antibody. Proc Natl Acad Sci U S A. 2004;101(51):17616-21. 
PMCID: 539732. 
167. Southwell AL, Khoshnan A, Dunn DE, Bugg CW, Lo DC, Patterson PH. Intrabodies 
binding the proline-rich domains of mutant huntingtin increase its turnover and reduce 
neurotoxicity. J Neurosci. 2008;28(36):9013-20. PMCID: 2633448. 
168. Li H, Li SH, Cheng AL, Mangiarini L, Bates GP, Li XJ. Ultrastructural localization and 
progressive formation of neuropil aggregates in Huntington's disease transgenic mice. 
Hum Mol Genet. 1999;8(7):1227-36. 
 201 
169. McGowan DP, van Roon-Mom W, Holloway H, Bates GP, Mangiarini L, Cooper GJ, et 
al. Amyloid-like inclusions in Huntington's disease. Neuroscience. 2000;100(4):677-80. 
170. Osmand AP, Berthelier V, Wetzel R. Imaging polyglutamine deposits in brain tissue. 
Methods Enzymol. 2006;412:106-22. 
171. Lajoie P, Snapp EL. Formation and toxicity of soluble polyglutamine oligomers in living 
cells. PLoS One. 2010;5(12):e15245. PMCID: 3011017. 
172. Ossato G, Digman MA, Aiken C, Lukacsovich T, Marsh JL, Gratton E. A two-step path 
to inclusion formation of huntingtin peptides revealed by number and brightness analysis. 
Biophys J. 2010;98(12):3078-85. PMCID: 2884247. 
173. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 
1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive 
neurological phenotype in transgenic mice. Cell. 1996;87(3):493-506. 
174. Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, et al. 
Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an 
aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem. 
2010;285(12):8808-23. PMCID: 2838303. 
175. Wetzel R. Physical Chemistry of Polyglutamine: Intriguing Tales of a Monotonous 
Sequence. J Mol Biol. 2012. 
176. Mishra R, Jayaraman M, Roland BP, Landrum E, Fullam T, Kodali R, et al. Inhibiting the 
nucleation of amyloid structure in a huntingtin fragment by targeting alpha-helix-rich 
oligomeric intermediates. J Mol Biol. 2012;415(5):900-17. PMCID: 3267848. 
177. Gautier R, Douguet D, Antonny B, Drin G. HELIQUEST: a web server to screen 
sequences with specific alpha-helical properties. Bioinformatics. 2008;24(18):2101-2. 
178. Eisenberg D, Weiss RM, Terwilliger TC. The helical hydrophobic moment: a measure of 
the amphiphilicity of a helix. Nature. 1982;299(5881):371-4. 
179. Munoz V, Serrano L. Elucidating the folding problem of helical peptides using empirical 
parameters. III. Temperature and pH dependence. J Mol Biol. 1995;245(3):297-308. 
180. Munoz V, Serrano L. Elucidating the folding problem of helical peptides using empirical 
parameters. II. Helix macrodipole effects and rational modification of the helical content 
of natural peptides. J Mol Biol. 1995;245(3):275-96. 
181. Munoz V, Serrano L. Elucidating the folding problem of helical peptides using empirical 
parameters. Nat Struct Biol. 1994;1(6):399-409. 
182. Eisenberg D, Weiss RM, Terwilliger TC. The hydrophobic moment detects periodicity in 
protein hydrophobicity. Proc Natl Acad Sci U S A. 1984;81(1):140-4. PMCID: 344626. 
 202 
183. Comeau SR, Gatchell DW, Vajda S, Camacho CJ. ClusPro: a fully automated algorithm 
for protein-protein docking. Nucleic Acids Res. 2004;32(Web Server issue):W96-9. 
PMCID: 441492. 
184. Comeau SR, Gatchell DW, Vajda S, Camacho CJ. ClusPro: an automated docking and 
discrimination method for the prediction of protein complexes. Bioinformatics. 
2004;20(1):45-50. 
185. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. 
CHARMM: A program for macromolecular energy, minimization, and dynamics 
calculations. Journal of Computational Chemistry. 1983;4(2):187-217. 
186. Comeau SR, Camacho CJ. Predicting oligomeric assemblies: N-mers a primer. J Struct 
Biol. 2005;150(3):233-44. 
187. Vriend G. WHAT IF: a molecular modeling and drug design program. J Mol Graph. 
1990;8(1):52-6, 29. 
188. Camacho CJ, Zhang C. FastContact: rapid estimate of contact and binding free energies. 
Bioinformatics. 2005;21(10):2534-6. 
189. Goormaghtigh E, Cabiaux V, Ruysschaert JM. Secondary structure and dosage of soluble 
and membrane proteins by attenuated total reflection Fourier-transform infrared 
spectroscopy on hydrated films. Eur J Biochem. 1990;193(2):409-20. 
190. LeVine H, 3rd. Quantification of beta-sheet amyloid fibril structures with thioflavin T. 
Methods Enzymol. 1999;309:274-84. 
191. Fiumara F, Fioriti L, Kandel ER, Hendrickson WA. Essential role of coiled coils for 
aggregation and activity of Q/N-rich prions and PolyQ proteins. Cell. 2010;143(7):1121-
35. 
192. Serio TR, Cashikar AG, Kowal AS, Sawicki GJ, Moslehi JJ, Serpell L, et al. Nucleated 
conformational conversion and the replication of conformational information by a prion 
determinant. Science. 2000;289(5483):1317-21. 
193. Atwal RS, Desmond CR, Caron N, Maiuri T, Xia J, Sipione S, et al. Kinase inhibitors 
modulate huntingtin cell localization and toxicity. Nat Chem Biol. 2011;7(7):453-60. 
194. Havel LS, Wang CE, Wade B, Huang B, Li S, Li XJ. Preferential accumulation of N-
terminal mutant huntingtin in the nuclei of striatal neurons is regulated by 
phosphorylation. Hum Mol Genet. 2011;20(7):1424-37. PMCID: 3049362. 
195. Zala D, Colin E, Rangone H, Liot G, Humbert S, Saudou F. Phosphorylation of mutant 
huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol 
Genet. 2008;17(24):3837-46. 
 
